var title_f2_63_3056="WBC differential CD4000";
var content_f2_63_3056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    WBC differential as obtained on an Abbott CD 4000 automated cell counter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a computer printout of a portion of a CBC as obtained on an Abbott CD 4000 automated cell counter. In this plot, white blood cells are separated by size (Y axis) and complexity (X axis). Shown here is the separation for neutrophils (orange), lymphocytes (light blue), and monocytes (purple). This CBC was obtained from a patient with a low total white blood cell count (3340 cells/microL), 16 percent neutrophils, 45 percent lymphocytes, and 38 percent monocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_63_3056=[""].join("\n");
var outline_f2_63_3056=null;
var title_f2_63_3057="Sacroiliitis grade 1 and 2";
var content_f2_63_3057=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Sacroiliitis grade 1 and 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right sacroiliitis is grade 1 (suspicious of sacroiliitis). Left sacroiliitis is grade 2 (minimal changes of sacroiliitis).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Xenofon Baraliakos, Rheumazentrum Ruhrgebiet, Herne, Germany.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_63_3057=[""].join("\n");
var outline_f2_63_3057=null;
var title_f2_63_3058="Radiologic imaging in Balamuthia mandrillaris amebic infection";
var content_f2_63_3058=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Radiologic imaging in Balamuthia mandrillaris amebic infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Panel A) Brain MRI showing a focal lesion surrounded by edema on the left temporal lobe that uptakes the gadolinium contrast on the T1 weighted image.",
"    <br/>",
"    (Panel B) Brain MRI showing two hyperintense focal lesions located on the left frontal and temporal lobes on the fluid attenuated inversion recovery (FLAIR) sequence.",
"    <div class=\"footnotes\">",
"     MRI: magnetic resonance imaging.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_63_3058=[""].join("\n");
var outline_f2_63_3058=null;
var title_f2_63_3059="Mycosis fungoides hyperpig";
var content_f2_63_3059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mycosis fungoides - patch/plaque",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient with wide-spread mycosis fungoides exhibits numerous hyperpigmented patches and thin plaques.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_63_3059=[""].join("\n");
var outline_f2_63_3059=null;
var title_f2_63_3060="Essential hypertension in women";
var content_f2_63_3060=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Essential hypertension in women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/63/3060/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3060/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3060/contributors\">",
"     Pamela S Douglas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/63/3060/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3060/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/63/3060/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3060/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/63/3060/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary or essential hypertension is a common problem in women as it is in men. The pathogenesis and clinical implications of hypertension of essential hypertension is women are generally similar to those in men, but there are some differences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before age 50, women have a lower prevalence of hypertension than men, but after age 55, they have a higher prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3060/abstract/1\">",
"     1",
"    </a>",
"    ]. The eventual prevalence of hypertension in women is similar to that in men, averaging 30 to 40 percent in blacks and roughly 20 percent in whites. The prevalence rises with age, approaching 80 to 90 percent in women over the age of 70 if subjects with isolated systolic hypertension are included (",
"    <a class=\"graphic graphic_figure graphicRef66935 \" href=\"UTD.htm?7/4/7247\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3060/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4755?source=see_link\">",
"     \"The prevalence and control of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are, however, several important gender-related differences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of hypertensive complications is significantly lower in women than in men, particularly in premenopausal women [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3060/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. The decrease in risk is primarily due to a reduced incidence of coronary heart disease (which is only one-half that in men at the same blood pressure), while the difference in the risk of stroke is much less prominent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3060/abstract/3\">",
"       3",
"      </a>",
"      ]. Left ventricular hypertrophy is less common in women than in men with similar degrees of hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3060/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A greater BP load seems to be required to produce cardiovascular injury in women. This difference is taken into account in a report from New Zealand that recommends that therapy be given only to those patients with an estimated overall 10-year risk for cardiovascular complications of at least 20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3060/abstract/6\">",
"       6",
"      </a>",
"      ]. At equal degrees of hypertension, women were at lower risk than men in all age groups from 40 to 70 (",
"      <a class=\"graphic graphic_figure graphicRef63561 \" href=\"UTD.htm?41/4/42062\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reasons for these differences are not clear, but hypertensive women have somewhat different hemodynamic findings from men (matched for blood pressure, race, age, and body surface area) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3060/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Women tend to have a 10 percent higher cardiac output and a 10 percent lower systemic vascular resistance (SVR). Women also then to have a wider pulse pressure, related to shorter stature (resulting in a more rapid return of the pulse wave to augment the peak pressure), and a faster heart rate (induces a short diastolic period) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3060/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women also have only two-thirds as great a rise in blood pressure with exercise. Premenopausal women have less effective baroreflex buffering of blood pressure than men of similar age, which may explain less effective blood pressure regulation in women in response to vasoactive drugs and acute stress [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3060/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that the lower SVR in some way minimizes vascular injury, thereby decreasing the incidence of coronary disease, heart failure, and stroke. The pathophysiologic mechanisms responsible for the hemodynamic differences are not known, but estrogens may play an important role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of hypertension is related to a variety of factors that include genetic predisposition and lifestyle and dietary factors, such as high salt and alcohol intake and obesity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of hypertension in adults\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=see_link\">",
"     \"Diet in the treatment and prevention of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of risk factors for essential hypertension in women was evaluated in a prospective cohort study of 83,882 adult women from the second Nurses' Health Study who did not have a history of hypertension, cardiovascular disease, or diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3060/abstract/11\">",
"     11",
"    </a>",
"    ]. Six lifestyle and dietary factors were independently associated with a lower risk of developing hypertension during 14 years of follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Body mass index of less than 25",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      A daily mean of 30 minutes of vigorous exercise",
"     </li>",
"     <li>",
"      Adherence to the DASH diet, modest alcohol intake",
"     </li>",
"     <li>",
"      Infrequent use of nonnarcotic analgesics",
"     </li>",
"     <li>",
"      Folate intake of 400",
"      <span class=\"nowrap\">",
"       microg/day",
"      </span>",
"      or more",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of all six factors was associated with a marked decrease in the risk for developing hypertension (hazard ratio of 0.22, 95% CI, 0.10-0.51).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women and men respond similarly to antihypertensive therapy. In elderly women with isolated systolic hypertension, for example, the benefit from antihypertensive therapy is equal to that of men [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3060/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=see_link\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women also derive substantial cardiovascular protection from antihypertensive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3060/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. A meta-analysis of seven major antihypertensive drug trials found that the relative benefit in women was similar to that in men [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3060/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the absolute benefit was less in women because of the lower number of events if untreated and the distribution of benefit was different in women and men. Antihypertensive therapy reduced both coronary and cerebrovascular events in men compared to primarily a reduction in stroke in women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thus, the indications for drug treatment of hypertension in women are probably similar to those in men [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3060/abstract/15\">",
"     15",
"    </a>",
"    ]. The following recommendations seem prudent at this time:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All women should be encouraged to follow a health lifestyle and periodically monitored for rises in blood pressure and end-organ damage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=see_link\">",
"       \"Hypertension: Who should be treated?\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of other cardiovascular risk factors (such as smoking, hypercholesterolemia, and diabetes mellitus) is an important determinant of the need for antihypertensive medications. The New Zealand report described above estimated that, in a 60 year-old woman with a diastolic pressure of 100 mmHg, the 10-year risk of a cardiovascular event was approximately 10 percent with no risk factors, 20 to 40 percent with two risk factors, and over 40 percent with three risk factors [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3060/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of left ventricular hypertrophy (LVH) by echocardiography carries an increased risk of cardiac events in women that is equivalent to that in men. Thus, LVH can be used as a guide to help decision making regarding the initiation of antihypertensive therapy in a woman. In this setting, it is important to use gender-specific criteria since LV mass is lower in women even after normalization for body size. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=see_link\">",
"       \"Definition and pathogenesis of left ventricular hypertrophy in hypertension\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     ERT and oral contraceptive",
"    </span>",
"    &nbsp;&mdash;&nbsp;An issue that often arises in hypertensive women is the possible additional risk of estrogen replacement therapy (ERT), which is no longer recommended is most postmenopausal women, and oral contraceptives. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37859?source=see_link\">",
"     \"Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H875120\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Before age 50, women have a lower incidence of hypertension than men, but after age 55, they have a higher incidence. The eventual prevalence of hypertension in women is similar to that in men, averaging 30 to 40 percent in blacks and roughly 20 percent in whites. The prevalence rises with age, approaching 80 to 90 percent in women over the age of 70 (",
"      <a class=\"graphic graphic_figure graphicRef66935 \" href=\"UTD.htm?7/4/7247\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared with hypertensive men, hypertensive women have a lower risk of coronary heart disease, stroke, and left ventricular hypertrophy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of hypertension in women is related to a variety of factors including genetic predisposition and lifestyle and dietary factors. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Meta-analyses of antihypertensive drug trials show that women derive similar relative benefits from antihypertensive therapy as do men. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The indications for drug treatment of hypertension in women are the same as they are in men. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Recommendations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3060/abstract/1\">",
"      Pemu, PI, Offili, E. Hypertension in women. J Clin Hypertens 2008; 10:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3060/abstract/2\">",
"      Franklin SS, Wong ND. Cardiovascular risk evaluation: an inexact science. J Hypertens 2002; 20:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3060/abstract/3\">",
"      Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997; 126:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3060/abstract/4\">",
"      August P, Oparil S. Hypertension in women. J Clin Endocrinol Metab 1999; 84:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3060/abstract/5\">",
"      Gosse, P, Ben Bouazza, S, Lassere, R, et al. Is high blood pressure different in males and females? (Abstract) J Hypertens 2002; 20:A1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3060/abstract/6\">",
"      Jackson R, Barham P, Bills J, et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ 1993; 307:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3060/abstract/7\">",
"      Messerli FH, Garavaglia GE, Schmieder RE, et al. Disparate cardiovascular findings in men and women with essential hypertension. Ann Intern Med 1987; 107:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3060/abstract/8\">",
"      Hayes SN, Taler SJ. Hypertension in women: current understanding of gender differences. Mayo Clin Proc 1998; 73:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3060/abstract/9\">",
"      Safar ME, Smulyan H. Hypertension in women. Am J Hypertens 2004; 17:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3060/abstract/10\">",
"      Christou DD, Jones PP, Jordan J, et al. Women have lower tonic autonomic support of arterial blood pressure and less effective baroreflex buffering than men. Circulation 2005; 111:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3060/abstract/11\">",
"      Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA 2009; 302:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3060/abstract/12\">",
"      Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265:3255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3060/abstract/13\">",
"      Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3060/abstract/14\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3060/abstract/15\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3880 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_63_3060=[""].join("\n");
var outline_f2_63_3060=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H875120\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ERT and oral contraceptive",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H875120\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3880\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3880|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/4/7247\" title=\"figure 1\">",
"      Prev htn in men women in US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/4/42062\" title=\"figure 2\">",
"      CV risk with HTN is lower in women than men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=related_link\">",
"      Definition and pathogenesis of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=related_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37859?source=related_link\">",
"      Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4755?source=related_link\">",
"      The prevalence and control of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=related_link\">",
"      Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_63_3061="Treatment of acute exacerbations of multiple sclerosis in adults";
var content_f2_63_3061=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acute exacerbations of multiple sclerosis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/63/3061/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3061/contributors\">",
"     Michael J Olek, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/63/3061/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3061/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/63/3061/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3061/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/63/3061/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system that is a leading cause of disability in young adults.",
"   </p>",
"   <p>",
"    Despite dramatic advances in the clinical assessment of MS due to the widespread availability of brain and spine MRI, our understanding of the basic etiology of the disease remains limited. Full control of the disease and the repair of damaged myelin are key objectives for current and future investigators.",
"   </p>",
"   <p>",
"    The treatment of acute exacerbations of MS is reviewed here. Other aspects of MS treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26265?source=see_link\">",
"     \"Treatment of progressive multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36985?source=see_link\">",
"     \"Comorbid problems associated with multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for treatment of an acute exacerbation (relapse) in patients with MS include functionally disabling symptoms with objective evidence of neurologic impairment such as loss of vision, motor,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cerebellar symptoms. Mild sensory attacks are often not treated in the same manner, although symptomatic relief is sometimes necessary because of patient discomfort (eg, due to paresthesia).",
"   </p>",
"   <p>",
"    Patients with relapsing-remitting MS who manifest current disease activity by either clinical symptoms or recent MRI lesions should be offered treatment with disease-modifying therapy. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'General principles of disease modifying therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute attacks of MS are usually treated with glucocorticoids. Three to seven day courses of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , 500 to 1000 mg daily, with or without a short",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    taper, are used most commonly [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3061/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis published in 2000 identified six randomized controlled trials comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    or adrenocorticotropic hormone (ACTH) to placebo in a total of 377 patients with acute exacerbations of MS [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3061/abstract/3\">",
"     3",
"    </a>",
"    ]. Methylprednisolone was tested in four trials with 140 patients; it was administered orally in one trial (500 mg daily for five days followed by a 10 day taper), and intravenously in three trials (500 mg daily or 1000 mg daily for five days in two trials, and 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily for three days in the third). The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with placebo, patients treated with ACTH or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      had a significant reduction in the risk of either worsening or not improving within five weeks from randomization (odds ratio [OR] 0.37, 95% CI 0.24-0.57).",
"     </li>",
"     <li>",
"      In a subgroup analysis by drug, both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      treatment and ACTH treatment reduced the risk of worsening or not improving within five weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Small randomized trials comparing oral versus intravenous glucocorticoids for acute MS attacks have found no important differences in benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3061/abstract/4\">",
"     4",
"    </a>",
"    ], as illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One randomized trial of 80 patients with acute MS relapse compared oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (48 mg daily for seven days, followed by 24 mg daily for seven days, and finally by 12 mg daily for seven days) versus intravenous methylprednisolone (1000 mg daily for three days) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3061/abstract/5\">",
"       5",
"      </a>",
"      ]. There was no statistical difference between the treatment groups for any of the outcome measures.",
"     </li>",
"     <li>",
"      In an assessor-blinded trial, 40 patients with an acute MS attack were randomly assigned to treatment with either oral or intravenous high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      at 1000 mg daily for five days [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3061/abstract/6\">",
"       6",
"      </a>",
"      ]. At one week, both groups showed a similar reduction of gadolinium enhancing lesions on brain MRI. At four weeks, both groups showed a similar improvement in clinical status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The bioavailability of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1250 mg) appears to be equal to that of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (1000 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3061/abstract/7\">",
"     7",
"    </a>",
"    ]. However, one study found a higher peak concentration after a single dose of intravenous methylprednisolone than after a single dose of the oral formulation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3061/abstract/7\">",
"     7",
"    </a>",
"    ]. The clinical significance of the peak concentration for efficacy is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the beneficial effects of oral glucocorticoids for acute MS attacks discussed above, some clinicians prefer to use intravenous glucocorticoids (with or without an oral taper) because of evidence that low-dose oral glucocorticoid treatment is associated with an increased risk of recurrent optic neuritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29944?source=see_link\">",
"     \"Optic neuritis: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, oral glucocorticoids are still widely used for MS exacerbations (other than those associated with optic neuritis) because, in spite of the empirical evidence, there is little theoretical rationale for oral glucocorticoids to worsen MS.",
"   </p>",
"   <p>",
"    We recommend treatment with glucocorticoids for patients with an acute multiple sclerosis exacerbation that results in neurologic symptoms and increased disability or impairments in vision, strength, or cerebellar function. Our preferred regimen is intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    1000 mg daily for five days without an oral taper. As an alternative, repository",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/62/2023?source=see_link\">",
"     corticotropin injection gel",
"    </a>",
"    , a purified form of bovine or porcine adrenocorticotropic hormone (ACTH), is available in the United States (as H.P. Acthar Gel) and several other countries. It can be used for patients with MS exacerbations who cannot tolerate high-dose glucocorticoids or have poor venous access or prefer self-injection. Various dosing schedules have been used in trials and in clinical practice for adults with acute MS exacerbations, generally starting corticotropin at 80 to 120 units daily administered by intramuscular (IM) or subcutaneous (SQ) injection for one week and continuing with or without a taper for a total of two to three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3061/abstract/8\">",
"     8",
"    </a>",
"    ]. We suggest using corticotropin 80 mg daily for one week followed by a tapering schedule over a second week (eg, 80 units for seven days, 40 units for four days, and 20 units for three days). The IM and SQ administration of corticotropin appear to be bio-equivalent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3061/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Before starting glucocorticoid or ACTH therapy, acute infection (particularly of the urinary tract) should be ruled out, since glucocorticoids are immunosuppressive and may exacerbate infection.",
"   </p>",
"   <p>",
"    Oral glucocorticoid therapy should not be offered to patients with acute optic neuritis; intravenous therapy is recommended instead. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29944?source=see_link\">",
"     \"Optic neuritis: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term high-dose intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    is associated with relatively few side effects in most patients, although mental status changes, unmasking of infection, and gastric disturbance may occur.",
"   </p>",
"   <p>",
"    An increased incidence of fractures has been reported in patients undergoing repeated glucocorticoid therapy; baseline and yearly bone density scans are recommended for these individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link&amp;anchor=H2#H2\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'General measures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PLASMA EXCHANGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma exchange (PE) may be beneficial in patients with acute central nervous system (CNS) inflammatory demyelinating disease who do not respond to glucocorticoid therapy. In the only formally reported clinical trial, 22 patients with CNS demyelinating disease (12 with MS) were randomly assigned to either active PE or sham treatment, with a total of seven treatments, given every two days over 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3061/abstract/10\">",
"     10",
"    </a>",
"    ]. Moderate or greater improvement in neurologic disability occurred during 8 of 19 (42 percent) courses of active treatment compared with 1 of 17 (6 percent) courses of sham treatment. Improvement occurred early in the course of treatment and was sustained on follow-up. However, four of the patients who responded to the active treatment experienced new attacks of demyelination during six months of follow-up. In an earlier randomized controlled trial of 116 patients with MS, a subgroup analysis of patients with relapsing forms of MS showed that plasma exchange led to faster improvement in disease exacerbations than sham plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3061/abstract/11\">",
"     11",
"    </a>",
"    ]. Based mainly upon the results of this trial, guidelines from the American Academy of Neurology state that plasmapheresis should be considered for the adjunctive treatment of exacerbations in patients with relapsing forms of MS [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3061/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these data, we suggest treatment with plasma exchange for patients with acute, severe neurologic deficits caused by multiple sclerosis who have a poor response to treatment with high-dose glucocorticoids.",
"   </p>",
"   <p>",
"    A small retrospective study found that patients with antibody and complement-associated CNS demyelination, demonstrated by biopsy or autopsy, were significantly more likely to benefit from PE treatment than those with other patterns of demyelination [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3061/abstract/13\">",
"     13",
"    </a>",
"    ]. These results suggest that pathologic differences in MS lesions play a role in the response to PE, but this finding needs confirmation in larger prospective studies. The utility of this approach is further limited by the need to obtain brain biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/31/40447?source=see_link\">",
"       \"Patient information: Multiple sclerosis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with an acute multiple sclerosis exacerbation that results in neurologic symptoms and increased disability or impairments in vision, strength, or cerebellar function, we recommend treatment with glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Our preferred regimen is intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      1000 mg daily for five days without an oral taper. Repository",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/62/2023?source=see_link\">",
"       corticotropin injection gel",
"      </a>",
"      , where available, is an alternative for patients with MS exacerbations who cannot tolerate high-dose glucocorticoids or have poor venous access or prefer self-injection. Infection must first be ruled out. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute, severe neurologic deficits caused by multiple sclerosis who have a poor response to treatment with high-dose glucocorticoids, we suggest treatment with plasma exchange (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Plasma exchange'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with relapsing-remitting MS who have current disease activity manifested by clinical symptoms or MRI lesions should be offered treatment with disease-modifying therapy, such as an interferon or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"      . This is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link\">",
"       \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3061/abstract/1\">",
"      Kupersmith MJ, Kaufman D, Paty DW, et al. Megadose corticosteroids in multiple sclerosis. Neurology 1994; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3061/abstract/2\">",
"      Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ 2006; 332:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3061/abstract/3\">",
"      Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000; :CD001331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3061/abstract/4\">",
"      Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2012; 12:CD006921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3061/abstract/5\">",
"      Barnes D, Hughes RA, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3061/abstract/6\">",
"      Martinelli V, Rocca MA, Annovazzi P, et al. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology 2009; 73:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3061/abstract/7\">",
"      Morrow SA, Stoian CA, Dmitrovic J, et al. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 2004; 63:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3061/abstract/8\">",
"      Thompson AJ, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989; 39:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3061/abstract/9\">",
"      Brod SA, Morales MM. Bio-equivalence of IM and SQ H.P. Acthar Gel. Biomed Pharmacother 2009; 63:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3061/abstract/10\">",
"      Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3061/abstract/11\">",
"      Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989; 39:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3061/abstract/12\">",
"      Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 76:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3061/abstract/13\">",
"      Keegan M, K&ouml;nig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366:579.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1698 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-24EF02F2C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_63_3061=[""].join("\n");
var outline_f2_63_3061=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PLASMA EXCHANGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36985?source=related_link\">",
"      Comorbid problems associated with multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29944?source=related_link\">",
"      Optic neuritis: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/31/40447?source=related_link\">",
"      Patient information: Multiple sclerosis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26265?source=related_link\">",
"      Treatment of progressive multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=related_link\">",
"      Treatment of relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_63_3062="Roux-en-Y limb inversion following Roux-en-Y bypass procedure";
var content_f2_63_3062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Roux-en-Y limb inversion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 623px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_63_3062=[""].join("\n");
var outline_f2_63_3062=null;
var title_f2_63_3063="Dientamoeba fragilis life cycle";
var content_f2_63_3063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Dientamoeba fragilis life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 416px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGgAhoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorK13xHofh/yP7e1nTdM8/d5X226SHzNuN23cRnGRnHTIrK/wCFj+B/+hy8N/8Ag0g/+KoA6qis/RNb0rXrV7rQ9TsdStkcxtLZzpMiuACVLKSM4IOPcVoUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBympHHxS8PE9P7F1P/wBH2FeUab8YLrXfjX4bs9O1vTYvCF+1zbrbK8TSysiMI3kJ+aMvJgImQSAvHzYr1LxQNSs/Gmh6vYaJfatbQafe2kq2csCPG8slqyEiaSMEEQv0J7etZt+5v/Emma/d/DnxJJq2mJIlpP8Aa7EeWsi7XG0Xm05B7g+1AGx4N/5GPx3/ANhqP/03Wdc14i8WeJPDfiDVBqd/pEuj6bpw1ecW+kyfaHh81lMSlrrbv2rw5GMn7tdL4Fh1D7X4nv8AUtLudM/tHU1uIILmSJ5PLW0tosnyndRlon43ZxWhrXhfR9ba+bU7Pzze2f8AZ9x+9dd8GS2z5SMcseRg89aAMDUPiPaWFxdR3Oia2qWUaXF7L5cO20hdmVJJB5u7DBWbaoLAD5lXpWbrvxOgFjq8FnYapZzr/aNpZ380cJgkurVJSyqA7N/yyYgsgBxjrxXVa74M0LXdRF9qdm8txsSOTZcSxpMiMWVZUVgsoDEkBwQMn1rH0f4aaNaS6lNqPn6jPe3V9PmSeYRwpdO5dEj3lEO1ypdQpPJ4zQBT0n4mW/8AZcaalpWsJq6xWW21aOHzLxrjcI2j2ybACUcneUKgHIFWLz4l29ta283/AAjuuyvLdtYNBH9l82O4DYMRQzgucfNlNy7ec4BxtX3gnw/fCT7RYMWeG3g3pPKjosDM0OxlYFGUuxDKQ3PJqj/wrXwyJbaWK31GCe3WRUmt9Wu4pD5jb5CzrKGdmbBLMSTgZPAoAzdV+J1hBp2o3ENlqMNvHDfG01CS3jkguJLVHaQIglVzjy3wG8sNtOG71QtvisLGHxHdeItMngsNP1FbG2uUaCNJi0ULKjb5/lc+Yz7m2oExlgwIrppvh54YmmvZJdOdxeJcRyRm6mMSicETGOPftjLgnLIFJyeakuPAXh2ea8ke0uFN2yPKI72dF8xAgSVVVwEkAjQeYoD4GM8mgDntP+MOg6jLp0Vja3k0l7I8S/6RaIqur7Codpwkh74iZzgg966Dxn4tg8LTwSXgla2Fle3sscUAd2S3jDkKxdQpwTgEHPquMlZ/AuiXMNvDdnVrqCEhhFcaxeSo5Dbh5itKRJzj74PQDpWjr/hvSfECgavafaB9nntf9Y6fuplCSr8pHVQBnqO2KAObX4l2O2aKXRtZh1FZraGKwdITNcGcM0RQiUoARG5O5l2hTnFZep/Grw7pdrG9/a39vclrlZbSaW1jki+zyGOTJaYI53KQFjZ2OOBXQ+JvA9jqtpdGxSC11Gc23+lS+e+zyC3llfLmjZWAdgGV1PPOelUfD/wy0nTdFtLW8nvZ76B55GvrW8uLOVzNKZHXdHLvKbiMBnbpkknJoAxvEvxet4dE8SS+HdPmub3S7N7lGuJLdUbABDmLzlnKYOd2wAgHBPGb+r/FzQ9F1eDS9ZtL2xv28rz4JprUPbeY+1NyiYmTsx8oSYBGccit688B+H76e5l1G3vL4zwyQMt3qFxOipIMOEV5CqZAxlQDSx+BtEjuoLmL+1Y7mJVQzJq92ryhWLKJWEuZcFiBv3YHHTigDCsvHFxrXjjQLXTLW/t9DuVvgbmdIRHeGLaA0eGMgAO77ypnPevRK5rSvA+gaVrCanY2c0d3GZWiBu5nii805k2RM5RNx5IVRXS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFcBp2hQeIPFPjGTUr3W/9F1OK3gjttZu7aOOP7DavgJFKqj5nc5xkljQB39Fcr/wgekf8/niT/wAKPUf/AI/R/wAIHpH/AD+eJP8Awo9R/wDj9AHVUVyv/CB6R/z+eJP/AAo9R/8Aj9H/AAgekf8AP54k/wDCj1H/AOP0AdVRXK/8IHpH/P54k/8ACj1H/wCP0f8ACB6R/wA/niT/AMKPUf8A4/QB1VFcr/wgekf8/niT/wAKPUf/AI/R/wAIHpH/AD+eJP8Awo9R/wDj9AHVUVyv/CB6R/z+eJP/AAo9R/8Aj9H/AAgekf8AP54k/wDCj1H/AOP0AdVRXK/8IHpH/P54k/8ACj1H/wCP0f8ACB6R/wA/niT/AMKPUf8A4/QB1VFcr/wgekf8/niT/wAKPUf/AI/R/wAIHpH/AD+eJP8Awo9R/wDj9AHVUVwtlpUeg/EnSbWwvNXe2utJv5JYrzVLm7RnjmswjATSMAQJHGRj7xruqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+UPD/xA8fatZWD/wDCX3CT3MKOd9vYxICVBPzNCAB9TX1fXyF8HtQtdKv/AAxfX8vlWsMMbO+0tgeVjoAT3oPGzivOl7NQny3dm/I39J8e+NV8SaLBc+KLm4gm1S0tpomtbTbIklwiONyRA8hjyD9DX09XyJFKk3jbR5YjujfX7FlPTIN5GRX13QPJK9SvQlKpK7UmvwQUUVSGracbgwC/tPPHWPzl3dM9M56c0HsF2iiigAooooAKKKKACiiigAooooAKKbJIkUbySsqRoCzMxwAB1JNctdfEbwdbTiF/EmmSTZ27IJxMQfQhM4/HtzQB1dFclB8R/B80ip/wkFjCWGR9pcwA8A9XAHcV1FrcwXcKzWs0c0LgFXjYMpBGQQR7GgCWiiigArlfBv8AyMfjv/sNR/8Apus66quV8G/8jH47/wCw1H/6brOgDzv9orUNQtdZ8LQWOp6lYxS2968i2V5Lb+YytbBS3lsM43NjPqa83mOuw6Tbag3iTxJ5M7sij+1r8cr/ALRYIfoGJ9cV3H7Tl3b2eu+EJLueKCM21+oaVwoJ3WvGT9DXBah440C58E6Vo8eoWwubS4lldjPHsIbpg7s5/Cg+WzWddYiahKSSirWva+nY9l/Z1vr298M67/aF/fXzQ6s0cb3lzJO6p9mt22hnJOMsxxnua7BfGenx61rVhqMM2mQ6SIWnvr2WGO3bzTiPa3mE8nj5gOeOpGeD/ZjnhufCviKW3lSaJtaba8bBlP8AotsOCK6PWvAN5q+pa/NdavbC11SawlWFbE7ohazrKAWMpDbgCp+UYyD2wQ+hwbk8PTct7K/3E2tfEjR4L7w/aaLqGiajJrE7xRStqiRwgJgNh1D7nLEKqAck4yK3oPF3hu4tL26t/EGjy2tjgXUyXsbJb5OB5jBsLzxziudX4dRnX7zUJdSYxXVxezPCkO1gLmGGIqG3HlfKznHO7oMc8/pnwelsbWIf23DLe2n2b7FcywXM2wQPuVZElunRk6/LGI8E5GOlB0HTv8UPCh1K7sbXV7G7mhsDqCNDe2/l3CjzdyRu0gUuoiYtkhVBBJAzjpYtb0uSFJP7QswrTfZubhD++xnysg434/h61x2ueBNY1mXVJrrXrBJtW0R9FvjFpjhSuZzHJEDOShHn8hi+7bxtzwl38MLO7166vZtQmFlcWbRNZxxhQLpofIa6Vuobyvlxj3zQB2Oi69o+urM2iarYaisDbJTaXKTCNvRtpOD9axPEPxF8K6Fb3z3OuadLPZMq3FrBdxNNHukWP5kLAjBYZzjFU/hz4Ek8I3FzNc6hHfzSW8VqkuLreI492FbzriVcfNwECAZPHOBl3Xwzv7j+2o01+K0sr/dJFZ21rN5EUvnrMJGjed1zlTkRiINvYnnGADsbLxf4av7+GxsfEOj3N7MoeK3hvYnkkUruBVQ2SCOcjtzRbeL/AA1dPeJa+IdHmezQyXKx3sTGBQcFnw3ygHgk4rjNT+Gusaz4ks9T1rxW1xFBdR3f2aKCeJFKx7Cka/aDGqnLEEozjd98jiuY0f4a67rNvJpWtmbTdKstKh02wmMEUMpMdxHKjMsFxJu/1S7mDRk54CnmgD2nSNV07WrJbzR7+0v7RiVE9rMsqEjqNykjirtcz4B8Lt4W068gmuYrq5u7o3UsyfaPnYoq5bz55mJwgGd2MAcdz01AHK6l/wAlT8Pf9gXU/wD0fYV1VcrqX/JU/D3/AGBdT/8AR9hXVUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFcf4p8bw6Xc3Gn6Rbf2nqkCeZcDzRFbWKcEvcznIiULlsYLEDIXHNAHYUV88WV/4v8AHlzqtxdeJLyx02G9itdPtdNhaykugdu9wN4k2bd5RjJg7SSEHylmufC6xuY7mOOHU557mCFob2e9aaaBmmO6WXdLG24KVIQAgiLkbuKAPoquV/4Vx4H/AOhN8N/+CuD/AOJrh/DNhc2drPb+HdZl07WbESPFBcvNLaXVt5gRJJreTDQ5KMMxbQCrNkq2D6R4W1w6xb3Ed1ClrqtnJ5N5aLJv8lyAykEgEqyMrg4Bw2CAwIABUtPAPg6zuobqz8J+H4LmB1kili06FHjdTkMrBcgggEEVP4t1i50u1jSwhhNzNuIubsmO1tlXG6SV+3UYQHcx6YAZl3icDJPFfPF95PxQg1TXtRs7XWtInkey0Ozh1B0MB8o7nnUDYj7N8oLKWTIA3koKALWqXp8Q7Dp+3xTaJ5Sza1esJ7RZ5WZBHBY7ljYgkZLNlFOWL/xUtShsda8JN5Wnpe6za3D2cElrC32RI2l2GVJI1EUaGIs4c5MTH+I7RXR6Vb31jNaXPiK0dIrS3ebUAmqyXMl+Irdj5oiQbZdwdFbdjdsUBQqqDp+DfFepeLvEN/o1/Y2FxoBhLO6W8oCoy7khkR1HlybHTIJbJDYA7AGFoGk3PhNoB4e8RWOnbSJJLG6uHk0+5V8rGsfmOzx/dyXBJBIGHyFX07wL4ts/F+kNdWqNb3UD+ReWcjAvbSgAlCRwRzkMOCCD7V5W19bXyNBaXWqjVbe/ug8G5F3Sm4RlijO4ZykeCYjtEXmGT5juqnZ68+h+L/CviWGaa4sdR36HqUkcHkQMiNI0cjRssbRyR/MSdhBjBI25oA+g6KKKACiiigAooooAK5TWPGCjUptH8NWT61rURCzRxvst7QkZHnzYITgfdAZzx8uDmj4gajfRWlho2iTCDV9auPskM/U20YUvNOB3KopxnjeyA9a43xpqEWgRW3gbwU66e7RNPf3cLFpraIkdGOT58pJO9jkAM/JxQ3YipUjTi5y2Rh+J72bVNRkt72XQ/FmpWshEn2iBl03S3+XCJEM+fKerbpMptH3N2GrLbalLEqX+vam8SqyrbWEp0+3jBPRUgKn/AL6Y/wBamsLK30+yhtLKFYbaJdqRr0A/qepJPJJyasVg5t7HzmIzGrVl7rsjP/s6VDm11jW4CeGH9oyzI3sySl0Pfqvf6YzktL7RpvtltDFLImHa50ZF0y+bjnKJm3nYckCSMZzjjiuhooUmjKljq9N6Sv66nZeDPGsk8um2ms3VveW+pqTpesW8Ziju2AJaCWM8wzqAflPDYOMEMq+hV87xQW1pqT6fdSPBoPiGdILkxMVazvicwXcXZXMgRScct5bHo2fZvAGs3Wt+GLefU1jTVIJJbO9WP7ouIXaOQj0BKlgPRh161tF3Vz6XD1416anE6KuV8G/8jH47/wCw1H/6brOuqrlfBv8AyMfjv/sNR/8Apus6ZsdVRXzr+1lBDcar4OS4ijlQQ35CuoYZ3W3PNcPovwstX8Pa3qOu6dFayW2ni9tIlMO9sk4Lx8uFOOMhc+taxp3V7m0aXNHmufYVFeK/spRRw+CdejhjSOMa0+FQYA/0a37V1Gq+PtSsLvxLOugQT6H4enEV7cpfkXGzyI5nkSExbSFWTp5gJwfpWbVnYykuVtHoVFcpJ450u2tb+6vDO1ta3Ulu0ljZ3N2FCIrlpNkXycNnuvox5AJfiD4Zjv7a0GoSyyXD28aPBaTSxK1xt8lXkVCiF9ykBiOCD0pCOrorj4fiT4Ul88/2m8UcMU05kntJoo3SJgsmx2QLIVJAIUk8jinj4h+HDGCLi+Mxm+zi0GmXRut+zfjyPL8zGz5s7cY5zQB1tFefr8S7J9Q120+x3NudMu7W2WW7t7mKOUT+QMs3knY+ZwAh5bAPyqSw6XRPFGla5fXFtpcl1OYC4acWcy27FW2sEnKCNyDxhWJ4PoaANuiuG8V/EnStE0fX7u0gvtRn0eOQypHZXAhMiYzH9oEZjBBIzycck9DWk/jnRIp7GK5OqWpvZEige60m7gjLu21UZ3iCoxPADEHkeooA6eiuQj+JHhV5ZU/tKRUjimn8+S0nSGRIWCyGOUoEk2syj5CeSBWz4f8AEOneIEuTpsk5e2cRzRXFtLbSxsVDDdHKqsAQQQcYPagDL1L/AJKn4e/7Aup/+j7CuqrldS/5Kn4e/wCwLqf/AKPsK6qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5r4izfZfCN9dLq0mkPAA6XaKWCtnChlAJKkkA8HrntUzlyxcuxth6Lr1Y0l9ppdXv5LX7jpaK+V9O+LvjWKZIftkd45YIqSWqEscgAfKASf15r6E8C3HiW80hbjxZBZWtzJgxwW6MGVfV8sRk+g6foOehjIV3aKZ7Oa8O4nKoKdeUddrPV/JpFzxbr9t4Z0K41K6V5ShWOGCPl55nYLHEo/vMxA/HPQGvJPEFratLb+CNHuA+mWcsMms3TxfapGwyPKkp45fPmvMy4JG084Wum8fazbp4tXz4vtUWgWX2yO13hftF9cb4reIZBBcqswGR1kWuN0LTX0rTNDiv5byztpzJqUkt7bG3nnnMLea88yyylJgm6dd2zGxBnOSnUeAaWoabpvivWtYnv9QvL7w4sFrCLiK4W3iYQo4lgMsLbpg5lyyoMB1AzwAee0/RtB8M3lvZWfgiO3v7jT7qO6ktY2uGKFwgKBmZ1aRC6rG2CrOqv2FQxaQ0Gnf8I74mudL1DVL3R7zTzJPayxveTW29klWTYBIEiMX+s5zEHTJ+Zt6bydfs4/EkNprdza28drLGur20hurPa29bizRVKsclAzEFSI8tuQncAQDTr/AE7VrWa4vtcu5Z9QhELwiGK1snKMzWs0hYyG3KhCY0AjOABhjx0qalNo9jpuvXFje6de6ZGINWtZWV2+xhmDNIwA8wIQZlkTdkmRRtDmsy8OmWn9q3Fzrd5qSFolgt7bUoVdZ5GZTtCrEkLo0YVHdydsbKMZO6vpDWtr45s47S6ttSfULiKPVp3m8kyqbGRQXt97FOIWdfkVds6gcLmgD0D4w6oul/D3VCwJN35dgArorfv5FiO0uQuQHJ54454zXlctnpOr20mo+HXhksIIoprG1S0hguokg8kYhl/1/m7Le4j3sQu7ao4jLVp+OPP1L4T+AIZJ5orkX8EUkkCHczxW84bA8yMYJjOSXUBSTwQBU/iKyMuqy6nFoFnOuo3TxvDqELzz38scTRWqCN+YUDtOxfC/JCWJw7CgDnNM8SaZbJoF/Dr+lqNY1CPVbqX7ZKfsBAjj2PKZfMZPmMYR02KJSx+WM563UfFviWJJ9PsT5r3TTWlpfw6fsDXC5DNJlsJsCzEnG1vJJQnBWk0qP7Tq0Gp+G7XVEjJb7VHewW9rPFd+YHaMeZHx5hLiTZwTgoeDUVlZk6ZYaVFFf21hp8LSW1nEy2d3aKzvGh8yQnDK6FVO8eYHYEFQS4BmarPpd1q2kXHje2uvDNi8VxZ3OnfblePULkYbbKIWxtVS21m2li6542h3a34ZlmVNKNxdXTXt3JDY3M+6ae0jZdrswZA2dm1S7ONrGJcHJB1rRJtC0NJ9PnvJtaUmKbTrqeB1muHCRiBro/N/rREBukLEYABACix8P9Kt/wC2Guxcf2pZaFDJHB50z3M0NycFgkzHDqse1FJwTgkYHAAO/wDAupS6x4L0PULgs09xZxSSs2OX2jceOCM55HB6it2vOdEk8W2/gPwpJ4bstJm32Mct1DeTOrAsqsFQr8oxlge3THApf+E78RaWM+JPAuqRRr96bTZUvFx67RggfU120sDVrQUqbT8uZJ/c2n9xlKtGLtK/3M9ForlfDvxB8MeIJRDYarCt3naba4zDLn02tjJ+ma6quetQq0JclWLi/NWLjOM1eLuFFFFZFHGKRqXxbfgGPRdJA55/eXUnb0wtuf8Avv6Z8q0EyyNq814QdRl1S8N5ht2JVmZMZ9AqIB/she2K6vWfGEWkeMvEmoaTardXMxtdFtojJtS5u4xLJM7EZIjiSRAzYJyCvXGeF8RXfiL+1JdYTS7M3c5Bu/7PkYw3IVcKzwt8yyAYG9GfIGCpwCOWviaVOSpzkk33MsVl2IxlBujFuz/pHR0VmaXB4g1jSLjVtHfR9ShspVS606yMxuyMfOuJVj2OoIYIVy2CMg4zDL4m0m3l8m/u/sFwGCtBfRtbyKT0yrgEfXp71XKz5irg61H4omzRSkFSQQQRwQe1JSOUxvGaK/hHWQ5wFtJHU56MqllP1DBSPcCvVvhszG98Vho/K3alHOyYPyyS2dtI456fM5OOvPvXmEdtZ33jvSbPXZzJoRtZ7u4tC4REMGHW4lOMtED8pUkKW2k5wRXq3wujnm8OTazdxyRXGu3UmqGKTrHG+BCp9CIUiyPXPTpW1NaH0eVU3Gi5X3OwrlfBv/Ix+O/+w1H/AOm6zrqq860fxZ4c0Hxb44tdc1/SNNuX1aKRYry8jhdkOn2YDAMwOMgjPsas9M4r9p3SdT1HUvCkumaVqV/HDFerIbKzkuPLLG3K7tinGdrYz6Gue1DxRrt7a6q0ngDxONR1PT0sJ5xZXPl/KMB1j8jIPqN3p0r3H/hY/gf/AKHLw3/4NIP/AIqj/hY/gf8A6HLw3/4NIP8A4qtI1GlaxrGq4q1jjP2Z9Ov9N8H60mqaffWEkurNJHHeWzwOyfZ4F3BXAOMqwzjsa6jUPh5Z3+o6tNPq+r/2fq063F9piPCtvORGke1iI/N2lY1yocA89jirf/Cx/A//AEOXhv8A8GkH/wAVR/wsfwP/ANDl4b/8GkH/AMVUN3dzOT5m2Y3iT4TaH4geVru7v1El1PdtGFgljLSqit8ksTqMCMbWA3LlsNzWPc/C+/t9b0qDRLxrfw9b3On3Vyst4rNO9oI1UmEW/DFYY1JEyrxnbkV2P/Cx/A//AEOXhv8A8GkH/wAVR/wsfwP/ANDl4b/8GkH/AMVSEUbz4ZaJd6ZZWE81+0FpDdxRkSqG/wBIcSMxIX7ysoK46Y5zUGpfDGy1Sxu4NR1rVbue8lWW4uriGzlkfamxAFe3KIFGSCiq2STmtX/hY/gf/ocvDf8A4NIP/iqP+Fj+B/8AocvDf/g0g/8AiqAKDfDXTf8AS401PVktLprOSa28yNlaS1MPlybmjL7sW6K3zYIJOMnI1/C/hdfDkkqWWralLprGQxadP5LQ25d952MIxJwSQAzsMH6Yr/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAZmr/AAv0jV9U1e+1C7vZH1K2mtZUjjt4cJIMH544ld8D7vmM+PrVS/8AhHpepa9bazqusatfahBNBcebOloWZ4WDJhhAGQHaAVjKhhyRkk1vf8LH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAcTY/Ci5u9TktdemH/AAi8FjdWNlZJeCdo0mkjbIP2eMoF8scM0vYZwOe78D+DrDwdaXNvprh1ncO7fY7W3PAwBi3ijB+rAn3qL/hY/gf/AKHLw3/4NIP/AIqj/hY/gf8A6HLw3/4NIP8A4qgA1L/kqfh7/sC6n/6PsK6quAtPEeh+IPinon9g6zpup+Ro2o+b9iukm8vdPY7d20nGcHGeuDXf0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVzGn+NNP1PxK+jaZBe3Tws6XFykBEEDqD8rMe+Rj61N4s8NN4jNtFJq2o2VnHu86Czk8vz84wGbrgYPHfNZ+05k3DU6/qjp1IwxPuJq+q1t00316bfcbV9cLZ2VxcusjpDG0hWNdzEAZwB3PHSsTwp4iufED3LvoeoabZoFMMt6AjTZzn5OoxxzznNbVhaxWFjb2lvu8mCNYk3sWO1RgZJ5NWKdpNp3M1OlGEo8t29nqrL0XV+d/1OX13wk+t6yl1da5q0NkgUrY20vlRlh3YgZPbiunYBhhgCPQ0tFNQUW2uoqmIqVYxhJ6R2/pfmcL4F+Hdh4dvZ9Vvdl7rdxI8jTsPliLEkiMH6/ePJ9uld1RRSp0401yxReLxdbGVPa15Xf9aLsj581c3M3xx8WNtmmtNNRL37Ip2i8mNkkcUe8NuXaZHO5VwhcFjyuNq9ub+O/uPsC2SXep2szQQvBFaSSfuQnnzQMzzSRMqIcIFZTCoKHLbc7x9Pd+GvjkNSt9Zh0mLUNK80vfSKLaYIdjoiuyr9oA8tlOcYzkYzmpF8L75fiLP4v1TVNJbR7fVW1SHVY55nu3izgWpwQCvRBgn7uApDbRZzDYZPF+vaZB/bv9nR6XCGJvorG5meIGOPaYXE0bmMrMVMiAcJh2b5yeb1fwxqbeHtUj8Waz4o1a+sE2W8NxGZLaS2yS0rmORk3rGWlw7hwVi6gDf19rpehw+I5o5tXGmzW72+p2ejXgCRXUzMSJFXcTJJyISyKCJFBwTkNpWmv3umX7RxQa1d3N1a+YbaG0huJTGsYT/WmQFniOUPnZLu42hiKAOeVPH2mfGxbfQ9LvbPwpC0FlHbhDJpf2HbmR8kqFk43Blycnae4bb8Nqs3xMCm5v7q2s7W/kgD2TLEluboxmKOZiu5QhQggkYUAcBRUFpfS6rZz2Nnpbx6IkEtzpjQxvNb3lqD8v7hcRcs2xV2Ox4ZlQ7GNGfWdI0L+x9UtwpsRqNzbRJBcKrXMKQymVLYIqHabokgZALLCV2hkVQDV16yupf2f3v7aJvtuk38usxiNUQjyb2SVmXcpUfJuI+UjpwRwdG4hlX7KfC8l0l1aTC8WTUIQltCXkkFxNKGEZfeHYsYThcoBtRst6P4Q0ltF8LaZpk7iWaC3VJn5IeTGXbnPBYk/jXk2oeHrHwd4k0GC+Ecy6fcXT+GkW4IknWaPEtm6MuwhPl2EuuRsGVAYgAh0+8i1PWdf1nTdZna+kjaxhW3sXjtgYgMwSRS4EUq7JFJkwdkwYFQG2yabqmmaqdDt4NVg8SwanH/AMTmzktY1VJEJnW5cIEAbeoUK331wVztOec8Jar4a8QeLtYuPDtlqGjeIbyZPttlqJVYpHgdZ0maHB3TvtK/ITgNLIQP4u7XUb3V9dM1tJZX7Ga2MVkyllg8q4xJL57LsMh+YhBtO1FAx3AM2OLXLr4i6hbXs8upeFLuyPnW8MoKLdpIMrw25fM+bC8Aq+DnYwFy01GXV/DGkaXbQQxajrbXFukcOXWCzaVzLIzK5U7I8DoQJZFUYzw/xbeJp2mnSoQZtfnkMOmxwMJLydnbMriNl3RKiOxG5wFUJ8w4NdX8OPCT6DZi91bZLrk8KQyMrF1t4l+7DGTzjOWZjy7szEngAA7CCJIIY4oVCRxqEVR0AAwBT6KKAMLxJ4R0HxLEU1vS7a6YjAlK7ZB9HGGH51x0nhrxZ4NDT+EdWOraWg3NpWrSZZVHaOXt7A4A75r06sfxV4dsfE+lPp2qG5+zOcsIJ2iz9cHDD2ORXoYTHTptUqkr0+qa5l8ldWfo0/MxqUlL3orX7jwiy+M2/wCKcOoTRyW2iXFvHY3MDuG8ohmPmZHB2szc91J4zXsPxP16/wBB8F3V9oiRteOVijuJOYrbecec+AflXr6ZxnAyR51rH7PGly7m0jWry2PULcxrMPpkbf616X8OtI1nQPDcOla7dW141ofLt54S2Wi/hDAgYI6DBPAFepnTy2tThVwMrOKs0007dHrv2er/AAOfC+3jJxqrfW589+FtX0u1s7K51e8aO6WAxQiaNlhgUsWdY5MFJGZss8gYs7cnAwB0Q8WaAcY1ey5Gf9aP89q4m51zXNA13xJ4Z0vxXd30b6qQUsoY7W5u7t2w8YI/eLyFXKkZxlSApz6BafAO/vrZJdc8TNHdMATDFG9wkZ/35XLMeSM4XrwBwB+eV8ohiaspuUm/l9x9Bh88nSj7KnTVo/L9dxun+KZbCa71fwhe6XdSwwj7dasqt9pjXc0as6ndGwzJtbkfM2VOOPb7Cez8SeG7a4eBZtP1O0WQwzKGDxyIDtYHg8HBFfNHivQNe+Gev6D9s1GPUdLuLkQxyLPKvlRM6rJmBmZQMvGcqx5CYCjcH90+C8rv8NdGt5jmSxWSwPsIJGiX/wAdQV2ZfTnhnLDuV0rNd1vdfk/mZYqvDFJV1Hllez9dLfgcZ4v+H2saFDdN4I8640yWIrHZeYHnsZcEK0Hmna0ZOMxsRjkqeqm54b+GmrXeh2dxrviHWLHVZIx9otkjs3SJu4UiNgRnPOeQRkAivXa5D4lPJc6bpmiQmVW1vUIrKQxOUYQANLP8w5GYopFyOfmGCDzXpcqPK+q0eZycVqcZo3hXStX1C60bQ/Pu9AEqnXNXuJfNk1OSPO2zV8Y8tTgvswowY8ZZ8exVDZWtvY2kNrZQRW1rCgjihhQIkagYCqo4AHoKmpm6SSsgooooGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUjEKpZiAoGST2qlfarYWFzaW97dwwT3b+XBG7ANI3oB/nt61k+L/AAqnih7SG91C8i0yPJns4G2Lc9MBmHOBg8fy61EpOz5dWdFGjFzj7Z8sX1s39y69u192jU12XUYtJuH0SCC41AKPJjncqhOepI9Bk4746iqvhS11u105x4kv4L2+kkL5gi2JEpA+Qf3gMHkjPNa1vClvbxQQrtijUIgyTgAYHJqSny3fML21qTpJLV3vbX0v0Xp87jVRUzsUKCSTgYyT1NOooqjAKKKKACiiigApGYKpZiAoGSTxiuD+KHiTxN4c0+S60PR7a4tETdLdyS7jF9Y+D+OSPUV4l4ev/EPxM8Y2Om6vqVzPZs/m3EStsjWJeW+VcDOPlBx1IrjrYxU5qmk22fR5bw5UxmHli51IxpxTbd7vTyXXybTPaPjH4Jj8a+HrO4s7W3vNV0uZb2yR5CgmxgtGHBG3eAME5AIUnivL20zQ9b07UGtQhcRWs5vbXyoFtrW4VQgmEJGyVstvZOoiQt8mAfpBFVEVEUKqgAADAA9K8u8Q/CHS3uGuvDttp0RO7/iXX0TvafMTv8vYyvEGDMCgJjOTlM812Hzj8jndIvhYarNcm8+2zXIj0sReJZGgkBVnEUcbNbLu85FLMm0HcoIZt3N5NQmi0ON9Ps7S70l5prmzndkUzNbyebHbs0i4jHmb1SUMxHLYDc1mT+FtS0Y3TDRPEWnhTi0XS7tNTtLdg5kjeKJvLcFZDkArgqzA9sZdvpevWl7Z3dlpuo6jrNveG6iubjwslvuZlkRjI3nIG+/vUZXacZLYAoA0LfSNX1LSLybUcaVbG6DapY+G7x55NxVMCaUFnBwMusIZpCy5PU1r/D3w2/iTxkPE11fPfaFp6hdNPmFormfYgadQQNv3AzrjHnFsjdEGaHSfhhrXiS+u73xsumaZaXrI11Y6YrrPdBEjVRNN5hAUbANi7hgdcktXsel6dZ6Tp8FjpltFa2cC7Y4YlCqo9h+tAFqqer6XY6zp01hq1pBeWcww8MyB1bnI4PcHkHsRmrlFAHmuufCi2vNIk0zTNc1G007YixWVyFvIICmdhQSDeMbiCN+GX5D8uAK9j8LdVSeVr3x1q/kTSiWSDT7eGzSRgAuWCggfKqj5doyucZJz6lRQBg+F/CWi+GEl/seyWOaX/W3MjGWeUDoHlYl2AAAAJ4xW9RRQAUUUUAFFFFABRRRQB534ETTX8beM7q8Wzh106ntEDKqzRwiGOOOQZ5IkC53Dg9OqkD0SsnXfDWh6/t/tzR9P1Aqu1WubdJCoPUAkZArCPw70yM7NP1LxBp1rkkWtnqs0cSkkklRuO3kngYHPTpQBw37U2jTXXhPT9YtVZ3spjaSoBkeVcMi5x6iVIMfjXU/BEkeGtVQspCazegBTkD94Sf1JP41wvirXr+48KaVB4iupPL0Fro62sakPcXFoYTCxyB8rB1mxxklMcVofswatJeaX4ltrpts8t+NVSIknZFcoGAB6EAow47g1xxmpYpxXRa+rt+i/E1cIwpJveTv8lp+p7bXF+KefiV4HVvuAX7j/AHxEoH44Lfrz2PaVxfxHddMn8OeInCiHStRVbl2OAlvOpgdifRWeNz7IfqOwyO0ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArNbXNNGuro32yI6m0RmFuDlgoxyfTrnB5xzUy6nZPqsmmJdQnUI4hM0Ab5whOA2PT/EeoqnonhzTdFvNQu7GAi6v5TNPNIxd2J7ZPO0dhUNttcvzOiEKcYyda6dvd879Xfp6LXy3I4vC2lL4nn1+SFptTkVUWSZi4hAGP3YP3c98e/qa3KKKcYqOyM6lapVt7STdkkvJLZBRRRVGYUUUUAFFFc7488WWngzQH1bULa6nt1bYRbqGKsQdu7JGASAuexYZwMkAHRVDd3MNnazXN1KsUEKF5JGOAqjkk15BZX3jb/haLSW7T3WlXSxTxqLiOS0FrIy/McfcKIjgbcl3bOSo51rtn+JmuvZwO6+DtOlxcSKcf2hMvOwEfwDuf/rEZ1KnIrLVvY7cFhFiJOVR8sI6yfZdl3b2S/RNi2kVx8Tr8Xd/FLb+DLd829u2UbUHB++/fYOw/+vjZ8D+BrXwvr3iDUIFjAvpv9HRBgRRYDFQO3zEjHoq12UMUcEMcUKLHFGoVEUYCgcAAdhT6iNCKalLWXc3r5rVlCVCj7tJq3L5Xvr3btq+u21kFFFFbnlhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFNkkSKN5JGVEQFmZjgADqSa4z/AITW41l2i8FaPNq0edo1KZvs9iGyQcSEFpQCDny1YZ4z1wAcT8ZtAEPiWLU5Pl0nWrb+ybvaOEuGz5Up92CiPOOoiGeBjyDwTrupeBfFcLrGr3tjutprVW4vLfIZ41JPDLlZI8/wlR/fx9OWvhObUtN1eHxlejVX1aJYp7eNTHbW6LuKrCuSQwLk+YTuJVT8uAB4b448JXcGqx6Tq536tErPp18W8salAhzjcPuTx5z7ElgCrMtebiYuhU9uvhdr+TWz9LaP7zo9n9apKknacXePn3X9dz6O8Pa3p/iLR7bVNHuUubG4Xcki8exUg8hgcgg8ggg1NrGnWusaVeabqEQms7yF4JoycbkYEEfka+afgLreoWfjxLCKaSOG5ne31W1mi2AyiIskyp0RyVRWC5U5PJCqx+oq7qVRVI3OOnPnWqs1o15nH+AdVvE+0+GfEErSa7pQA86Tg31sSRFcj1JAw/o4bsRnsK5/xb4dOtLZ3VjdGw1rT3MlleBN2zON0brkb4nAAZcjOAQQVBGbaeNWsLuCw8ZabLol3IyxJdlhLYTyHIAjmH3ScHCyBG6cHIzoaHZUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFN3r5mzcN+M7c849adXL6L4YltvFuqeINUuxeXc/7i0AUqttb8HYBnqT1PfGeMkVMm00kjalTpyjJzlay0Vr3fb9W/zLfhvwxZaFdajdwNNPe38zSz3M7bnIzwmeygcAVu0UURioqyJrVp1p89R3YUUUVRmFFFFABRRRQAyeaO3gkmnkWOGNS7u5wFUDJJPYYryHxR4rPiWeeHRLLU7t4IRc6bPp4e2u4pCpAZ4pgokgfIG8Bk5wwHBrtfiReXNvo0MI0+W70u5mEOqPHEZfKtD/AKz5FO85Hy5UEgEntXMsLLwxo8Pi2TXptfgtrNrPRU2RgFZSmELIAZGPloMnkBTxnNKUlFOT2NKNKdepGlTV5N2Rm3OkfZJovB/h2CytNe1WJJdevrGIxpDEM5Crk7dxZsKCB83Qbsj1fRdMtNF0u20/TohFa26BEQfzPqT1J7k1z/w58OzaLpct5qrebrupP9pvpT13Hog9lBxj1zXW1lSi3+8lu/wXb/M78fWhFLCUHeEN3/NLrL06R8vNsKKKK2PMCiiigAooooAKKKKACiiigAooooAKKKKACiiigAoork9e8VS/2pJoPhe2Gpa6FUzN1ttPDcK9w2R6EiNTvYD+EHdQB1lc3r3jTRdGuvsL3D3urEHZptghuLlyBnGxfu8d22j3rP8A+EFOojd4q1/VtYJ+9bpMbO2+nlQldw9nZug9yej0PQ9K0G1+zaLp1pYQcZS3iVNx9Tgcnk8nnk0Acunh/VfFsyz+NUS10lW3RaDDIJEkwTg3TjiT+E+WPkHffxjt40SKNY4lVI0AVVUYAA6ACnVBfXlvYWU93fTx29rAhklllYKqKBksSegAoAmZgqlmICgZJPQVzXj/AMPJ4r8K3NpBIsd8g+0afcjB8m4UHy3B54ycEd1Zh0NeXeINTX4g3CXWqaaE0SBs6fa3G7dKD1mmjJ284XarAlRnnLECXwQ3/CL+N9Kt9JCwaZrEslvdWKcRCQRM6TInRWHl7Wx94MMgkAjy1mlCpiPqqV76X6en6Ho/2bWjQ+sbdbdfU4/w/PFd/EjwdrMUaQf2xDE0sY7SRyIQM5GSBKy9TkL3wK+gb3xr4XsdUbTr3xFpFvfq21oJbuNXVuuCCeDx0NfKep6tc6H4f8F6jYP5d3FBKsMhwdjs0ahueOC2efToa9Qs9IsbPSl02K2jazC7WjkUMJPUvn7xJ5JPU8muCOYrAUIx5b3clv0Tt/kdEcveLxFSSdtn83FHvtQ3trb31pNa3sEVxazIY5YZkDpIpGCrKeCD6GvEvDfiC48ATKrtLP4PY4mgOXfS/wDprH3MA/iTnYPmXABWvcY3SWNJI2V43AZWU5BB6EGvawuKp4qn7Sm/+AebicNPDT9nM4ePTdb8FsP7BWbWfDaj/kFvIDdWajtbux/eJ/0zcggABWxha6/TNSsdVtFu9Lvba9tW+7NbSrIh+jKSO9W65bU/AXh2+vGvUsW0/UWyTeaZM9nMx9WeIqW6n72ep9a6TA6miuJks/F/h0CTT79fE1gvL2l8FhuwMf8ALOZAEY98Oozj7wzxv+GPENh4jsHudPaRWikMNxbzJsmtpR96ORD91h+RGCCQQSAa9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVz/xC1C60jwD4l1LT5fJvbPTLm4gk2htkiRMynBBBwQOCCK6CuV+LH/JLPGX/AGBb3/0Q9AHNeL31jw1FNM2v+PNRt7e2e7uJrO20kJDGmSctJCgJwCdq5PtUmj3968/gbVbDxXrWp6Vrt0yNb6hbWiBojZXEyn93AjBg0SdGx16g1p/EzQdW8S6fPpdvpHhvU9Nnt2Uf2rK6PbXBDKJUAicHCtxjYwOfm54ow6Nc+HrP4XaRfXz6hc2eotDJcvnMhGnXnPJJx2HsKAPRqKKxPF+s3Gh6Mbuy0+fUbppUiit4gfmZmA5IB2j3+nrSlJRV2aUqUq01Thu9Che/29eePbKK38yz0CyhM00vyn7XI2QI++AvXsf0NdVSKSVBYANjkA5xS0oxtfXcqtW9oorlS5VbTr5vu3f9FoFFFFUYhRRRQAUUUUAFUtbvbTTdHvbzUpjDZwxM8sikghQOcFec+mOc9Oau1578X9Wtrew07ThqmjW97JeQ3H2LUbowC7jjfd5e8Z27mCjLAqeQaAM/4feKZ7/WRYabqk17aAuHstbiMN9AqOUdo5VBS4UOCpHUHq5PFWoVXxl8SHcAHQ/DT7UUfdmvD1P/AAD+Y96oRIvgnwbqWvm11O01WdWtLTT7yaOYW7NK5VI/L4ZS7F8sSxGPTFdr4A0AeGvCtlp7fNchfNuXzkvK3LEnvzx9AKwn781DotX+n9eR6uF/2XDTxX2pXjH7vefyTS/7e8joqKKK3PKCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA57x7rFxonhm4m04I2p3Dx2dirjKm4mcRxlv9kMwY+wNW/C2g2nhvRodPsd74JkmuJTmW5mbl5pG/idjkk/0wKqeKbBr7VPCzBN0dtqhuJPYC1uAD/30y10NABRRRQAV438R9YPinxFJ4fgbdoWlSK1/g5W7ueGSE+qR/KzDuxVT91ge/8AiJ4ifwx4Tu7+2RZdQcrbWULdJLiQ7YweR8uTk+ihjXlOj6eml6bDaJJJKUyzzSHLyyMSzyMf7zMWY+5rxc6xrw9L2cPil+CPWynBqvU55fDH8y1HIkqB4nV0P8SnINJZceNPB/JH/EzbkDP/AC63H+e39DyzCx8P+N9OtrCzgthrcVwZ/KAQPJDtZWx0zh5MkDJyM9BXU2X/ACOng85I/wCJm3IGf+XW4/z/AJwfncBDlxVJrZ6/p+aPcxs3LC1E90eKeMjt8F+DieBs5yMcebD7Hj88+np7eeteH+NRjwP4Q+UYMTYycf8ALWH/ABH6cV7PPqECavFYu7faJ45J49w++qMob8fnXj39jWuYJunC3ef5mOXtKrUv/c/9JRYYBlIYAgjBB71rfCjWW0bVm8I3spaylRrjRmcj5FXmS1/4BkMg5+QkdI6yqzdetbm4sVl01xHqlnIt3ZSE4Czpyuf9k8q3qrMO9Y5ZjXhKyb+F6P8Az+R0ZjhFiaTS+Jar+vM+gKKyfCmuW3iXw5p+sWQZYbuISbG+9G3Rkb3VgVPuDWtX3p8WFcN44hTw9rNh4xtCYiksVhqoB+We0kcIrsO7RO6sG6hfMHO7juawvHemf214K17TQAXurGaJMnADFDtP4HBoA3aKyfCWpHWfCuj6mxy95Zwzt06sgJ6cdTWtQAUUV5T488ezy39jpvhe+khtpr1bC51GCyM/7xiAFhc/uwFPyvIQ4Qug2sd20A9Wor5EsbHWfFdpJqVz4s8Q32s2t1GH8LC7uLczQ+asbTb22lIyHDlxEAoyCB27OSxu7HVba18BeO7qHULwrHZWM32i6hBRWlcSeaXHKywhiuNpO/A3EAA+iKK8x8D/ABHu59cXw142tbOx14yvbxXFlLvtbqZI45JI03fMrqJVyDkEggMSMV6dQAUVxXjrxsNEl/s3SIReay/ll84MNlG7hBLPyDjkkRqd74wMcsPI9T1J/EFtqUOl2vinxZeK7RT3kertp9vbzEshURGRBGFkTIRlJVShZjvXAB9I0V82eGda1u1tzc6Jfa7oY04yR3MOty/2hZPGjpCHnMsiPbHf5hKozYCMeRjd638MPiLpvjmykSFlg1W3UGe2+YB1PAmi3AM0THoSAR0YA8UAdxRRRQAUUUUAFRXdtBeWk1reQxT20yNHLFKgZJEIwVYHgggkEGpaKAOV/wCFceB/+hN8N/8Agrg/+Jq1pfgrwrpF/FfaV4a0SxvYs+XcW1hFFImQQcMqgjIJH0Jrzm08SeLrfWtKtbXUE1YXHiPUNPdNQeK2BihglZE3RW5I+5uLYySoHRjjoviFrWsaR448NnRoUu0/s3U55rSa9a2ikEZtiGYqj5YAsF+X+I8jJoA9Eoryy6+Lccd9oYt9LS4stRNiszpLOZbRroKUEgEBiGA6nBlBI6Cui8F+L73XtXvrDU9Jj0m4t08xbeWWYzsm8ruKvCiFePvRvIM8ZoA7GivG4PiJfeFf7Zn1qye90k6xqUMM6Xpe4XyY5JtghKYEYWIqCH4JHygc1ZHxdvk0tZ7rwnfRT3F1b21mPLvPKnMscj8E2okJURHISNx8y4JBJAB63RXlF38VNVg06W7/AOETeL7Jpcmq30N5dSW0kUaSyRsERodzEiPeu4JkEZ2nivVYnEkaOucMARmgB1FFFABRRRQAV5z4o8OXviPxbrEGm302mW8umwWl/JNaLcQ3alpSqIrgYdAzHcCR+8AKnFdJ8Qm09PBuqPrGnjUbNYwxtc481gw2DPb5tvPbrXAfB+8urnX5bcf2tZWkVu8gtH1VdQtGUStENhkUTJgxsQOmOuOlAGxqdpHqfxC8N+HICzadoFsL+YMc5cAJCCfUcN7gmvSa8/8AhR/xM5PEPiZ/mOq37LCx5/cRfIn9fyr0CsKGqc+/5dPwPUzT93UjhVtTSX/b28v/ACZteiQUUUVueWFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBgXl6B470nT8Z36dd3B4PylZLZR7dHb3/Wt+uNmjaP4xWcjjKTaDOsZPYpcRbsfXzEz9B+HZUAFFFFAHkXxPvf7S8eaXpYO630i1a/mXcCPPm3Rw5HqqLOf+Br61xXiPxZB4emI1DTdVa3wCtzBb+bE3tlTlTnj5gM9s1smc6h4t8Wai6hWk1N7ZfZIEWED/AL6R2/4Eat18PmleM8ZLnV0tN7bf8E+wy6g4YWPK7N6nk2ua+niLW9D1LTbee3bSp2eJLtPLa9LBQ0UR5XcVBIBYE5XAwcjqNV8Ubr7Sn8PQ3lxqsFxKY4jayxeWzW00IdyyjaqvKpY+me9dTfWlvqFpLa3sEdxbyjDxyLuVh7iuEu7GeTxKNP8ADt3qXmIVsIFkvJZYvtkw+UbWJBWGIPMeuPl6YwXhKsalSHs42lHbqt+vzf8AwSMVTlThL2krxlv0fy+SOT8WTxX+mJpOwomjrBPpr7T/AKZaRsIZW+XPAaIycdVXI4ruvihC82g2uu6bd+VfadOlxb3KENvWQhGXPdWDAkc52gd6ofGiFfCXioxaK8duNK0zTILaWYBhGBJLHls+qswPThj65OPefY/7FeJAsYDN9nga+zpEsvzDfDKoOw4JKxuyYLcDgEehi8N7GpBRekX990r/AH/q9jzMFi/bqqpLXRfcrp/K9vkj1HSbpr3SbG7dBG1xBHMVHQblDcfnVuvHYr2bwwI9R0kReVagNqGmpHJbyLC3AYxs7o6jjEqNgHqSpYr6xpt9banYQXthMs1rOgeORehH9D2IPIPBrwsThnS95axf9W/y7o+gw2IVVcr3R0/wavPsuo+I/D7n5I5l1S2BOT5dwW3j8JUkP/AxXqNeJ+FpmsfijoEqDC39vdWEhz94hRMg+o8qTH1Ne2V9rldZ1sLCT3tb7tD5LMaSpYmcVtv9+oUUUV3nEcb8JU+y+DU03crf2ZeXengg9VindFz77QP5967KuL+GKsYfE9xtKxz6/elOOCEcRsR/wKNvXnPToN3xfrcXhvwvqmsTrvWzt3lWPODK4HyRj/aZsKB3JFAHEfFbxdaWlpqtlc3FzbaLpsCS61e2jDzVEhAitIueJZMgk/woR08xWHLaPaaxfaXdavYXi6VHA0cEOkR7YbeFI5CBbNsUM4TztzNGSJThMfKN+HZeRJdz2uo3dtNJplysE5mj+W71eaeNriSTPyyQoVjTdtHlo44yFFd9b+Dk0uSzsvC6WmlJFexz3mmeUWhf51JlG0nI2rKi5AHzqWwY1wAY+pX13qHi/wAPapq0d94deM3Fvb6X/rri+knxFL5MqNs2JuilB9mY8JlamhXniKz0vVDdeK7W9sRBNaWt/qKG1vtNucMDDcyLG6BRgncSSzhMDlax/EvjDUtVtv7TvfD8ttc6JF9qtNN02fMwe5ZLeNC2z/XbpPNVkQrsIA3+YdvT6HrF9ceFNYutY06DUoDfCG1a8uIvOe6LLGuTsMXyzmSBJVBB8tOAoLkA4rxpp/inX/AulNp0OoyeKtA/4l98beJxKJ7VkkWTeQCYmQrN8u5pG8nauVJHr+ufEi10v4N/8J2LWSaNrKK4S2yMmSQqqoTxwHYAkdgSAeK4jV7aHSZ9R07xb4i1H+ytLsPP069tIHSUIx/0iK5RFaNwA1sSHjAw/Cgbq850iDxLqGsaT4UuoLS80PwNcXIctcuizTK+IJZtjbokQSKy552RTH5tpUAG/wCF/Ck9zrsA+JMZ1O51u2a6s7q83nTXup8L8wbYyT+XGgSNcEKQAqFCT0d+uoeDBrs/g3wjdXd+9uslxDdzyOdyT3Ucc8caIWkdguS3mBsPESc7npsltf6p4ug1uLUbi0sdWeIa74V1O3N1amYRCMRiVf3SO6+WEDlSzeWcHKoG6He3dlpWmWXhbw/pvlX9zd3ekwz6gjFHRGk+aGTdIJcO1tKBJhGDNhQQaAOo1Cy1pZtXvbyey1Wy/tNruOLWbhIrK1tvK8ryhIoLKzCV87ldcIQVBcM/N/EK81W3nTxXaaZaaV4k0ZYjKZtTP2YI8qKYR9xXWSM5aUphdoAYlcxu0LS47jwjrGj6xfXviCFlMEGnXvkxZMCvJbwSFvKlkkIAlLgAMAuGKqS21p2rQa5rGpaZo1miQ2cy+H5rJ7GOGKdIBI8iK+JD5QVkT5lRQJMA7nXAB6R4U1y28SeH7LVrMMkdwp3Rt96KRSVeM44yrqynHGRxkVrV4t8F5Lzwz468SeDdTVIvtKDW7GGO1jgWGIkRNHtjO0bQIh8vBYSEFvvH2mgAooooAKKKKAMAeC/CwspLMeGtE+ySTC4eD7BFsaUDAcrtwWwevWta4sLO5njnubW3lmjjeJJJIwzKj43qCRkBtq5HfAz0rwnw/wDDPW9T0aWWO00/w9O9vqFu06tILq/Ms+UW5HlqVjAXjDOcMCMdK09S+FuqXWm3SW+keHLPzLxbm30yC6/0K2xDsLFJLR0kLHkjylxgENu5oA9CtdF8HalrVwIdE0ebU9FeG2Z209N9sRGkkSqxXoqshG04HHQin2dv4c8L+IbLTdJ0Sz0+71hZZPMsrSOJX8oAnzCuCT8/HB79K89l+Fmqw6leXtlY+Gftj3WnahFdJutm8y2Fv5lvtWJtkTtCz5DHBI+U9aut4B8Tyi4u2k0KPUJpNTmMTl7iAG6SNUUhkG9RsYNkdD0PSgDt7rTPCmi65bX02k6Xbatq1w1ol0livnTyMjuys6rnlY3JLHBx7ipofBfhaCyurODw1okdpdlWuIEsIgkxXO0uoXDYycZ6ZryTT/g7q0EG68sPDd8seqw38Wm3Dp9nZBbyRSITHaIi7i0b8Q8lBnJG6nyfCDXzqWtTpqFus139r8u8S5WN5VlJKxTKtqJGQDC/68gAZUD7tAHp2j2fhqe81jQbHQrGCPT40sp4hZxLE8Uq+b5YA6p85JUgDJPBzmrNt4s0q4n0SGyaWePVZJ4beRI9qAwhi+4Ngj7jAYB/Lmsb4beE7jw5da/LcaZoul2+oyxPFY6U5eKIJEEbJMceSSM/d71y/h/4Sx2zaPZ6ponho6ZYXl1NN5K7jepIsgjMkZiA3JuUYLMABwegoA9hqlo2q2Ws2P2zTZvOtvNlh37WX545GjcYIB4ZGHvjjivEbr4TeK5o/DyNcaE0ulRWSR3YIWePyZQ7r5jWzSspHC7ZIwMkEEE16J8LvCLeDrPU7NtN0e3WW7lmju7HiS5jeaR0Eq+Wu0orhANzjA4x0oA7eiiigDkPiZf3Om6PY3NpdQxNHfwtJbveLatdoCSYUkYgbicHBI3BSp4Nc7budG8FeN/En9mWulTai8k8UcawmUHyljHmvFkM3m+Y33mI3EZzmud+KSeItX8Ri3utIvobexaQ2t9a6Y1/FNC7wMFZFcMGzEwJG0gcAYO6tjxbZpB8K9I0mKW4mOsalEjvcWzW7vJNO0z5iPzJ827CnJAwOetZVpONOTXY7sspKtjKUJbOSv6X1/A7zwDpn9j+C9Fsdu147VC4/wBthub/AMeJrfpAAAABgVzt/wCNvDun6xqGlXmpJFqFhZtqFxCY3ysCjJcHGGwBnC5PtVxioxUV0OavVlWqSqy3k2/vOjoqK1uI7u1huLdt8MyCRGwRlSMg4PtUtUZBRRVJ9Vs01qHSWmxqE1u90kW1uYkZFZs4xwZEGM559jQBdooqlo+qWes6fHfabN51rIzqr7SuSrFW4IB4KkUAXaKKKACiszTtat7/AFjVtNhSVZ9NeNJmYDaxdA4285PB5yBzWnQAUUUUAFFFFABRRRQAUUUUAYmtTxWmv+H5DCrz3U8tgshHKI0LzNj6m3StusXXrFrzV/DcqbT9iv3uXB6hfss8WR+Mqj8a2qACiivPvhNq9zf3njewvZ5JpNO8Q3McRZi22F9rooJ9CzDHbFAHmXhu/jj8LHU711jikkubt37ANNI5PH19Oc1iP48vbgltH8Ia9ewHBSVovJEgPdQeT144re8EKU8M2sbAB4nmjfHdllcE/mP8Sepg8beIn0O1trexge51a/cxWkCJvJIGWcjIyFHuBkjJAyw+CnaWJnFw5m5Prpv5f5n2kG44eElLlSS6XMKXxjqlzG8cmmyaEThVNwjTXMrMcBYIQoDyHBwCcDGTkAg43hOy1K91Wz1qzu59GtdNaVLDaUubiV23LLO7tlSzknJwenHH3uw8GeH7jT3m1LWPJl1a5ALuVV5Ix3Uy4yc8ZC4QbQFUAZOb4Z/0C3/sO5wl9p67Cp482LJCTL6hhjJ7NuB5FelgZ0ozkqW6t/wbem3z0t1dDDe3nH6y7p30f4f528tb2Ld5p8+qa8ms6/qNzqmoRxLEjSJHEgClipKRqoJBd8E5xkdwDVa+0x7e4k1HRY4kvSpE9uwAivk7xyDGNx7ORkHHbIraorvnJz+PU9eOBoQpunCKSfbv39Tm7/QbXVfD8GteDt9tOqtPDbAfLu5DqqHIjfO5SB8rHKuGB4r+BNGF3odrrXhDUZdF+1nfdWDRefa+avyuojZtyfMvUMDjHbGOk8FYiuvEFqv3I7/zVHp5kUbn/wAeLH8TWLceb4E8TXV6I2bwtq03mXBjHFhcEAGRh/cbHJ7fgAfFnOalPDp3a2vrddnfd9V+G54c6MKclUktNU7aWe19NvP/AIB2s0vkeJ/CEozuGsxKPo8UqH/0L/Pb3uvBQn2vxR4OiibcJNWSQFD94JDLJ+I+TNd38ItaudeXxjeXMzywr4iure2JJKiGNY41256D5SfqSeM4Hu5Cv9l17v8AQ8TOX/tPyR39UPEGoro+g6lqci7ksraW5YeoRS39Kv1leK9POreFtY05WKteWc1uCBnG9Cv9a9k8oo/DjTH0fwHoVnOCLpbRHuSerTuN8rfi7Mfxrk/j1eXA0HT9Ps0s5zJP9tuLe8VmimgtwHKMF5w0hgX6sMgjNdl4E1D+1vBGgagSC1zYQSsQSeTGCeT15zzXlnx61VrXxl4cs5NS0bTbe40+73TavbrNAwEtu7IQxC5YR4H3jnHC5DgArQa9YeEPhpNo8N9pVx4msreOFnhdrmedsR7y6qBIN7KUQ55/dfMuVqZvDl3q0lzOmgW/huNwt3f2dhqheaVcOfKvYVUK0TqcBFyRhucHFWvB2ow+KvFOgajZWUuj6RZzNb2+meXExlUW7tHJKAd0QAxhMY3AH5jyvmXh/wAa+IfDnxk1a7vtOk1vWpZH0/UbXTIJ4XlVXRIZ2Qlo2CqoUEYx5oyWJoA6m3j1Cyt9FZ9fubPV9IaOKSKFCP7Us/3jQW6NKRGQB5iNIflO0MSxWrugT6t4p02O2vpbb/iSJFDFZQWMcCWdxG5jM8JDTP5keDGgZEVidwUgEDdlv38L+P8AxJbx6Df6xosyfao4tNt0lMJKH7TEQ5XKu7rJsUsNxY4BauKg+Iek3GnadqcdzLpmpG/bU/3CwaeNSj8xylrNPIIlbYqQRyFS4OUzuwSoBNawxy+J7E/2pd39wfDSXKLe6i5F0vlRh4IwdgEZRfNfzFR2OCCo3GtHwD4Yv/BuoazqgkttRTWbiEWmnuUhMcNuHW2JLNkjebdQY94x/eyMNvbC4utFv/F9x4givP7Phu9YSG0DOWV1aaO3kbeHEBQoHh+6fLXDAkg9q1nNZ6db6jol/qN3bTyxTrDb2wmSdppbdo/KZnDLbooY7FYKF3k8AAgGE7XUV1/aP9ua82r2umfZG8OzGOZbiebdJA5m8sxMPlKifbjEQ3t8kga5o9zZWl1a3em2XiS3jNxPe6pbynyzvvEe4kRAU8yVomhX93CVPzA/P8wqrrkl3pDXni3xRbpqF+kLWAuNHmlig2NcRi3gKByWJ3OzOwwvmbcP0q7Z2ms+F/7RItNMn+03k2qXm2aRFtpmgjdtrbSp3SK2GcIMKw/j20AcwL7SvFMvjNdTm0q+1lLiaK6srm4dQthDJA5RZNiSRqmH/iVBIzltw+50enzapo+p38+palJrF5qeu3NxpcNjOqiCyVo45fMd12KYxtBRiDuUIG+dhWVF8R9N8N/EGz8FeBdFspfD+lwyJqUtuCZI5RwIk5+Zy+xMtne74yCrGjwr42i8U6NP4q8P6bf6PaXuqNoYg3xvbs0zLsv5YvlUuHlAYAnd0JbAwAM8WS3uk/FDwL4gH9lJFPq8um3RtHlbzPtShI1MjACTa0T5VcBWUEgbjj3ivnH4peEc+NfBus2d3b3YXVLO7uHeVUaJftMcYSCALuRC0m5snG7Ofmbn6OoAKKKKACkOcHaAT2BOKWigDyfwZ458U3WnaHb3+k6fe6jqj3ohmXUSiAQSEHzAIBtAB2jaGJwCcZOIZPjKY59TQaLFcRQWEt/aT29xOIrpElSMgPLboP8AloDlDIvBGemfSbHw5omn3z3tho+m215I7SPPDaokjM33mLAZJPc96rQeDfDFvNcS2/hzRYpbkMs7pYxKZQxBYMQvIJAJz1IFAHJX3xE1myGowS+GI2vdOu1t7ow3c01vEjQLKsheO3aTGGCn91gHqcc1BcfE3VHvZY9L0DT72zS7s7FLkaqyCSW5t45UZR5B/djzAC2c45CnoO51bwr4e1hpG1bQtJvmkcSObqzjlLOFChjuByQoAz6DFWho2lqxZdNsgWljnJEC8yIoVH6feVVUA9QAAOlAHncHxG1K5uz5GiXM1/BZ6j5um29yskbzW15FbttbyfMb7zMCMcZGxjjEk3xNvorCzu30WzW2d5Eu7prm7EFmyMBskP2Tej4OSJERRj73Ndzc+GdBuUlS50TTJkmEgkWS0jYOJHEkgYEc7nVWOerAE8is+Lwp4Smmit18MaVnTGHkb9LRUhLfP+6Ypt68koeD15oA5BfiTexNqcFnpqX01lJqdxO19qCW4S3trlosRlYcMeOAwGABuck5N3T/AIk3V9qqCPQ410dtUh0r7U16RN5ktukyt5Pl4wPMAPz5HbNdffeFfD2oJGl/oOk3SRzPcIs1nG4WV23O4yOGY8k9SeTVz+ydN3s39n2e5rgXbHyVyZgoUSnj74CgbuuABQBdooooAKKKKAOB8Y/ER9A186VZaFdapJHCZpXjnjiC/I8m1Qx+Y7I2bt2xk8CHxzcrqeofD7C7UudRjuwhIJG2MsPY4z1rlPi1oenQ6g8vivUNdt9BmdZDfJb2NxEsu6TCuGiMwCrIVXhhtJHrnrvFoRfGfw8EbF4xNPtYgDI8kYOAAB+AFY4j4PmvzR6WU/7zftGb+6Emeg15J8R/hdqHiq58U3lje21pf3kNqumzlmBjZI5o5Vkwp+R0mK8Z65xwK9bryzWvF+p+HPG/iadrYX2i2/8AZscivesjwGZmTMMWxg5JIJG5M4HU9NjzSvZfDfVoPElpeOukSNHeWt1/apkk+2QxRRIjWiLsx5TFG53gYdsoTzW/4w8JXOq+MLHV/wCy9E1yzitfs4stWkZFt5PM3edF+6kBYjg5APyjDda5x/jPIltf358Lak+kwiYQ3KRXBy6SiNVkJgEa7iT/AKt5CMEEZ4rTsfiLrd9LY2cPhNodSu7uW2jW8nuLWFlSHzfMVpbZZCOq/wCrGCO45oAxY/AN1qlx4qs5LZpNIs3ltdFt7h2tF/fuk9wwbY/yBsIp2MCAy4IJqbw18Mr7S9f8O6peaT4WuXsUngeNYkiNurTRyRzRmO3VXlQI/ISLlzgjknp7zxmbr4S/8JZbQXFs0tolwIo5E3xkkAgMyMvryVP0Fcvr/j++fxPol4lsbbQLLUtTgmEV4xuLs2tpc71eAIAF3R7ly5OQp2jIoA2/HXgm/wBc8b6RrVha6U5tBCjTX7rKEVZS7bIGt3w2CcOksbZ25yFAPIXXwl1YeGYdEsdJ8IxW8d1cSSTBI/MuFcsYnJktJBGyBtuAGJHR1xW7p3xV1a+htPL8IyxzXtxbQ2jzy3EFvJ5yyNzJLbKcrsGQiuMMCGPSoI/iD4h1LxBZ/Y7G1gshpepPe2zXvKTWt0kLvG/kNvI52ghQ287gNoyAcjqvgvWLG80bS7vTINd1Yro0Y1E21zI1gLd4/OEUxgMQRgjsSZEY7iCrZUV2ngD4b6p4d8cS6xf3MVyCbnN3HcRrLcCV9wE0YtVdscY3Tvgjjg4GHpninWrnxF/a12br7H52i2cIj1Ugr9q8ktvg8nyX3ea25sBhgBNudw2LT4yTT2F3qB8LX401Yme2uNs6I7CVYlSV3gWNNxbOUeQAK2enIBo+IPhzJqXifU9cjj04ajLqOm3VndPu82CKAx+cobblS6q4wDhsgEjtyll8JvEX9qavd6hHoTx39hNazQ2U62i3EjTxyK7CO0G3AVs7/OOTjJDGu18B65eP4k8YReJbm1tZxqsFrb2yX7Twoxs4W8uJnVCSfmYqFHO7rjJ9CoA5b4baDeeG/DCafqEemxSrNI4SwiRI1UngHZHErNjqwjTPpXU0UUAFFFFABRRRQAUUUUAQvbxteRXJB82NHjXnjDFSf/QBU1FFABXkHws/0X4n+Mgn+p1OaeYHpmS3uXjfj1xJHyP8K9frxzQXXT7nRvE0RxbT6/qlhckEkGK5umCMe3EkMIyMgbj7kAGNaQvZa74m0+QBTbavcOqjskxFwv4Ym/z0q0YozMspRTKqlVfHzAHGQD6HA/IVd+Kmn3fh3xDqHie3sXutJu7RDeGOVFMM8WQHbew+V0Krxk5jAAJYA+L3XiXxL4kRjDINGsWJAWBv3xHcGTB5HooXHTdkcfJ4rKK1XEzmrRg3fme2uvq+uiR9ZgcbTeHinq1p/X9XPVHlvbm+Gn6Hp0uqaiV3NHG6pHAOzTOf9WDg44JbB2g4OOms/hJb32nPP4mv5pfED7TFd2LGNbHH8EIOQykk7t4O/jIwFA8D0yLW9Htmh0bX7ixV28yXyt481sdWIkBb8Sep9av2vjP4k6S4a31r7egyMNMd5z3xKHX9etevl2CwOGWlROXdp/hoceLnXxD+NRS2Sv8Amlf8DtNe0nWfCczR+I4VfTxny9YgXFuwyMeaM/uWOQPmO0ngNkgVGjK6K6MGVhkEHIIquvxj8Qaho17pXiLw6ssd3byWzvH8hw6EdUZwevov4V5bpSeVp1m1jDdwfuUzNZTzQpIduS20R7eeSMjJ6+1dNbBL4qck1/ij+rR0087xGEio4iKku/NFP7m1+h6l4T48R+JvvD57Xg/9cc9fxzj0P4t1LAMpVgCCMEHvXjPhq8t9Je5S5utYs7i5uDOk1vdFvNGFyJI512sU/vddvB9B3GkXep3oY6T4isdSKHJhvrEwS7fUlG47DIQjO7r28jG8O4yrJ16dmnbr5L5fib0cwi4c8ouzbd1ZrV33T3O18FW/2/4oaeAGMel6fNdtjoryssUf5qJ/yNa37PFi2neENQtpNwl+3LNIrfwvJa28jD/vpyfqT9at/A+wQ+GJtdnl83VtVmb7aAu1bdomaP7OoyfljIcZJJYkt0IA2PBRSLxP43tEPEepQyhQMBQ9nb+3qp/DH1PsYDDPDYeNJ7rf1PmcbX9vXlNbdDr6KKK6zlM/QdJtNC0i20zTUaOztwVjVmLFQSTjJ7c1538ZFj03xN4F8Rzq7W9leT2sqIE/eCWEsisXwoBeJRkkAEjkdR6pXI+K9L0v4lfDu/sbK8instRiP2a7ibKiRGyjgjqA6g8dQKAMTWtU0zVvCllqLalERA8MtpfRukhSZnMMbEgHc4Z2IwNjncOVznL1Lxr4vtNP0GGbTILKDV5otPj1WZ1e5ilkVhG72nyhXchX2byEDc5wQOE8H+FNC1fT5LDVIrG08dBIYr6bU4ReAyQsBID5smGeQSKWK/wuO55h0Dwz4Q0mwt7zUP7Xm0nWJVuDYWly16ktx5rrbq04273LyNtVMqWRmZmABAB23jLwrrlz4Zvmsde3XJkhmvY3CWtrdAIon3vH+8ijfy3fO7H7zB4AI0PBd5Z+K/Dtnc3WnarY6czqltZ3b+XuAtQfvRgL9n8tyNxPJRc84WsG3jsPtnhnRvHkS3WsQo18NOhdZRZQsrGSa+dsRBEJBUKoCsBtDDmpNJuLmG/sy82qaZepaX1rb+IdTu1uBeeXI5CyphFICMZ49xUYVuqgswAWXw10LUtVh0e2tLXRks5I9UjltDCt5JCWlAhLxhZY0z5Z37izKMEhskRab4SsNV1DV5PBfijWtH1DTp3VVS+S+WOTc28GGSSRi7GLJIZAyyYPR1q/Bcrpnjud73V9Qt5pbGSFbxbMPb6hdLI7pskJZi6hpVWAKOAyKWC8+Y/DvV/GNj4gEd5p9teX2vRvqOkQXieYrRNGQWgnmuRIofy4t8R3HYATtHUA6/XdW8dW6xJHqfg+4hvLeaSCWy1GXT5y6qEXyxI7Rbv3Q6KVAWQEru3GloviTxDregiLx5oviS2e1vri3fVdBgjYJJbyIfMKIrlyGFwjSKgjPmFSDnKbHiDxFqWt2/iG++GrW+r+MrHUlsb+O/skg+xWiyOPKjMuAQzQoSC56swVGOBp6Ne2erSalLrni200TV9Ohntr220+9SKBZmVkMrrneGTYQmJMhVB+QsygA5bUdK8D/FPxzba7pvjK20PXYbL7KtpaEJKl6SSJVmDL5uHlVRt4fbwxBrd8R+HL+TQdH8IeF7SM2+lO97d6zdIYLefUI1ZwPLGTLmXc7gAqu0DJK7Ru3drb+KLHw3LHdWNnepqhm01hcW92uITIxiYrtzhGljKpv2MqsGO0sWajYan4V0RYtAvkkh1K7aG3ZYFllsoijsJNpl2zyQsqnIDOUQ537cgA5G4tLzWfHOh3N4iHWk1Kw0e5mVfKWaOONNRnBidQch41IkAj3eYQUG0Z+ia8c+G3hyxi8dx2mkbZvD/g2yextXeIlze3LB5yXJILBAmcAY84rgYwPY6ACiiigAooooA8RHwn1w2t1BHLo9nObSeCW/gllM2rs8ySA3Q2LtG1WU4aQ/OcEDg6tz8P7qS9065Hg/wW1nbxSxHRHuG+yRuzIRcIRa4MhClTmMHAGG6is3QviXf+G/C0MviHTpLyCSHULi2ukvGmmmMFxt2SIU+QfvFAIZ+F6DpVifx7q1/q3h2e60m/0lbe/ufNhJuIob2MadcSgAzQxMwDKMgpgMoIzxQAl58OPEkssllHJo40uO61e6hna4k85zeRTKisnl7V2NLgkM2RzgdDPrPwulN5oE2jaZoazWcUQubi6Kyq8gZS7+S9u5dyF/1gkjc8AnAFOPxU1uK3e4uvCtkkEWm2urylNXZmFtO7IuB5ABkGxiVyBx96rc3xB1ODUJbHTtKTUbg3GqHN5fiBY47R4gQCkBznzeAQSMcsc5ABt/ErwrqfiCOxufDt9Dp+r2/m2xuJd2Ps06bJQMD7wwjrnjdGM8E1y3iT4Z6lKt9aaJDobaTLcWhjtLtEYrFDbeUAplgmRGBA58tsrkZUmsnVvHHiXV9D8UXtlHFBpyLpdxZ+XemO4hE4gfZ8sYzu3kMS/GSBkV6b4X8TXGpw66mq6fHZXujXJtriO2nNyjfuUlDIxRCcrIOCo5FADvhvod74a8DaPo2qTxz3lnD5TyRsWU4JxgkA8DA6DpXS15Fpfxhu7/Sxe/8ACK3ccd0Lf7BI5nihlaaVY0SSaSBEU/OrEoZBjOCcc30+JWpyXD6cmg6f/bEc95HIjaqy2ypbJEzsJfI3Fj5ygLs7EkgCgD06ivONE+I17qV94eWbQ47DT9YtbW4juri4m2s80Qk8uNlgMbMuduHeMtgkCvQLG8tdQtUubC5hurZ87ZYZA6NgkHBHBwQR+FAE9FFFAHGeJ73wRoXiO31PxHPpkGtvGBA9yd8yoDwY15K891Ayao+OJ45PFPw/v4XDQveOqMRgESR8Hnv7VT+Ia6jZ+LYZvDl3rI1O+s1Sa10q0tZXMULsRIz3BCoMzEADkn1xUXjLUYrzwj4L1uKW4lW21a1eSS5VVlOCySbwvyhtw52jGenFY4j+G36fmellGuLjHupL74tfqepVk3XhrQrvWItWutF0ybVYtpjvZLWNpkx0w5G4Y7c1rUVseaYv/CJ+HPt91ff2BpH227VkuLj7FH5kyt94O23LA989afpXhnQdHEY0nRNLsRHI0qC2tI4trsu1mG0DBKgAnuOK16KAKQ0nThpY0wWFoNNC7BaeSvlBeuNmMY9sVVTwzoKaw2rJomlrqrMWa9FpGJiSpUkvjdnaSOvQkVr0UAYmneEvDemSGTTfD+kWchkWYtb2UcZLrna2Qo5G5sHqNx9afdeGNAu/I+1aHpc32eV54fMtI28uR23O65HDM3JI5J5NbFFAGcmh6SiBE0uwVQ8UgAt0A3RY8punVNq7T/DgYxiqqeEvDaXd5dJ4f0hbq8Ro7mYWUYedWOWV225YEgZBzmtuigDI0/wxoOnRRxafoml2sccwuESC0jQLKF2iQADhgvGeuOK16KKACiiigAooooAKKKKACiiigAooooAK5ODwVbJ8Om8KTXUkivbvG94FCyCZiXM6j+FhId45OCBzxmusooA+ZPip4xvPE+m+GtAumMNyiPNrEScD7TFI0RXjoA8UrD6xsOgrmkVUQKihVUYAAwAPQVR1y6hufjL41+zbdgvJQSBj5lKI3/jyNUj6nYR3Bge9tVnBIMZlUMCOoxn3FeVmMnKoqa2S/F6/5L5HtYZRhSS/q7/pL5Dr69gskVp3IZztSNQWeQ+iqOSar2+rQS3EcEsN1bSynEa3EDR+YcZwpPGcc461Kt3aPLcyiSFxa24laSMhyqMWyOOn+qzjvge1Zel6mNc+16fqumSWcqKrNbznJZTyG6AjHyn2JGK5vq8401UlHTuePi83q0K8owheELX+Zf1jVE0+Jlj8uS8MbSJC77RtXlmY9lABOT1xgckCn6HC9vomnQyrskjto0ZfQhQCKht9LFjdt/Z7rDaXJX7XA480zbDvi2s2WXa3zcHnFadRPkUIqG/X/L+u54ubZlHG8igrJENytyGt7mwlWK+tZVngdvu7hkbW/wBllLKfZjXQJbWniaD+0fDSDT/EFowaS0XCskmDhGHT5uQr/dcdcjOOdvJZ1C2+n273epThltraNdxkYDqfRRxuYkADvyK9S0z4d6Bb2NtHcWX2jUVUedfrI8dxM5ADEyKQ209kztA4xiqpZ5HKrc6un0X9bfmelw5HEWk4/B59/wDLuU/A+rXF78ONW0+zcR6v4i1xrFVt8/6KJYl8yTnpiOKeTAzhhg9Ca9qsdDSz8T6rrEUx/wCJjBBHLCV4Dxb8OD7q4BH+wK+aPgz9ns/jOtjplwkuhQXtyloUffGCYZNqq3tiVQe4Xqcgn6l1PULPSrCa+1O6gtLOFd0k87hEQepJ4FfQynGpapHRSSfpdXt8jtxKSqvl9fv1LVYHiXxXpugSw2s3nXeqXClrbTbNPNuZwM5KpnheDlmIUdyKxRquv+Lig8ORvo2hOMnVrqL/AEideD+4hb7oIz88g9wp4Nb3hnwxpnhyKX7BE73c5DXN7cOZLi5b+9JIeTznjhRnAAHFSYGEugaz4qxN4xmNjpzD5dCsZjtYelzMMGXPGUXanUHzBzXbqoVQqgBRwAO1LRQB5V8W/A01zqlh4w8OWMNzrGntm5tGj3fa4SNrFVyAZgmQpJ5HB6LjnLW78LeK4odf8OXMdiLCbT3urS5ihBleJ3VLdxIf3RI3qhXYu8nJJzj3ivOfHXw0TV9TOt+GbuHRtbYEXWYN9vqS5UiO5UEFlyuMg5wTkHgUAYGm2egWnjrx7Ym8e7129f8AtHUVFn5gW0VFWO0PmhlYksDgbchwARgVbv8AVrjxHfaj4QurSwtNubp5biaOZ7q2SQxrLHbgFcB4wrJLtC9Tnmucl0v4oaJZ6Np2oabN4nttOLOJ7PVIh9oYMDEsyTxgkLt65YglSGyOZtX0Xx14z8Q2uqR+HIvD2qWkc0VtqOo3FvMlssnlh2WJA5kk2hlUsQoBOecGgCx4tv8AVvFhs/BYsobO4vLqQT7k8ye0hWVt1zGJDlI2iLKkm3hxtXaCpHcfE/whPr/hdR4ceKw8SaahbSbzlTbkrsdAR0Dx7k9sq3VQRf8AA/g+38MWzyzXU2qa1cIq3ep3I/eTYzhQBwiDJwi8DqckknqKAPnL/hPtEl8Syab8Q1uPDt5cedb/ANl3lt/okXnfuzI0gx5rFVOZWwmJflPysT2jatbXN5Yah4U1WG7gSSdZLS0ijl/tOYQSSW8ct06ny2CQkEZLjcm7bkV6Pr2g6T4hszaa5ptnqFt/zzuYlkA9xnoeByPSvNL39n/wfJI7aZPrukLJtMkdlqDFJMPvG4Sb8/Ng/VQeucgGHrOp6Lpmr6JZaJFb6nHBHf3NlBbW0MVlA6qw88TLtjQhy0RTd/y1Vnw23dkeD9J1LWpLW48O311qHiPc0U+s3832u10SBmeTy4JkYJczr5m3I3AgsrbFJU+i+Hvgd4A0NFEGifaWHDm8uJJlk5B+aMtsPIH8PavSIo44Y1jhRY41GFVRgAewoAzvDOh2XhvRLbStMWQW0AY7pXLvIzMWd2Y9WZizE+prUoooAKKKKACiiigDO/sPSfLjj/sux8uNJY0X7OmFWTmRQMcBv4h375qrYeEvDenRiPT/AA/pFrGHaQLBZRxgMyFC2AvUozKT6Ejoa8utPhZrVr9qls7fQrV0vrTULaNphLJM8NyJSstyttHJtIGPmErAnOccVaPw61ybUBqOr6Z4Z1sSXV5cSaTe3EhtYzMYysisYG3OoRl5j6NkEcigDvtFTQNdg1AW+kWwjtpG0iVZraPDJAxAQAZzGCSVB6ZPArVXRtLWYzLptkJj5uXEC7j5pBk5x/HtXd64Gc4rgNJ+G8lh4mstcih0yG/TXLu+uJ4t3mvaSxSqsO7aCcMyHacLwSOetT4qfD/X/FniS3vdNfRo4YEg8i4lVI7mFkl3t85t5HKnjASSLGWzuzQB37eFPDrzxzvoOktNHClukhs4yyxJgqgOMhRgYHQYFR3+teH/AA/rdnY3MttaanrkxMSJEd9zIqqpZio7AIu5v9kZ6CuX8D+Cr/QfHOr6s9rpVvY3gmO5HW4unZ5Q4zL9njcJwco7y/wgEBRmjqnw81vVddHiO71kLq66lazR2SFTaR2kE4YRhzF5u4oZGOCoLtgjABoA6298CeHZrDUrey0jTdNk1BdlzcWun2++Qbgx3B42V8kfxKfXrzWDL8I9BfwxFoaSyx2yXMl00n2OydmkcYJCvAUjwAAPLVMYGK5iL4X64I9TcWugx/a7mKaW1a5Mj3aeaZJYZbxLaOXy2+X5WWQ/Lgkg4pvir4Xa1rs1nBaaZ4U0XTIPJaKKxWPdbHzA0+1jabySB8rI8PPUHrQB6KnhXwvoNvaXceh232iygis4buGyM12kYURIA6KZOFwMjoMk4AJrf0rT7XSdNtdP06FYLO1jWGGJc4RFGAOefzrzP/hWUxexv5bfSJdaOuTatf3LFt8kYeSSCBJNhYKGFvkYAGwnBOM6nwn8FXXhE6o15baZCLkp5X2YrNPgbi3m3AghaXlhjerMOSWYmgD0KiiigDzz4q6c1+9gTb6dEysIob261W4sz84ZpIgIAGYYjU7SwB56beefeWHxB8BdQSyks/8AQog6LZWktqkSxlZkwkhLcxlW3HqGB713PxO06DUPBmoG4tLm7a1Q3McdrM0UoZQeUZec7S3AzkEjvXMfDJpr86xajS4Lfw7qEcn2WSCCVAIomNqis0hIYtDFGwwFwOxyCYqR54uPc6MJX+r14Vl9lp/c7nomiXy6no1hfpjbdQJMMf7Sg/1q7XDfBu5kfwWun3J/0vSbiXT5vYo3H6ED8K7mlSnzwUi8dQ+r4mpSWybt6dPwCiiitDkCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqmr30Wl6Ve6hcnEFpC88n+6qlj+gq3XIfF64e2+GXiV48AtZPESRkBXG1j+AY/8A16APmPwj4Ohv/ipc2uus7xnTY7u4i3lWuJpY4JnWQg5xumJIB5288cH3OHQ9Kh02PT49MsRYxtvS38hCitnO4DGN2e/Wud8VaDJY/HeydIDFp11ZC7hkixu8yGIwtGcciPa8ec4BO0dcVofEEvH4aeaKa7gaK5t2L2kvly7DMiuF9SULAKc5JAHOK+I4g56uYQpKe6j6J7f0z2sLKPsXNq9v0OW8SfDKEXV7eeFo7a3fUCEvbKQ+VA6bdu5CqkowyT0IOTxnBrkdV8Oa1N4p0w6to95Yy2WkpZvqWiwCeCWRC+2UxjaWDLtV0wDxkfw16n4lvrr4cPaweI7wanpVzK0Vndo26+I42rLD1lI3AGRMk8EqCeYYPiN4VkR2l1VLTbyFvInt2dezKrgFgfYVp9ZzXAL2FSHPFbOzf4r8mczoYKu3K6Upb/8ADM8a06xTUIrmfVtFvb+7aaSFkGnTSRwkNtWFdy4VjhSc4IJ+Yjium0PwB4pmFzEzQaTZCX9yb1xczqhxkAIxU4JbG5vYjABPo7ePfCgs1um8Q6aImIAHnDzMnt5f38+2M1Rm+IOnbXmsYftVkH8lbqS8t7SN5e6gzyISBxl1BHI684dTNMwxcVRo4flt5P8AN6HLDJsFSfNUnzLtfT8DU8M+ENK8PzNPYRTy3zxeVJdXEzSyOoOcc8KM84UAe1Z2t3C+KtRXQtP8+TTre4I1i4QtHHtVc/Zg4wWZmK7wpwFDAnJxV6z8Lf8ACYeG5dQ1vxXY3+npbySG20I4ijlKNgtMHLvsDcAbMlQSO1UPD6aq/gjw3DoMOnWH2ixikmmdSy25ZFYlIgAHYlmPLAA8ndnB8/F5fXwfLWxErzlfrtbrfy6Jf8A9SjVpzvTpRtFeRxOk3+naDqvjfV74wWd3Y6zpptrOEAMRbu6vHEgxuzbnJ4AG85xtzXv+l+DTNqEWreLrz+2tVjbzIEZNlpZnn/UxZIzg43uWc+oHFeYfDnwtFD8KfiBql8I7zU9Sk1NF1OSJfMmhQNGrZHAGUZsDA5r36vvMNHlowj2S/I8eo+aTYUUUVsQFFFFABWJaeLvDd5fz2Np4g0ee9gDmW3ivY2kjCffLKGyMd89O9bdeB6T4P8Y2t5b+VZarHLaajqVxE1xNZfY4opzNhoTG3n+awdMb+BlunFAHvFvNFc28U9tKksEqh45I2DK6kZBBHBBHepK8ft/DPjLKX011rH9oQTaQIo/7VPlGNViF7uj8zY+cSZ3AkkZXk5OHqOifE241HXpbK31KyW6sL+NI01RmjE7MpgaJpLt8Hg4Kxwhc4wRjAB75WXruvafoQtP7RllD3cvkQRQW8k8kr7SxCpGrMcBSScYAHOK4DxPp+q2njLSNB0TWNQNtrMBN75l9I01tHDMJHnjJJ2eYJDF8uAMpgYXjofGXhqXW/GHhC9C3f2XT5rh53gvXg2BoiFyEdS2WAHfgkHgmgDq7G7tr+zhu7G4hubWZQ8U0Lh0dT0KsOCPcUXN3bWr26XNxDC9xJ5MKyOFMr7S21c9ThWOBzgE9q8Y0vQvHUEnhk3sev3U8VjbxX5k1ICKGQKfMdWW7HmSc9JIpFYgfMoyal0LQ/HsVtaRIup2zxaijtdX+os8ksX2W4UtLGbmdNolaE7UIDHnywFFAHtNFeJ2vh7xtLodzbQp4hsZJIdPjnN1rYmllnW6RrmWFxK3lp5QfgFN2cBB0PongPTdS0mLWrXUZLuS1XUpG09rq7a5k+zFI8fOzM5G/zOGOfwxQB1FFFFABRRRQAUUUUAeQyfGUxz6mg0WK4igsJb+0nt7icRXSJKkZAeW3Qf8ALQHKGReCM9M63/Cw9U/tptAOgWa+IRefZhG2pkWu37OJ9/neTuztbG0RnnPOBmuqg8G+GLea4lt/DmixS3IZZ3SxiUyhiCwYheQSATnqQKs6l4b0PVVmXU9G0y8WeRZpRcWqSCR1XarNuByQvAJ5A4oA4fQPEt7YfASPX55pLnU006SSN3cytJOSwjG5vvZYqOag07XfFOjPplte2mu6jrGpzraxW2t3Gn28IIikkklV7RHYKvl4IYfxrgE16HLoekzaN/ZEul2Emk7Qv2JrdDBgHIHl424yAenWodK8MaBo+z+ydD0ux2Mzr9ltI4trMArEbQMEhQCe4AoA83PxM1K5vdN1WO1trTQLXSptS1WJ7nc5XzzEhjxES/8AqnKjKb93JXHN6x+Jur3bw23/AAiFxDf3d5Da2aXMk9tFMHjlkdi01ujAxrCSwVGHzLhjmu5Phbw+Xt3OhaUXtrc2kLG0jzFCQQYl44TBI2jjBNGleF9A0cxnSdD0qxMbtKn2a0ji2uV2lhtAwSvBPpxQBxCfFG5je1mvtFtY9Omnu7TzYdR8yXzLWORpnEZiX9yGiZd5ZTypKDcK53w34717T9C0nQNat3bXLyOykS7t9RWaUG6nORKJImEZVA7BfnBRCAVwMes/8IvoH2q+uf7D0r7Rfo0d3L9kj33Kt95ZDjLg9wc5pdO8MaDpkMUWm6HpdnFFN9ojS3tI4wku0rvAAGG2kjPXBI70AchZfEt9Q0/TptN0OW9u7zTLvVVtLe4DOIonVIsZUZMpYY9MH72K3fBnixNdske/On2V7JcSQRWsVzKzsY1BYFZoYZA4ycrs4GDnni2vgzwukV5GnhvRVjvf+PpRYxAT/MG+cbfm+YA855GauWOhaRYR2iWGlWFslnuNssNuiCDcMNsAHy5HXHWgDSooooAr38EtzaPFb3UlpKxGJo1VmXBBOAwI5GR07+teI+FLyCw+Ia3Gp6pJ/aEdxJZjTrhrnUdRZCxRXcAiOBDxJlUwVx81e7V5N8Sra38O3mq6oNe1Sxhv4GvZNNsCkDXUsKpGzG5KlkG1ovlXH3WYZ5oA2dGP9hfFrWdPb5bbW7dL+D081PlkUe5+8fpXoFeV+Lr2S+8KaR4vtLSW3v8Aw/eus9u0nmMFSQw3EYf+IZX73cDPWvT7O4ivLSC5t3DwTIsiMP4lIyD+RrCl7spQ+fyf/Buepj/31Klil1XK/WNl+MeV+tyWiiitzywooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArkfizdW8Hw+1q2nO6fUbZ9PtIV+/PcTKUjjQf3ixH0AJOACR11cWiDW/ipLJIUe08OWarEu05F3cZLNn1WFUA9pnoA5nXEuB8SrASktcweHkS9diMMzzHZt75zFLu7cpWd8SIpJfAeu+SIvMitWnVpG27DHiTep7OuzcvbcBnjNaviAN/wtu9e8UxudIhSxwCBLGJXMxz0JV2iHPQMMD5iTdkRJEZJUR42BVldQysD1BB4I9q/Pc8qunmTnbbl/BI93Bx5sPbvc5v4yXU15qOiXQQJZSWJktywAky5BkHXOMCLI6dK8amvtYhuEXypTuY+aqWQkSNRIANj+cu/wDdkt8wU7hjAHNdvrGrWX/CLW/hWbRLa/1bR7q6RWu7qaJ9OgaQtbCKVBudWiKcBhgRgMOBXn+NT03WNOh1fxDDa6LdziA3TQoWte/zM33htDDdySRyATX6RQq+0oxmr2evTqfD4qjH63KN4uT0s76WRqQvewXYvkuri0aNW/02YRQNErKVbZGpcDKlhukkYruJChgGGZpV3psF9Bb6JprXLb/Kkudy70UAAuxY79vGBnAO3C5xXdQz/D2yW5e5uNf1hzbyLHe6paeXYQyFSFcxBUJGcYYq23g5HWuL8M6no9to1rAt1BbTLGvnRXDiOXzAAG3hsEtnv9McYrWDvL/PcxxMHClrr0tH4V69Wz0f4PvJafFa1SwjAS9sLj7cI+AVRkMcjgdSGYqGPPzkZrY+Gt5ZxeGNL0f7RCuoWcDQPB5oLP5TtE0ijqYyyMQRwAQB0rh/BXiK78AXE2qWVyNR064ZJL1J40eaWPPWOVcEbVJKqcqeem4tXX+GtDsNY8DWR1G2hkRmmu7PeSr2aySO8arKMOCqsoLAgnGORXyvFkYulD2ml5dPR/10PouHZJ0+Wm723+86Hw7Y3ep/AjX9L0iMreMdUtYbQEZiPnzBYQc4zggDnbyO1eu1498LbbxR4f8AA+jahYbPEOn6lAuo3VvORFepLMA7tHITtlXJOA+DjHz9BXoHw+10eJfBWjasZI5Jrm1RpyhBAlAxIOPRgw7V7dKLjCMXukgk7ts6GiiitBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeNah8Urrwl4/wBV0XxDC1zpizbopox+8hRwGA9GUbvqPfGK9Y0fVbHWbCO90u6iurWT7skZyPofQ+x5rxX4weCb7xJ8TdOh0tVVryy3ySv9xPLYgsSPYoPqRXZ/CfwHF4Z0y2vbiO9ttWljIuYWut8een3V+U+ozkjPWuChOsqsoNXjfc+uzTC5ZLL6OJpy5azirxXV6q7V9NU9V81qeiUUUV3nyIUUUUAFFFFABXM/EXw8PEnhW8tIre0lv4x51m1xEriOZfusu4Ha3UBsHGeh6V01FAHmHhi/02zv10O/0yLR01uN/wDRtRvjcaleuV5aQAvtXaHGWfrwAOhv/Cu5l006n4Q1BybrRpf9HZjzLbOco34ZwfTIFcn4p8NW2g+KZ5r2bUVttZvRcq9ja/aJLmRJFmSFgAWWQN5m2QDAj+UkbRjoPGxvbH+x/HkWnT2l3YgxahZMys7WjMchipI3LkNwSBk8nFYVvdtUXTf0/rU9TLmq6ngpfb+Hymtvv1j80+h6ZRUNncw3tpBdWsiyQTIJI3XoykZBqat9zzGnF2YUUUUCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK434ev9p1PxneMq+ZLrckW7HJWKCGIA/98E/jnqTXZVxnwuXOm67MCGWbXtQYOAfmAuGTr3xtxxnpjtgAGT8Tbd9P8UeHNdTa8MxbRp1Y42ecyvG4P+/HtIP98dMcvrtfEOjWXiDRrvS9Ui820uU2uucEEHIZT2YEAgjkEAjpXlxbxD4eVbHX9H1PVHi+RNU02Dz0ulHR3jU745CPvLgrnOGOQK+S4hyurXmsRQjfSzS39T08BiY004TdjmPHng2HU7jWbrSBqx8Q3GmSXcUVpcbUlaAxp93BJfEowFIB2AHOa4I6po0Qgha5g82B1EUDktOrrwAEPz7+Rjjdz719IeAHnvry8vLjRr+wjiRYrea9iWJ5txy+1CS6qNqcsFznpxXF/tL3cejWnhTXZELLp2piZtnEjBFMgUH/AIB+HXBr38klWoYKEKq97z6au34WPHzTBUsVWcou3p1OHvvCPii08Nt4g1TTVTSHUmawMbPd28OBiWRBnIOW3IBlVwT/ABAcjDq2ntog0eDX7qTRdzFbBHDLzuLKGC+ZglmyobGSRivY08Opr8S6h4zU6pqNwm94Z2LW9tuAJiiiztUL03cscZJNWPDfiK2+GrtouoFm8PzLJcaWIwZJ45dy7rUL1kLtJuQ5zksD0BrHC8Q4fFV3QS72b2YTyOVGCqU5ON7XSZ5Vqfh7U7nSFMtpdaXbyDy9NtngKXN/cAZVUiIzHEgG9ncKPlUDg5r0jxfZQ2ngs+HdGR1nvEXTtPt42Id2Y4x1zjbuZjngbmJ65u239oX+o/8ACTeLLpba4SGWOCyZo1h0+F3Vipf+J8RpufdjIOOMY2fhvp0uvaqnjC8ZRZJHNbaRAE6xM4DXLE8kybBtxgBD3LGvLr1nnWPhGm/3dPVvu/628rs9HDYaGXYZxW8j0e1t4bS2it7WJIYIlCJGgwqqOgAryrwf4Ot3vPE0mj3U+havZazcQi5sSCsqPtuEWaI5STAnxyAwHAI6161XH+DmA8Y+O4V6DULeQjJPLWcAz/4769u2BX1BxkH/AAk+teHfk8Z6X5tovH9r6TG0sOPWWHmSL6jeo7sK63S9RstWsYr3S7uC8tJRujmgkDow9iOKtVyeqeB7J76XUtAuZ9A1eQ7pLixwEnP/AE2hPySfUjd6MKAOsoriP+En1rw78njPS/Ms1/5jGkxtLDj1lh5ki+o3qO7Cuztp4bqCOe2ljmhkAZJI2DKwPQgjgigCSiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBNq7wxUbgMA45x/kVheNrvWdP0N7zw9bw3VzbusktvIDuliH3lTB+9j69++K3qKmSumk7GtGoqdSM2lJLo9n5FPSL5NT0u0vo4pokuI1kEcyFXXIzgg96uVheMtYvdC0Y6hYaa2orC6m4iR8OsX8TqMfMR6VoaNqVrrGl22oWEhktbhBJGxGCQfY0lJX5XuXUoT9n7dL3G2lre3k/l3tcu0UUVZzhRRRQAUUUUAcd48steN1pt74cv7qBWkFnexRIJMQSMuZkRjt8xCOpB+Vm4OAK2NF8N6dpGn3NpBHJOLolrqW5kMslyxGCZGbk8cY6AcAAcVB4h8SNpGq2Gm22jalq17eQzXCx2TQLsjiaJWLGaWMdZkAAJPX0qr/wAJRq//AEIniT/v/p3/AMlUDTs7ow/A08nhPxHceC792No2650eZz9+InLRZ/vKc/r7V6NXn2sQj4g6Nfpb2V9ouv6HehYDdmLzIbgRRzLhondSrLInf8OK2vAPib/hJNJf7VH9m1ezfyL61PBilHB49DjI/LtXPT/dy9k9un+Xy/I9XGJYyl9dh8W0159Jekuv96/dHT0UUV0HkhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ/iLURpHh/U9SbBFnay3ByMj5ELdPwrN+HemtpHgPw/YyIUmisYfOBOSZSoLk+5YsfxqP4nxvL8NvFccalmbSroBQu4n9y3AB7mtzSpo7nS7OeAqYpYUdCucFSoIxntQBaooooAK8F8R6PD8RPAWv6/4lv55Lm0hvhBpgkMUOlyIrAJIq4ZpFABYscHPCgYr3qvPPir4Dttd0LW77SY5rXxBNZuhktG2G9UIQIZl+7ICPlG4ZHGCKwxFOdSNoSs/z8hp2Of1bxDBo3hWHW9RSRIStsZlIy0fmvGhJAHO3fkjGflIwDxVu40+w10aXenZdR2s/wBrtZYmDKWCMuQRwRhyfrg9qyddmk8SeErCbw/PCk1/dWL2j3CEqCbiNvmUEElQrErkH5W9K6vTfhD4TtoXa7s5by+nkaa5ujM8BmdiScpEVQLyflAx65JJPw2W5NLGUnUjLkkm1+C06d2e1iMX7GfK1dWMCCxk8b68um20MT6FpV9FJqVzIQyTSR4kFsi4O4hvL3k4C4I5PT2FVCqFUAKBgAdqq6TptlpGnQWGl2sNpZwjbHDCoVV5yeB6kkk9ySat19pgcFTwVFUqfz831Z5NatKtLmkFcb4bjaL4m+Mww4lg0+dT7FJUx+cZ/OuyrjI2MXxkuEGMXOgRk4AyPKuHxn/v8cdO/XnHYZHZ0UUUAFc1reoab4G8ORJp2moFaYW9jp1oqxCWaRiwReioM7mZjwqhmPSulrz7xA8V78UbeO88o22i6ULrbLP5Sg3UrwvITnqkcTgDHPmHleMgFhfFuvabcEeIPDQe0Q7JbnRLh7428hCsFki8tJMYbO5A3UZx1pL34qeGY7Ytpst9rN50/s/TbOSa6B44aPAKdf49vQjqCKoeKfE1v4UsdPuDa3mseLblpYNO04XL5uGldJHVWChDGilfn24ATGcg155LqU3h9Itc+IGv2fhrWLgtp0sc8BvlurcI7osSRFZrdV+0ncC24GOIlvmywB3Fl8QPGmozMsPgCLTY8jyjrGspbSSgsEGIxGzfeZR6ZYAEk1l6h8adQ8NTwDxv4Pm0uCSUwFrbUIp5Ff5ih8s7SUcI5DccqRjPWrqfj2O02eM1MOqeDdZcWkup2Vo8bWUURk8sTIT5hJkYox4UqBgISNz49W8PQ2+qReNwbSyuhHcxt4hsh58qGNovKkCxrmUAZXDvJtJ6YYAA9h0XVbHW9Mg1DSrlLmzmGUkXI6HBUg8qwIIKkAggggEEVcjkSQExsrDplTmvlPVLfTtF8Xvq1np8eteHpXlluNOW+byrhUG2WQrL8u6Jo2Jx+78oQZK5BburuPTtN8N2/jPwp4b0/TbmNbGW1uLdIoAGmljins5Io8ZwMqTJkq0nG3ZkAHulFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVleIr260jQ5rnStNbUJoANtrEwQsuRnbx2GeO+MVq0UmrqyLpyUJKUldLp38tNTK8M67ZeJNHh1LTS5gkyMSLtZWHBUj1B49K1ar3fnQ2U5sIY3uArNHGzbFZ+SASBxk9T71ieDPEU+uwXMWo6Zc6bqdmwjuYJVOzcehR+jKcf54JlStaMtzeVB1IzrUlaCe102k9uzfa9rXOjoooqzlCiiigDldS/5Kn4e/7Aup/+j7CvEfD+s+GvEHx300eEjpmg2Ojzzpd3k1wsN3rE8hI8oKx3yru6bs/hwD7n4j0PVbzX9M1fQ9TsbG5s7W5tGW8sXuUkSZ4WJAWWMqQYB3P3jUX2Hxx/0MPhv/wQz/8AyZQAeDf+Rj8d/wDYaj/9N1nWV460i90jVk8Y+GojJfQJs1CzX/l8gH/s6jp9B1xg7/hLRL7SH1m41W/tr691O9F5I9tatbxpiCGEKFaSQ9IQc7up6CugqKkFNWOrCYqWFqc6V09Gns090/60eq1RneH9Zstf0i31LTJhLbTrkHup7qR2I6EVo15prdldfD/WZ/EGhwSXHh66bfqmnxD/AFB/57xj+Y/pyvoWm31tqVhBe2EyT2s6B45EOQwNTTqN+7L4l/VzXG4SNNKvQd6ctn1T6xfmvxWqLNFFFanAFFchr3xL8GaFNJBqfiTTUuY2KPbxS+dKhAJIMaZYdD2/mKpW/wAXvAc1wYH8SWtrKCylb1JLXBU4YfvVXkEEfUEdRQB3lFcuvxC8GtjHivQuTjm/iHbP97/PStbRtd0nXIml0bU7G/jXhmtp1k2n0O0nB5HBoA0qKKKACiiigAooooAKKKKACiiigBGAZSrAEHgg964/4TN5Pg6PSy7M2jXNxpXI5CQSskf/AJDEfPvXY1x3hFha+OPG2nBdoa4ttSUDptmgEZ9877dz3HP1AAOxooooAKK5bx34tTwzbWcVtatf6vfTLDZ2KNtaU5GST2UDv9K6hCxUFgA2OQDnBrWVGcIRqSWkr2+X9b/5EqabcV0PGNL8G3dp8TLTSFvrVtI0+5m8QKgMiznz3k2LjGwBZPMHBAKn7oJJPtFee6Vceb8ePEEQYHytBslPy8r++nbGf+Bf5xXoVc9OnGmmoK12383uW5OW4UUUVYgrjbRVuPi/qUqNn7HotvCwA6NJNK2CfXEakfU12Vcb4ICXfijxrqandv1COxU56LBCgI6f33k/P05IB2VFFFABXnfiJVtPibNPd3ENpY3vhyVZrmdVZIkt51Zyd3y/cuG5YFRgEgjIPoleS/HW2kk1HwgYrxbNr67l0bzjO8LJ9oVWyrqCQ37gAccsyg/KWoA5DU30jWZp/Fvi/wAPa1LHcTLHpU8BMZ0m0CwtAxAkXynkkywcZ27sMQAVHnPxM8L+MzqQvL/SYfEOoaJftqd6iKJ4XtpRDHArBVjabBtZUchc/IS3Br1ltZu9U8HzeG47VNUvr+w/s2xuFuPtNq6vmAzs0CySRISrNlyMklN2FyuDrHhD4heE722udJ8c6hcs4WGYNC22KIbyUghlL/aXXEj4B8zZHxkyCgDkPhZ4a1XTW8XpPpV3ouh38tpLZ6frVswa4eCcTqXO0YhVUcSMAdokHDEDPYfGvXPD8rz+FdYskhttOgh1E3Ooi5eO6uXQRRlng3uEEXmfNnl1QdFO7qdchuLnwFB4kl1i4/4SGOxjuLHUrHz8z3MiROIoYWOySOQxKPLKgFudqk5qXwrfM1zHpt54Tv8AwvqCARM7eU4ml52rA+WknwJJHLYKxqGBHXIByfiazzLpkmo32nwaZDNa2tlp97cSXsy3P2WVIITC8UYtpJFkDs8rHDIhyAtVYLu807TdVtNE0FbfRLiWPW9LtLrU/tF2JLSaC4uItnzODIsauULHD7vmO9cdHcm9s/FjXM2gXd4bjTrS5Mdu8lvfXLPJFDN5kAlaPy4lIJQptyRggFmq+tiJvFHg3ULk2cFz/aN/YaXHp9rHGfsaWs3lyKHLLnEatuUBcSKCBjFAHsOn3ltqNhb3tjMk9pcRrLFKhyrowyGB9CDVivLZGh8G6rJrek3D/wBmXE7jWrGUqd22URPfxrH8sZVmzLwAygsQGXn1KgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDltNufFNt4pms9UtLW80adnkgvrc7Gtx2jkQ9ewyP/AKw6miuX8WeG7/U7231HRdcu9L1G3Ty1A/eQSLnJDxngn3+lZ2cFpqdilTxVRKdqelrpO1+7Sva/Wy87HUUVQ1jVrLQ9Ma+1e6S3toyqvKwOMkgDgZPU1Ysru3vrWO5sriK4t5BlJInDKw9iKvmV7dTmdOah7Sz5b2v0v2uT0UUUyAooooARlDqVcBlIwQRkEV5leWN78Nb+fU9Ghku/CUzGS8sE5ezbvJEP7vqO305Hp1IQGBBAIPBBrOpT59Vo1szsweMeGbjJc0JfFF7P/Jro+npdFXS9RtNW0+C+06dLi1nXfHIh4I/ofbtXzl43uvG3xM1XVBZl7LwXpjFZbKK48lr3YAZUecHacYdCVLIj7QwK5kr0/wAVNZ3cl34L0iWDStItLQ3etz2xSNreBySsKZwFaXbISx+6inoXUjy/w1cX0AutJ8IambHSbaWPSrWDVdPjiuPtT3Ci4miRWjlPkwyxOXdcknJwckWr213Oapyc79n8PS+9vMs+K18HW/hV/C87aV4YsvtgEA1CIJPGQuFaJAZGKtIuJJZMcM6nlcDTvvF+m+J/Dks2onSdW0SaSNL65015JhawKwZGkjIEsJLfaADtARXQ72Kc70+jDQtas5bae1ury9mnheL7NidQ6y3L7JUj8yLJAfy+gMzDklDWCZ9X0m90+81qzub3SLmSCW5vrqzSCSOSJZfJ89o9s0qiXZlpIUCqASMlqZBN8PtZuNA8UyeGbnWdMvNGu5N+lTTT/NbREZa1PUb9rq0WcqyKxGM4rtdQ8Kf2pMt6Leaz8SKJZLXVoUWNojvAjMoyd2AzfuslGUNuCkqq8drfh3QPH/iR7maO91KztbRY0kknFu185eXzULqVdQgypjIUBmQEKvLZ+ieO7Pw5qeoWOsTJdaFbCSXSNQuDIzzrCqzLbMz9W/eny2yWwpB3AgsAe2+FNUfWvDtjfzxCG5ljxcRLkiOZSVkQEgEgOGGe+M1rVg+BNLm0bwdpFjd4+2R26tclehnb5pSPQF2Y47Vb1rX9I0Pyf7Z1K0sRMGMZuJRHv2jLYz1wDQBp0Vgp4x8MSDKeI9GYcci+iPUZ/vehFV7vx94StVJk8SaS7c4jhuklc4znCISx6HoO1AHTUV4zrPxiu9XuIrL4caM98k0iQf2zqUcsFlC7qWTjbvcEKecKB8vODXM+Irj4u6dr2jW2oeNdKtYNUuYrMTWtpF5dvMwYsm10ywBQgHOGOV4J4APoyivDPFtz4+8J2yalpfjeHVuFC6Tq2mxo0jjl182NUxhEdiTjAQk8c10umfE68tdIhm8U+Gr+K5eFrhZdKK3dvJEuP3m7IMYIIYCQDhhyTkAA1LPxD4g1C1PiLTrS3ufDxZ/JsURxdz24JH2hWPBZtoZIsDKty24hR2djdwX9lb3lnKs1tcRrLFIvR0YZBH1BFYOlwRaXpcGnRLJ9n063jt7SOZGhRyhEaBpCSCxeMY9nHBzkxeEEbS9Z1vQyFWCN01G1VWyEjnLbkHA4EqTEeiuo4oA6quNuCbP4vWbs+E1PRZYgCTy9vMrAD8Lhzz6cYwc9lUMlrBLcw3EkETzwhhFIyAsgbG7aeozgZx1xQBNWP4s8Raf4W0S41TVZdkMYwqD70r9kUdyf/r9BTPFvifS/CmltfaxOI0+7HEvMkzf3UXuf5d65Lwz4f1LxTrFv4p8bW4hMBJ0zSTytqp/5aSZ6yHA69MDocBe/DYWLj9YxGlNffJ9l+r2XrZPGpUd+SG/5epP8PvD+oXmqTeMfFke3WrtdlranpYW/ZAOznuevPbJFeg0UVhicTLE1OeWnRJbJLZL0LpwUFZHkvhhnb9ovxZIZGZH0+OBADlR5S27Hv1zcH/Oa9aryDw+s4+IsWqjaUuvEGp6e2AD8oto8cjuDZ9Pc9etev1zlhRRRQAVx3wkR38CWN9LH5c2pvNqbgg5PnytKuc99rKPwrsap6LYx6Xo9hp8IAjtbeOBQOgCqFH8qALlFFFABXmnxuaeM+BJbSPzJk8T2uFGMkeXNnGSOcc4z1Ar0uvLf2gtPu9Y8OaPp2jytHrT6gbmxMYUyebBbTzDbnoSUC57bhQBzet2GqXHiCC0jfTINQigS40nRdRlMf2ny1kiuGk8g+TuaOeTITGCMFSozWRf6b498U6LYzaB4u0pDfQzwltKDtZt5rNn97+8kXaiBRujRU2bVYMRnZ8NalpXinTLk+EzrOj6H5/mPc/uoFvrhwjebvuQ5Z43TYxUcuQckHjKtdIh+JngW/wD7Smk1h7LUrnR7CS3nNpHcQAo0ckjRxssZICsMJ5bkRblJ2lQDSihhex0e38GadaFtN1NzcWXiB5Y5rcFUVPLM6s8cjvJFIHjXaHYZJ53Ri3vvHejpeww3WlXumtJps/2ebbNp0wuYVu4odqAHcigiUSSMQWCqzZFcn8NbbUdP8MTy6HZ6q+jQTGOGXXnQPpXzRm7SHyCJpDkOSgMIbYRguSDNpkWo6PY+IZH1fw3Y+GI7ic2dxqUe+TTLm7ikxBDsLrGVZoy6ZcbWLccigDcstP0F/BcetXmp3F9qNvps2qPqcmuPb3QupESOWNyGxFgpFGFIlAEe0qD/AKxvhuXStS8XeAvE2k3eq6xfajc3FxJJeFVWEtYzJ5ZIjVA7NFtO0cmIg5CLt0dEtk0awm0jxH4SS/tNMt5fNuIhbvb3BkuTcLbQLMiGRVEeAF2gMNu3hXGPbpdeKZfDunaD4t07TLS7kOoadb2yCSay862mR4F2EbRHGs+xhswwIYAhdwB6T401NtUstZ8G6Na31xrU1u8QV1PkwxTI8fmzSsSCoO9ghIdtowuPmr0OKMRRJGpJCKFGfaszw1oNj4c0wWWnI+GcyzTSuXluJT96WVzy7nAyT7DgACtWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAjnhiuIXhuI0licbWR1DKw9CD1qloeiaboVtLb6RZxWkEkpmaOPgFyACcduAPyrRopcqvctVJqLgm7PddDltK1bxGPET6frOhRrZOztBqFpPvjCjJUOp5BxgZ7k9K6cuiuqFlDtkqpPJx1xTqwPFXhLSfFCQf2rDIZrfJgnilaN4icZKkH2HXNRaUY6avz/wCGOhzo16sedckba8qb+dm/v19Eb9FUYreXT9FW3smkup7e32RNcyEtKyrgF29SRyayvCusa3qE9xba94fk0uWFQRKs6yxS5/ukfninz2aT6maw7lCVSDVo+aT9Um7v5XsdHVbU7630vTbu/vpPKtLWF55nwTtRQWY8egBqKbVtOg1BbGe/tYr1kDrA8qq5UkgEKTk8g1zfxln8j4VeKjuVTJp8sALOEAMi7ByfdqpNPYylCUbOStc8b8u48a50OO1jupLxp9V143BnEAnYIy2PnRrx5P8AoxddwJMKICDuqrqekfa7zQZLrUNM1DXori9ivLa9vLeOSa5uIYoCNm3y45IpFh/dDeDlWVnJNaHhjT7fQ9TtdLji0xYtXlmWSxs7tr5NQsmQXBkETbQFyrKuwMNksqnLgMdHw/4w8JRaBr58XahpVvMmpXNvrUMSvKtw4mkQYQks6tHsC7Q20KfugUyTE01dM1jVYrBrlL7QU1D7PdaoZJ4ZYTuKxwuWG+3lWT7Mqk5WYW6DcpTaXf21pOmeNtK0n4X/AGA3syxafqM9rbfabSzt3nRopPNBI3lnYEKdpeTk5QE8/wCFr+88RyNJpemSado2qTx2N9rk1quoX11Hw8SSwrlCWbCGZ4yGz853A7urfSrKGKSL4c6Hd332e6F5JqV3q7KZLzyYZ0lRZHaOabY7swKqMDGRyCAYVh4o8Nt9n04+BTqHgzUNSm0wajLdNPPcTvMgWRGZ9wZ/LVyvyn5cgnFWviH4Z1NfCF8tlrFxdR6e91bQ6dOJDPP++aOMtKsiKx+Tcqlcv82RIRzrXHivRrzxZZm80zRrHxJEk1peXod1ewfAI8tJNkYeRgSsgfGOA7EgMviS5bWLDV4dcS2l8G2ccT2s8k8ktq88UY3RuyuHnUSiQeYi5YxtuVuCAD6CsLlbyxtrpAVSeNZAD1AYA/1rE8YTazZQwX2jxG8toA4vbCIATzRsB88Lf89EwSFPDAkcHaaw7PSdb0SyiPhzW57yK2iVTpursskbEjHlrPgSq+QB85cDd06Y6vw1rVt4h0O01SyDrDOpykgw0bqSro3urBlOOMjjIoA5ez/sfUtFgvrXTdL1GGWAvbFbdfJdQHym58bH++G3dMEEZyK5D4yXTtpi+HtDu7bw690kzahfgeSYbVR8xWLKl97IcFSxCI2M7sV1/iKxTw1rL61ZzRWNjfnZeSP/AKu1mJDC425A2OUVZQCMja25drE+feJYJr7Sbm6udPV7ya2kvB5WoeW8UCukarE8qqiIsK+a/mgsvnMu0bjgAqWEf9r+AvCY0q7gNxpwtpEbTrvMUIjkEZkjjIIlfCsNsjDaXOBuI3dH8SNI1XxsNM0SfTr2LT7qVbibeiHYGCL5qvJG+xo9znygVYjdhgOnM+HNB8N32vahpUWparLYtJPFK6FIMSxSI6M+VxK6hFKFeQoYhSDub0KG/u7+aC6ee0tp9Om+0yx+TJ86CWWFzlmUIHXDgrkctncNrEA8o17x/f8AhrWprXwP4K0S/wDCFrLctdXGfNMkkYd7jL5AjfykYhCCcdMgha9DglS90e2ZdJu7vRdb0xNQjsPK+0Mrshd7fcXGMoMRnARSCC2HVTmeOfDuh+JLAapp9xf6bY3kT/2raaJpqyzX6l0+UyIPmAKMflyWVnx8u6tjTrLxFqcVhr2hpY2dzBatBb6ZNG3krBuHlRTuWyJFMYY4QMpO0kDJoAveBvE9zqmy31eNtP1a3ZbZhqE++SWRGZAywrtXLqs25lO3KErvVSRpaZGbf4jW1tEjpBDojQ42MqjZOoTGSexPOee/TipoNvfWXi6S7X7NdidvstwtrZLGY1WN5Fk3+YdqMQihTz8wPKlSun4eiL+NtUMlxNcPYadaWZeZlL72Msj7wuF3EGLoMf0ALnj3xZY+DfD02p353MPkggBw00h6KP5k9gDXj/wz+JniLVbPVLOx0yXWPEd7etcqztstrWIoijcc8KCvCjr6569V8QPhTqPjjxA19qfiQQWcXyW1rFaFhGnfkuPmPc4/QCoPDPwPtNA1S31Cz8R6rFdwkESQKkefUEEMCD6HI+tfVYN5TQwTjVmpVZa7SsrbLpp3s9fkefU+sTqpxVor0+86Xwt4EaDVF1/xbef2z4i/gdhiG1/2YU6DH97Ge/GTXd0AYAGc+9FfOYjE1MRLmqP07JdktkjthCMFZBRRRWBZ514JtBe6dpd8oTA8R6neZQ5BDPeRg+/DAd/w7ei1yvhHQrzR/CNnYXi28l5HdvcP5Zwg33LSEjjjCueB9MnrXVUAFFFFABRRRQAUUUUAFebiCTX/AIra4Znu4m0O2tbaxlt/L/cGbMk0mHyNzBI0PynCqccsa9IrivFGi6naa+2v+H7O31E3FutrqOnSyCFp0XdskikIwsiiSQYbAYNjK4yQDz3xJYp4Y1G81HWbCBvBHiIrczJPK7xWV4wJSOflkWB5GLl9jqJHIK4KmrHh3TdL1m78SR+GoZvDejX9jBG0emHyp0lZWkM0kLJ+4VkQIGG3eDk7iUMfQ3OoXWqm5gfwFfXbTeb9rt72wt44rgZ3RxNI87LgEqSQHDMrEAdK831nwx4q8JI6XGjand6TLbmy006PfSai+lAQyIPOiaJTPH+9dlBBEeCq7dwBAOt0PWb3wx8P/D2i3VpBFrSW1tFp5jAltnuGhZYUuAyrLFuKBmJVSDkBjgisXWvBdh4ubRNLuNPsbGHTLwXt5p9ujxrcSNBGI41ZB5bxO8cimcjKiMIMHdmLxR8RvDniFLO0l1K2s9IuLm1e5nh1VYr60YyyMsggljAjZZCpkZGLoCCMhQagk+IeknRrqd7weJdXu45JYYdGviJvNmkCxrB5jfaICkaR7kRW+aRuDtNAGr4quNE1jxBpN2NV0+9tzqnm213avO0VtqSxRQRGULlJ2DiPaC0RVQCSwc52vghptzrZ/wCEu1JzLaYki0jzNPitXmVyGmvJFQn947ZUHj5VJ581iee0r4X3Xj7VdO1LxVo0egeGbT95FpICrdXzEk+ZdbMBWYbdwOWyD93Ne+wQxW8EcFvGkUMahEjRQqooGAABwAB2oAkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMXXvCuheIGDaxpdrdSAbRI6YcD03DBx7ZrmPj8ly3wg8RCxwLgRxFSW27cTISc9sDJyeB1PFeg1Q1/S7fXND1HSrzd9mvreS2l29drqVOPfBpKKTukaSrVJxUJSbS2V9F6djwTX/EXh7xSNH0nSNQf+0bu/thEIrHZLZozvG5yAqx4EhDZZwzmQKqkg1hyzeGdVguLnwToWreGfGGm2L6lZQu7ol9axXDNJbFY5G53Agp8pDjHAUiustY7nxR4esdK1qK3j8V6AJoPO8/z5bWSBom81lkHmusyhTwHDLgFh5mVy7XwpcQeEby28O2kpk1LSVtZL251X7dcxWzRylLK3d0W3WMOm1tjsQD0zsYMzIdMu7PRtLDz6tceG47XUY9VkOi2C+TfxtaxuwZYwwhJEcm1PlJQKzoSS1al5d3ugsq6zoV/La6pqStb/AGW8Nusc8paWOJ1jbcGeRYxgxsAc5lkB4ztX8SJfa7qemF7rw7apfHTnjsdVWwa3SOFBHciNQXuZGAKrFHnCxorA5FSwxapcXukaldX93BPot1ePcQT6V5zyyRqY0FzNarsR/Jd2RgGKb85kJAIBcOuXUHhMy+PLrU7SI2uonVbOeyP+nRSM5hRJmBA2F/LWMlGJbkAZBz7m28Ty+FIPD+oabYw2N1e2dkGnby7qS3lmUTQq21FCnDKoRAFjj4DBlapNT8XWf/CRWcOpw2P9r6VC9xHpgQ362N1vfE91cRIqxxxjy+QHZVJJCsAa2tD0nU5/EF6fFF9Be6R4bSS6u9RnLoHu5QJ9yoMeX5KSEjBOAIQCpU7AD0HxFN/Y1pcXFjpzPrV9O1tYJ5SYklJLrv2ZGzIeQuQCFDZw2M7XhPRhoHh6z04zG4ljUvPOQQZpnYvJJjJxudmbHbOBWN4ItL+9mbxDq5vYWnjaKwsbh/mt7ZiG3Sr/AM9XKhjn7g2oOjFuwoA8++Pdwlt8KdZklW3aIvbK4uSREQbiMEORyAc4z2zzxmuU1WHSNT8NaIvh630e7uTpM0VrbGOSSOZFKhYsRMS8QdI9wfduVOOC7Dpv2hVJ+EWtthCI3tZW8w4Xal1ExycHjAPY/Q9K5h/9G1qy8R+FdO0WDw0LcaX55MK27xu4eIxsgUovmyhCoJVsOGwyqWAL9vpNheX+ieLL6OeeW1uTZW8d0JTHahp2HmbZkLiQvHGDINpCsMgKOb/xH8V6Bc+DL6zfULdi8YnniMkjMu2dAY2RcTYaRhHkL8ueQMbTFaRNo3ii8fWHjH9o3K3dlPFaxxmOf5omKxnEpJV4AzncoV9pIAZzW8J3E/8AZutvqfhi7uIdQmuLoWh8lJLiORWLxmEhG+8HOxi2TKSGkxuoAsW13q+iCKO9tNG0+x1ScNZ2Yu2V4blyPMSQk+WxQtIQkbAs0akBcuVzNLtIPFXiHxpba48loss0MFxpdjPIPtEDRqweSQFc5Xa2VK7VYo4IxnnvFPi/V9F8TS+HYvCnirxesaN5gUtbW8YkKyqiCOMlyg2KZJG3E7/WtrXPDCv4yF1Nf3ElwupwGx1K3lSa8iUReW1nIXQokW5m43FiWZmDEk0AV/Cc+kaxqujxRakNWhgla2jsnty6pBLBcx7AX2Bjtg2F1XcBEylcNK7enfDwLJpmo3MhVr2XUrpLggjgxStCi4AGMRxx8DjvznJ4rwrDNbXkGhuNRvZYYLi42tdPKJkVmjK/aZI03uTclty7SFVBuxkHsPCrfZfGHimxBTZK1vqCgYDEuhhckDjlrfPHdjnBzQB11FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXE/FuXVNP8IXuraNrd7plxZRFwkEVu6Skso+cSxueOcbSvXnPFYy+N9U0eDVrdrOTVk07VY9IF7fXscMk88whMeRFAqIg8/DHGQFGN5JAAPT6K82HxE1Sa7h0600GwfVftN3bXCy6oUt4mt0jdisohJYESDqi4IIOOSOf0f4kahJqGoeIIdOkn0G4ttIleGe9ZHtPtBKfu49hVzlgTymQoOTQB6zqeiaVqoI1TTLG9BGCLiBJOMEfxA+p/OpdO0yw0yNo9NsrW0Rm3MsESxgngZIAHPA/KvPrf4mXMwjnOlabbWN2l5JZT3OqlMi2fDm4AiPkjAJypkwcA4JpsPxG1x7e1WXwva219PbXOoCK51NoozaQlB5gZoA29i+QjIuAMsVzigD06ivGv+Fha7qnizSIvDkKNaXeoJG9vqFysStG+lLdKgKwMyAFixyWO5cZCthdLS/ipqGqy3rab4P1K6tUS5a2kjSceY0TbQrs0AjUthsbJJDxgjPFAHqdFcloPimTWPCOqanJDDb3Nn5ySQ28spaJkQNhvOgjZX5Bw0fGR1rmbH4l3+22ZtFWbTo20yC5u5L8CffeLHtIjWEK21pBu5QdwOwAPU6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDy74r/Du71jUrbxT4PuJLHxTaL5UgikWNb6A4zGxZWVX4G1yp6YIOFK8PHrEV1pU0HhO9gbVksDbWWnnUI44IzFPDILma3KBYJmLsWV+pTbySK+ia53xP4K8N+KHWTXdHtbq4QAJc7Sk6AZwFlXDrjJPBHWgDzrS9XjtVNndaNDqn29ki0JoJ4/JedI1MsUTZ3qsciyObgqGIH8TKm7i9Zs9J1C6it/EFxqtreeFVtbJ7aDWhZ2b3O13ZipDTKrKQPtBC7wWOVCk16NJ8CPBzmABtaWK3QxwRDU5isSE52pkkqBk8A45Oc0y9+BXhQXkN/o8clpqEM7XStdMb2GWViNzTJKSZMgY+8MZJBB5oA4Lw69/4h1nVdP8FWGgX/h26gNpdalLpptbeKcfKZBIWc3hcsThiSSq5K53N3mg6Clu+geAba4mvLLSIY7/AFueYs3mSB/MhiILMFLylpGUE/LGByGFbbxeN1OG0LwtdyNKJWmk1S4Ee5RiN0iaFvLIIUkBj0POTmur8P6Y+m2b/a5o7nUbhzNd3KQiLzpCAM7R0VVCooJJCqoJYjJANOivFf2rYo5vBOgxzRpJGdaTKuMg/wCjXHavJ/AHwstdcnjm1nTorXTZ7aaaB0MKSylB1VGyxXPUhce9aRp80ea5rClzR5rn1nr+lW+uaJf6VfAm2vIXgkx1AYEZHoR1B7EV4b4Fu9YtPBc3g3Vru1F7pJawKRWUkk0Xl7lEpjI2PHiS0kRioDDdncx5rfsmwQ2+q+MUt4o4kMNgSqKFGd1zzxXpXj/wZPda7p/i3w4qnXtO+WazZgsWqW/IaF88BwGbY54DHnjlZlHldiJx5ZNHM2GuWM2mXFtYQT3VyZbyyjtbvNrFLeRu7LaZJO0sSAAHK+XHg7c7TlfDnxBba94dg1LU4YdNTWTdJdy2Nw9laSXEM2PMjwC4kljlOWJVyIDxtHE+nfEOXVpEj0ZZtDf7Wtpcw6o7RSM6QeZIkYKysrxlRlXCoVJA3M+Vd4P8TafqN5da5bWesanFdXe6zvLCwEUFtExYjzSyIuVeS43MQ+0HcWywJkk1I4ri0sdZsbAa3rttqGnxSWsh1SaVNredna/lgoNuMFN+f3RIBKlsy6tdFtoPD+heGMQ3lvqFvcQPJC0TqYkaRpbg7VbzJEBVgy5YP0I+YSaV4jbSY119tIFp4U1eeLUrV5ZbO1MbyLCC8isQXYksfMMhPzEhTtRjm2HiC71nSZvDmjaXdXepHVbuzE4eOKXS5RNIxnYqjpEQsr4kzufb8q88AHYfDpZ9dutV8Q3l/M0MqTWFnNDb+RDFGhVZJYQ7OUViiYAO3MRbBJJPSaQTL8QdZbZHGYbC3jdEbOCZrllJ46lcMfTd361YfVNNl024lWXT5DDa7mumXfAkYD/O7YA2B4n6H+EHjNR+AradrK91m+ieG71m5N4YpE2vFDtVIY2HYiNFJHZmbvkkA6eiiigAooooAKKKKACiiigAooooAKKKKACiiigDG8VX+nWdlaw6vafa7a/u4rHyjGsilpGwu4Mcbc9ev0q3Po+mT217bT6dZyW982+6ieBStw2AuZARhjhVGTnhR6Vm+MdFuNah0lLV4kNpqdtev5hIykb7mAwDzjp/OvL3+F3ia40a30i4k0VbOw0i60u3lW5lLz+bPC6u6+UAnyxYIBbB7nPAB6LqXw98L6jJpK3OjWBsdMEwgsPssX2bMgXJMZXGRt4Ix1Nbj6LpbpKj6bZMkojEimBCHEZzHnjnaeV9O2K82i+E9vY+IbjUdHstHsQus2l7ZNBHse3tkhRZo1wnyl2Eh2j5W3cn05zSfgzrNtp+pWt5dWk8t1bpbvdfalAu8XMUpeaNLVHL7UbDNLIQWIzhiQAevy+EfDcs19NL4e0d5b8Yu3ayiLXAyG/eHb8/IB5zyM1keItA8F+HvC1xPeeFtIbTLN/tItYdNhYGZtqAomAN7fKueO3OKm8H+Ez4c/4SW2shbWWnX959osYLNdq2yGCJDhMBVO9XbA45z1JrzuD4Q6jLo0tjdWnh2D/Q4LWQws8g1GVJ45Gup90YxIVRx/GcyMC2KAPU/wCwdG1rTg+reGrNTcOlxNa3ttBKwkVQil9pZSwUBQQTgAAGll8HeGZry7u5vDujSXV2GW5maxiLzBvvB225YHAznrWT468Jtq2h6RYaRZ6Y9np11HMdKusxWlzCqOghbajbVBZWA2sMoMj05S7+G+pXGtRXcGm+HbFTJZSQzQzOZdIWFgXitQIlBV8HvHy7ZVhigDvPBP8AYd74VjOgaVb2GkTNMgtEt44k4dkfKJ8vJU/UHmtFdD0lYjGul2AjLRMVFumCYseUcY6ptXb/AHdoxjFeQ6j8KNansFt8aHeStZy2sU91LIG0uRrmWX7Rb4jOZCsi55Q5jX5iOK6HS/hvLYeJ7PXI109b9dcu765ulyJpbSWKVViLbcnDMjFCdvBIJPUA9OooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPIv2mNOv9S8H6Kml6ffX8kWrLJJHZ2zzuqfZ513FUBOMsozjuK4HRvFGu2MOlPc+APE9xe6dYvp8cqWVzGjRN0ynkH5hxznnnj0+m6KuM2lY0jUcVy2PBf2YtJ1PTtS8Vy6npWpWEc0VksZvbOS38wqbgtt3qM43LnHqK96ooqZS5ndkyk5O7Oa8UeCdG8R3trqNzDJa6zaf8euqWb+VdQdeA4+8vzN8rBlOTkHNefSfDjxxo8kh8OeKtJv7aS5luWsdX00CFWcHIUpllBLSZC7QfMbjJbd7NRSJPBYvgx4v1LQ5tK17x55NjdIyXdtZWpZbgmRn3lnbhuQuFUAKijHGR1/wd0uyt/h7CthY2y6pMMXslwzSm6kjleLzHdssQfLYqpPy5A4r0pslTtIB7EjNebeHYfFln4f0PSY/Dwt9R0u3+y/brnUwLNiqbPN8uJt0qtjcEdVwT1U80Aa12sXiDxANAlluL+z02WO7vpmRAglVUMVsxAGWYnzmx0ACkbXArtKzPDeh2HhzR4NN0qHyraLJJY7nkY8s7seWZjkljySa06ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArmvibcz2fw28WXVnNLBcwaTdyRSxOVeN1hchlI5BBAIIrpa5X4sf8ks8Zf9gW9/9EPQBxHxUXTfAek2t+th4s1KKa4jt2kXxXexRxF2CjcTOWJOeAqEcckcV0Wo6FB4f8U+DpNNvdb/ANK1OW3njudZu7mOSP7DdPgpLKyn5kQ5xkFRXN/FfUvC3jvRbfS7b4k+EdNtUnS4kMk0Vw7OjBlwROgUdc8HPqK17nxVo2teIfANnZeJdC1jU49UkkmGm3CHIGn3gLiMSOyrkgck9RzQB0vi7xa/hq4s0fQNX1CK6ljgjns2ttnmyMVWMiSZGzwOcbeRz1xNF4z8Pizee/1bTtOkiXNzBdX0Ae2IcoVkKuVBDgqcEjcCM5qx4n0P+3ItNT7R5H2O/gvs7N2/y23beoxn15x6Guaf4evFYRrYanDDqEOvXGvQzy2fmR+ZK0vySRhwXwspUMGU5VSMYxQB0Nx4w8M2y2jXPiLRoVu1D25kvol85SSAUy3zAkEAj0NVNA8a6Xquuano8t1ZWuqWl7Jax2jXSmadUVW8xU4bHzHoD9081wMvwt1g3l3psGp2semX+kTWl9fPYqzSNPdSyypDGJR5X+s4JDgcdSK6c/DeD5VF+wQa2dXyIvnKm3MPlbt2c4Od/wCnegDoD408LCC6nPiXRBDaOI7iT7fFthYnAVzuwpyCMGl/4TLwx5VlL/wkei+VesVtX+3RYuCG2kId3zEHjjPPFcZa/DXW7KwihsfFVvbXFrpqaRZzw6YUaO2Dqx34mBaQhAN6lMZYgAnNJffC28ubKa2i1jTLSO80waReJb6S2w26yO6mENMxjk/eNliXycNgEUAdJN8QdAtvEllod7dxWt7eSTxRebcwbS8Tom04kJDOz4VcbjtYEAjFaK+MfDLwXkyeItGaGyYLdSC+iKwEnADnd8pyCOcVzSfDu4t9Yt9QstYjRkub+SRJbQvvhu2jZ0UiRSrjyhh+RzkqawtK+DkunWH2ddXtLmSGCO3tLi5ivnkgRHDrjF6ArAqCDEI8HoAOKAPSrjX9PTw++tWtzb3unhN6zW9xF5cgzjIkZgnXuWApLfxLoVzrD6Tb61pkuqpuDWcd1G0y7fvZQHdxg544rHufCN1e/DqTwzqGsy3V1LEY5NQljLMx37s7SxJA6DLE4AySeTXtfASQalZXgvl3W+uXOtEC3wX86KSPy87u3mA7u+0DA7AE2s+OLPT/ABzZ+G/N0xJWtWvLmS71BYGijGeETaS7YVmIJUBVJzWmPGPhk6SdVHiLRjpYl8k3n26LyRJjOzfu27sds5rJ8YeBYvE9zq8lxfyQR6hpS6aVjT5oysrSCTdnnkgbeOnXmsHTfhhfaddW+p22tWf9uQXRnFzNa3VzHIDCYiJFmu3ckDGGWRcYxg0AdxB4p8Pz38NjBrulSXs0Qnjt0vIzI8ZXcHVQclSvzZHGOelT6Lr+j66JzomrafqIgYLKbO5SbyyegbaTg8HrXAr8LJT4jl1S51W2uo57n7fLbTQ3Xli5MWxmRFuhGFznAZHYKSpY9a6P4f8Aha+8LwXcN5q/26CTyxb20aSpDaqoI2oJZpWAORxu2gAAAdwDraKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The complete life cycle of this parasite has not yet been determined, but assumptions were made based on clinical data. To date, the cyst stage has not been identified in",
"    <em>",
"     D. fragilis",
"    </em>",
"    life cycle, and the trophozoite is the only stage found in stools of infected individuals",
"    <strong>",
"     (1)",
"    </strong>",
"    .",
"    <em>",
"     D. fragilis",
"    </em>",
"    is probably transmitted by fecal-oral route",
"    <strong>",
"     (2)",
"    </strong>",
"    and transmission via helminth eggs (eg,",
"    <em>",
"     Ascaris",
"    </em>",
"    ,",
"    <em>",
"     Enterobius",
"    </em>",
"    spp) has been postulated",
"    <strong>",
"     (3)",
"    </strong>",
"    . Trophozoites of",
"    <em>",
"     D. fragilis",
"    </em>",
"    have characteristically one or two nuclei",
"    <strong>",
"     (1,4)",
"    </strong>",
"    , and it is found in children complaining of intestinal (eg, intermittent diarrhea, abdominal pain) and other symptoms (eg, nausea, anorexia, fatigue, malaise, poor weight gain).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Dientamoeba fragilis infection. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/frames/a-f/Dientamoeba/body_Dientamoeba_page1.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/frames/a-f/Dientamoeba/body_Dientamoeba_page1.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_63_3063=[""].join("\n");
var outline_f2_63_3063=null;
var title_f2_63_3064="Use of oxygen in patients with hypercapnia";
var content_f2_63_3064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of oxygen in patients with hypercapnia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/63/3064/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3064/contributors\">",
"     David J Feller-Kopman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3064/contributors\">",
"     Richard M Schwartzstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/63/3064/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3064/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/63/3064/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3064/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/63/3064/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians have observed for many years that the administration of oxygen to patients with chronic obstructive pulmonary disease (COPD) may be followed by hypercapnia. Traditional teaching emphasizes that hypercapnia results from suppression of hypoxic ventilatory drive and warns that \"patients will stop breathing\" if given oxygen. However, this interpretation does not account for the many factors that contribute to the control of breathing in these patients, and has resulted in oxygen being withheld inappropriately from some patients with acute respiratory failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=see_link\">",
"     \"Control of ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major processes which contribute to worsening hypercapnia in the setting of administration of supplemental oxygen to patients with COPD (in order of decreasing importance) are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Worsened ventilation-perfusion matching due to attenuation of hypoxic pulmonary vasoconstriction",
"     </li>",
"     <li>",
"      Decreased binding affinity of hemoglobin for carbon dioxide",
"     </li>",
"     <li>",
"      Decreased minute ventilation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the mechanism of hypercapnia, it is essential to administer oxygen to patients with significant hypoxemia to avoid the potentially life-threatening complications of a low arterial oxygen tension (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ). In addition, a meta-analysis of 31 studies confirmed that administering supplemental oxygen to hypoxemic patients reduced dyspnea and minute ventilation during exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relevant physiology of ventilatory control, the causes and effects of hypercapnia, and the use of oxygen in the treatment of patients with acute-on-chronic respiratory failure will be presented here. The use of chronic oxygen therapy and general issues related to the management of acute exacerbations of COPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONTROL OF VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many reflexes, feedback loops, and control systems that match gas exchange with the metabolic needs of an individual [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. The respiratory system is under negative feedback control that is regulated primarily by the arterial carbon dioxide tension (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ) via changes in local pH in the brainstem and, to a much lesser degree in normal individuals, by the arterial oxygen tension (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ). Both neural and chemical regulators act to maintain PaCO",
"    <sub>",
"     2",
"    </sub>",
"    within a very tight range; in experimental studies of the ventilatory response to hypercapnia a 1 mmHg rise in PaCO",
"    <sub>",
"     2",
"    </sub>",
"    normally produces an increase in ventilation of 2 to 4 L per minute (",
"    <a class=\"graphic graphic_figure graphicRef52101 \" href=\"UTD.htm?37/16/38157\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=see_link\">",
"     \"Control of ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The central pattern generator in the medulla is thought to control the rate, depth, and timing of ventilation during quiet respirations, although additional neurons in the brainstem, sensorimotor cortex, limbic system, amygdala, and hypothalamus also play a role. However, under conditions of respiratory distress, the stimulus to breathe and the resulting mechanical output of the system become more complex because of mechanical loading of the respiratory system, stimulation of pulmonary and chest wall receptors, and behavioral factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanoreceptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of receptors in the upper airways, lungs, and chest wall that are responsive to both mechanical and chemical factors. Mechanical stimuli associated with changes in flow, pressure, or volume tend to have an inhibitory effect on ventilation and are mediated by flow or temperature receptors in the nasopharynx, slowly adapting pulmonary stretch receptors located in airway smooth muscle, and muscle spindle cells and Golgi tendon organ receptors in the chest wall. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=see_link\">",
"     \"Control of ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemical or irritant stimuli, which tend to have a stimulatory effect on ventilation, are transmitted primarily via the rapidly adapting pulmonary stretch receptors and c-fiber nerve endings located throughout the airways and lung parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, acute tracheobronchitis, pneumonia, interstitial edema, bronchospasm, and hyperinflation resulting from a variety of causes may stimulate pulmonary and chest wall receptors and lead to increased respiratory drive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chemoreceptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blood pH, determined primarily by changes in the PaCO",
"    <sub>",
"     2",
"    </sub>",
"    , is the main chemical stimulus for respiration; its effects are mediated through both peripheral and central chemoreceptors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28852?source=see_link\">",
"     \"Chapter 11C: Effect of arterial pH on ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The central chemoreceptors lie within the brainstem, close to the ventrolateral surface of the medulla. They are highly sensitive to changes in hydrogen ion concentration due to the low buffering capacity of the cerebrospinal fluid (CSF).",
"     </li>",
"     <li>",
"      The peripheral arterial chemoreceptors are located in the carotid and aortic bodies, with the carotid body playing the more important role in humans. Both sympathetic and parasympathetic innervation of the carotid body contribute to the rate of discharge at any given level of PaCO",
"      <sub>",
"       2",
"      </sub>",
"      and PaO",
"      <sub>",
"       2",
"      </sub>",
"      , and changes in PaO",
"      <sub>",
"       2",
"      </sub>",
"      and PaCO",
"      <sub>",
"       2",
"      </sub>",
"      act synergistically to affect chemoreceptor activity. However, carotid body input contributes only approximately 10 to 15 percent of the resting ventilatory drive [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is a linear relationship between PaCO",
"    <sub>",
"     2",
"    </sub>",
"    and minute ventilation (",
"    <a class=\"graphic graphic_figure graphicRef52101 \" href=\"UTD.htm?37/16/38157\">",
"     figure 1",
"    </a>",
"    ). As PaO",
"    <sub>",
"     2",
"    </sub>",
"    is decreased, the slope of the curve becomes steeper and shifts to the left, resulting in a greater sensitivity to changes in the level of PaCO",
"    <sub>",
"     2",
"    </sub>",
"    .",
"   </p>",
"   <p>",
"    The relationship between minute ventilation and PaO",
"    <sub>",
"     2",
"    </sub>",
"    is somewhat different (",
"    <a class=\"graphic graphic_figure graphicRef79832 \" href=\"UTD.htm?26/28/27086\">",
"     figure 2",
"    </a>",
"    ). Minute ventilation does not significantly increase until the PaO",
"    <sub>",
"     2",
"    </sub>",
"    falls below approximately 60 mmHg, at which point there is usually an increase in alveolar ventilation which will increase PaO",
"    <sub>",
"     2",
"    </sub>",
"    , decrease PaCO",
"    <sub>",
"     2",
"    </sub>",
"    , and blunt the subsequent ventilatory response. A greater minute ventilation response to hypoxemia is noted when secondary hypocapnia fails to occur.",
"   </p>",
"   <p>",
"    Patients who have a robust ventilatory response to CO",
"    <sub>",
"     2",
"    </sub>",
"    also generally have a greater response to hypoxemia. The sensitivity of an individual's ventilatory response to hypoxemia and hypercapnia may be partially determined by genetics; families have been identified that have subnormal responses to hypercapnia and hypoxemia. Members of these families are more likely to retain CO",
"    <sub>",
"     2",
"    </sub>",
"    if COPD develops [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Behavioral control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The respiratory system is unique among the physiologic systems essential to life in that its function is regulated both by automatic mechanisms originating in the brainstem and by voluntary inputs originating in the cortex. The emotional or affective condition of the patient influences respiratory drive; as an example, anxiety, pain, or general discomfort may be associated with ventilation that is excessive for the metabolic demands of the body [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. A rapid shallow breathing pattern may result, particularly when behavioral factors coexist with acute respiratory insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CAUSES OF HYPERCAPNIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;PaCO",
"    <sub>",
"     2",
"    </sub>",
"    is dependent upon both CO",
"    <sub>",
"     2",
"    </sub>",
"    production and alveolar ventilation, according to the formula:",
"   </p>",
"   <p>",
"    &nbsp;PaCO2 &nbsp; = &nbsp; (k &nbsp;x &nbsp;VCO2) &nbsp;&divide; &nbsp;VA &nbsp; = &nbsp; (k &nbsp;x VCO2) &nbsp;&divide; &nbsp;(VE &nbsp;x &nbsp;[1 &nbsp;- &nbsp;",
"    <span class=\"nowrap\">",
"     (VD/VT)])",
"    </span>",
"   </p>",
"   <p>",
"    where k is a constant, VCO",
"    <sub>",
"     2",
"    </sub>",
"    is CO",
"    <sub>",
"     2",
"    </sub>",
"    production, VA is alveolar ventilation (the component of the minute ventilation that reaches perfused alveoli), VE is expired minute volume, and",
"    <span class=\"nowrap\">",
"     VD/VT",
"    </span>",
"    is the ratio of physiologic dead space to tidal volume.",
"   </p>",
"   <p>",
"    Hypercapnia therefore can result from an increase in CO",
"    <sub>",
"     2",
"    </sub>",
"    production or a decrease in alveolar ventilation (due either to decreased minute ventilation or an increased ratio of dead space to tidal volume). Reduced alveolar ventilation is the most common cause of hypercapnia. Unless a patient has limited pulmonary reserve, increased CO",
"    <sub>",
"     2",
"    </sub>",
"    production (as may occur with sepsis, overfeeding, lactic acidosis, or thyrotoxicosis) will not result in clinically important hypercapnia.",
"   </p>",
"   <p>",
"    The differences between oxygen and carbon dioxide binding to hemoglobin explain why hypoxemia is much more common than hypercapnia in conditions in which alveolar hypoventilation is due to",
"    <span class=\"nowrap\">",
"     ventilation/perfusion",
"    </span>",
"    <span class=\"nowrap\">",
"     (V/Q)",
"    </span>",
"    mismatch; the linear relationship of the CO",
"    <sub>",
"     2",
"    </sub>",
"    -Hgb curve permits well ventilated alveoli to compensate for poorly ventilated lung units.",
"   </p>",
"   <p>",
"    Central nervous system (CNS) injury or CNS depressant drugs can produce hypercapnia by decreasing overall minute ventilation. In contrast, rapid shallow breathing can contribute to hypercapnia by increasing the dead space to tidal volume ratio, because the anatomic dead space in the central airways comprises a larger proportion of the smaller tidal breath.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EFFECTS OF HYPERCAPNIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute hypercapnia may produce a depressed level of consciousness, increases in cerebral blood flow and intracranial pressure, and depression of myocardial contractility [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/9\">",
"     9",
"    </a>",
"    ]. It also depresses diaphragmatic function and shifts the oxyhemoglobin dissociation curve to the right, leading to increased release of O",
"    <sub>",
"     2",
"    </sub>",
"    to tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of hypercapnia is associated with increases in brain glutamine and gamma-aminobutyric acid (GABA), as well as reductions in glutamate and aspartate. This change in the CNS milieu can negatively impact the level of consciousness and depress minute ventilation and inspiratory drive [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of acute hypercapnia required to provoke these responses is variable. Normal individuals do not exhibit a depressed level of consciousness until the PaCO",
"    <sub>",
"     2",
"    </sub>",
"    is greater than 60 to 70 mmHg (8.0 to 9.3 kPa), while patients with chronic hypercapnia may not develop symptoms until the PaCO",
"    <sub>",
"     2",
"    </sub>",
"    rises acutely to greater than 90 to 100 mmHg. The latter patients have a compensatory loss of hydrogen ions from the kidney, associated with a rise in the plasma bicarbonate concentration. As a result, a larger elevation in PaCO",
"    <sub>",
"     2",
"    </sub>",
"    is required to produce the same reduction in pH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EFFECTS OF HYPOXEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxemia can adversely affect every tissue in the body. Cellular hypoxia is a state in which there is insufficient oxygen to meet the metabolic demands of a given tissue. It can result from impaired perfusion (ischemia)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diminished arterial oxygen content (due to anemia or hypoxemia).",
"   </p>",
"   <p>",
"    Cellular tolerance of hypoxia is variable. As examples, skeletal muscle cells can recover fully after 30 minutes of hypoxia, but irreversible damage occurs in brain cells after only 4 to 6 minutes of similar hypoxic stress [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Therefore, life-threatening hypoxemia needs to be treated with the administration of oxygen (and sometimes with red cell transfusion) while measures are being initiated to treat the primary cardiopulmonary insult.",
"   </p>",
"   <p>",
"    Cellular mechanisms that contribute to hypoxic cell injury include depletion of ATP, development of intracellular acidosis, increased concentrations of metabolic by-products, generation of oxygen free radicals, and destruction of membrane phospholipids. There is also a dramatic increase in intracellular calcium concentration, contributing to cellular injury via a variety of mechanisms, including direct damage to the cytoskeleton and induction of genes that contribute to apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/12\">",
"     12",
"    </a>",
"    ]. Hypoxia also induces an inflammatory reaction characterized by neutrophilic infiltration, thus augmenting cellular damage via release of cytokine mediators, oxygen free radicals, and by intensifying ischemia due to disruption of the microcirculation.",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) statement on the detection, correction, and prevention of tissue hypoxia, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HYPERCAPNIA IN COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major cause of hypercapnia in patients with COPD is impaired matching of ventilation (V) and perfusion (Q), which, if sufficiently severe, is functionally equivalent to increasing the amount of dead space [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/14\">",
"     14",
"    </a>",
"    ]. Normocapnic patients with COPD have a higher minute ventilation in order to compensate for this inefficient removal of CO",
"    <sub>",
"     2",
"    </sub>",
"    created by worsened ventilation-perfusion matching. This prevents hypercapnia in some patients but increases the work of breathing. The classic \"pink puffer\" phenotype exemplifies the normocapnic patient with COPD and dyspnea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22520?source=see_link\">",
"     \"Disorders of ventilatory control\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mechanical inefficiency of the respiratory system also contributes to the hypercapnia of COPD via several mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Airflow obstruction leads to hyperinflation, causing the diaphragm to operate at a lower position within the thorax. Laplace's law states that the pressure developed is inversely proportional to the radius of curvature; as a result, there is less pressure produced by a flattened diaphragm for any given effort.",
"     </li>",
"     <li>",
"      The shortened muscle fibers generate less force at a given level of stimulation because the diaphragmatic configuration negatively affects sarcomere length and",
"      <span class=\"nowrap\">",
"       actin/myosin",
"      </span>",
"      overlap.",
"     </li>",
"     <li>",
"      Lung compliance is reduced at larger volumes, producing less change in lung volume for the same change in pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The breathing pattern in patients with COPD and hypercapnia is different from that found in their normocapnic counterparts; hypercapnic patients tend to have lower tidal volumes and an increased respiratory rate, which increases",
"    <span class=\"nowrap\">",
"     VD/VT",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. The lower tidal volumes seem to reflect a shortened inspiratory time rather than a reduction in respiratory drive, as measured by mouth occlusion pressure or inspiratory flow rate [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]. The mechanisms of this abnormal breathing pattern remain unclear and at least three factors may contribute: hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/18\">",
"     18",
"    </a>",
"    ]; stimulation of pulmonary irritant and J receptors by coexisting chronic bronchitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]; and reduced inspiratory reserve due to hyperinflation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Effects of supplemental oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been many mechanisms postulated to explain why patients with COPD sometimes develop hypercapnia when given supplemental oxygen. It had been thought that patients with COPD rely on their hypoxic ventilatory drive due to a blunted sensitivity to CO",
"    <sub>",
"     2",
"    </sub>",
"    (ie, pH), and that hypercapnia in this setting resulted from \"removal\" of hypoxic drive with a consequent reduction in alveolar ventilation. One report described different ventilatory responses to oxygen in the same patients when they were stable, compared to responses obtained during episodes of acute respiratory insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two studies have improved the understanding of the effects of supplemental oxygen in patients with COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/19,22\">",
"     19,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    The first study examined 20 patients with COPD, both in the chronic state and during acute respiratory failure (ARF); their responses to supplemental oxygen were compared to those of normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/19\">",
"     19",
"    </a>",
"    ]. No differences in minute ventilation were observed between the groups when breathing air. However, the patients with ARF had a different respiratory pattern when breathing air; specifically, they had a significantly increased respiratory rate and lower tidal volume when compared to normal controls. Mouth occlusion pressure, an index of ventilatory drive, was five times greater in patients with ARF than in normal subjects.",
"   </p>",
"   <p>",
"    When patients with ARF were given supplemental O",
"    <sub>",
"     2",
"    </sub>",
"    at 5",
"    <span class=\"nowrap\">",
"     L/min,",
"    </span>",
"    minute ventilation dropped by 14 percent, due to a small decrease in respiratory rate without a compensatory change in tidal volume. The reduction in minute ventilation could not account for the entire increase in PaCO",
"    <sub>",
"     2",
"    </sub>",
"    , and hypercapnia was postulated to result primarily from an increase in the dead space to tidal volume ratio. Ventilatory drive, as measured by mouth occlusion pressure, decreased, but remained three times greater than in normal controls, implying that ventilatory drive was still being augmented by factors other than hypoxemia, such as input from mechanoreceptors and behavioral factors.",
"   </p>",
"   <p>",
"    Viewed from the standpoint of reducing dyspnea and the work of breathing, the slight reduction in ventilatory drive is actually one of the goals of treatment with oxygen. The dramatically increased ventilatory drive in patients with ARF cannot be sustained for a long period of time in a patient with a mechanically disadvantaged respiratory system without the risk of developing respiratory muscle fatigue.",
"   </p>",
"   <p>",
"    The second study examined the effects of administration of a fraction of inspired oxygen (FiO",
"    <sub>",
"     2",
"    </sub>",
"    ) of 1.0 to patients with COPD and ARF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/22\">",
"     22",
"    </a>",
"    ]. All patients had an initial decrease in minute ventilation of approximately 18 percent, which then returned to approximately 93 percent of baseline after 12 minutes despite continued oxygen administration. The initial decrease in minute ventilation was due to reductions in both tidal volume and respiratory rate.",
"   </p>",
"   <p>",
"    After 15 minutes of oxygen administration, PaCO",
"    <sub>",
"     2",
"    </sub>",
"    increased an average of 23 mmHg, which was due to three components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Decreased minute ventilation",
"      </strong>",
"      ��� Only about 5 mmHg (22 percent) could be directly attributed to the small (7 percent) decrease in minute ventilation.",
"     </li>",
"     <li>",
"      <strong>",
"       Haldane effect",
"      </strong>",
"      ��� An additional 7 mmHg (30 percent) was attributed to decreased hemoglobin affinity for CO",
"      <sub>",
"       2",
"      </sub>",
"      (the Haldane effect). The Haldane effect refers to the rightward displacement of the CO",
"      <sub>",
"       2",
"      </sub>",
"      -hemoglobin dissociation curve in the presence of increased oxygen saturation (",
"      <a class=\"graphic graphic_figure graphicRef63166 \" href=\"UTD.htm?17/29/17886\">",
"       figure 3",
"      </a>",
"      ). This occurs because oxyhemoglobin binds CO",
"      <sub>",
"       2",
"      </sub>",
"      less avidly than deoxyhemoglobin, thereby increasing the amount of CO",
"      <sub>",
"       2",
"      </sub>",
"      dissolved in blood, which in turn determines PaCO",
"      <sub>",
"       2",
"      </sub>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/23\">",
"       23",
"      </a>",
"      ]. The Haldane effect is most pronounced when the arterial oxygen saturation (SaO",
"      <sub>",
"       2",
"      </sub>",
"      ) changes most per mmHg of PaO",
"      <sub>",
"       2",
"      </sub>",
"      , ie, on the steep part of the oxygen-hemoglobin dissociation curve, which is between a PaO",
"      <sub>",
"       2",
"      </sub>",
"      of 20 and 60 mmHg (",
"      <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Increased dead space ventilation",
"      </strong>",
"      ��� The largest component of acute hypercapnia (11 mmHg, 48 percent) was due to an increase in dead space ventilation. This probably reflects worsening of",
"      <span class=\"nowrap\">",
"       V/Q",
"      </span>",
"      matching due to a loss of hypoxic pulmonary vasoconstriction (HPV). HPV serves to limit blood flow to poorly ventilated units and to redirect blood flow to units with high",
"      <span class=\"nowrap\">",
"       V/Q",
"      </span>",
"      ratios at baseline; this compensatory response improves",
"      <span class=\"nowrap\">",
"       V/Q",
"      </span>",
"      homogeneity and decreases the physiologic dead space. As with the Haldane effect, the effect of loss of HPV is most pronounced in patients with a low initial PaO",
"      <sub>",
"       2",
"      </sub>",
"      . The importance of",
"      <span class=\"nowrap\">",
"       V/Q",
"      </span>",
"      mismatching has been confirmed in other studies [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a subsequent study concluded that the primary cause of hypercapnia in patients who retain CO",
"    <sub>",
"     2",
"    </sub>",
"    is actually due to a reduction in ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/25\">",
"     25",
"    </a>",
"    ]. A limitation of this study is the definition of CO",
"    <sub>",
"     2",
"    </sub>",
"    retention as an increase in PaCO",
"    <sub>",
"     2",
"    </sub>",
"    of 3 mmHg. This is likely clinically insignificant and makes the physiologic differences between retainers and non-retainers less clear. Additionally, both retainers and non-retainers had mean PaO",
"    <sub>",
"     2",
"    </sub>",
"    levels &gt;54 mmHg. This would minimize the role of hypoxic pulmonary vasoconstriction and the Haldane effect, both of which are more prominent at lower partial pressures of oxygen.",
"   </p>",
"   <p>",
"    The relative contributions of a reduction in minute ventilation, the Haldane effect, and changes in",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    matching have been confirmed by computer models of gas exchange and pulmonary hemodynamics [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/26\">",
"     26",
"    </a>",
"    ]. Subsequent trials have documented more modest degrees of hypercapnia when lower fractions of inspired oxygen are administered. As an example, one study of 12 intubated but spontaneously breathing patients with COPD and CO",
"    <sub>",
"     2",
"    </sub>",
"    retention who were recovering from ARF found that increases in FiO",
"    <sub>",
"     2",
"    </sub>",
"    from 0.3 or 0.4 to 0.7 did not result in worsening hypercapnia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/27\">",
"     27",
"    </a>",
"    ]. No changes in PaCO",
"    <sub>",
"     2",
"    </sub>",
"    , minute ventilation, tidal volume, respiratory rate, dead space, or mouth occlusion pressure were noted, possibly because the baseline PaO",
"    <sub>",
"     2",
"    </sub>",
"    was greater than 60 mmHg, a setting in which HPV would be minimized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Response to oxygen administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three possible outcomes when administering uncontrolled oxygen therapy to a patient with COPD and respiratory insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient's clinical state and PaCO",
"      <sub>",
"       2",
"      </sub>",
"      may improve or not change",
"     </li>",
"     <li>",
"      The patient may become drowsy but can be roused to cooperate with therapy; in these cases, the PaCO",
"      <sub>",
"       2",
"      </sub>",
"      generally rises slowly by up to 20 mmHg and then stabilizes after approximately 12 hours",
"     </li>",
"     <li>",
"      The patient rapidly becomes unconscious, cough becomes ineffective, and the PaCO",
"      <sub>",
"       2",
"      </sub>",
"      rises at a rate of 30 mmHg or more per hour",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk for developing severe hypercapnia and CO",
"    <sub>",
"     2",
"    </sub>",
"    narcosis is greater in patients with a low initial pH",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PaO",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective study of 95 patients with COPD and hypercapnia who presented with acute respiratory distress, oxygen therapy targeting a PaO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;74 mmHg was associated with increased length of stay, increased need for noninvasive mechanical ventilation, and increased rate of admission to an ICU [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/30\">",
"     30",
"    </a>",
"    ]. A causal relationship cannot be concluded, however, due to the study's observational design.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Effect of withdrawing oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major danger facing patients who develop hypercapnia during treatment with oxygen is that the abrupt removal of supplemental oxygen may cause the PaO",
"    <sub>",
"     2",
"    </sub>",
"    to fall to a level lower than when oxygen therapy was begun. The development of hypoxemia in this setting is more rapid than the resolution of hypercapnia, and subsequent tissue hypoxia can potentially worsen the patient's acidemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     HYPERCAPNIA IN NEUROMUSCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of hypercapnia in patients with neuromuscular disease (eg, amyotrophic lateral sclerosis and inflammatory neuropathies) when supplemental oxygen is administered has been less well studied than among patients with COPD. One series of eight retrospectively identified patients with neuromuscular disease found that seven had baseline hypercapnia, and six had worsening of their hypercapnia by a mean of 28 mmHg after receiving low flow supplemental oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/31\">",
"     31",
"    </a>",
"    ]. There were no measurements of breathing pattern, respiratory drive, or dead space, and it is unclear if these findings are due to the same mechanisms that are operative in patients with COPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12669889\">",
"    <span class=\"h1\">",
"     SAFE ADMINISTRATION OF OXYGEN TO HYPERCAPNIC PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute-on-chronic respiratory failure have a compensated respiratory acidosis (in which the arterial pH is only modestly reduced), but they are at risk for both hypoxemia and worsening hypercapnia. Thus, the primary goal of supplemental oxygen therapy should be the maintenance of a pulse oxygen saturation (SpO",
"    <sub>",
"     2",
"    </sub>",
"    ) of 90 to 93 percent or a PaO",
"    <sub>",
"     2",
"    </sub>",
"    of 60 to 70 mmHg (8 to 9.3 kPa) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/21,32,33\">",
"     21,32,33",
"    </a>",
"    ]. Gradual increases in the fraction of inspired oxygen (FiO",
"    <sub>",
"     2",
"    </sub>",
"    ) by increments of 4 to 7 percent (eg, from 24 to 28 percent FIO",
"    <sub>",
"     2",
"    </sub>",
"    ) with close monitoring of both PaO",
"    <sub>",
"     2",
"    </sub>",
"    and PaCO",
"    <sub>",
"     2",
"    </sub>",
"    are used to achieve this goal [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/34\">",
"     34",
"    </a>",
"    ]. The PaCO",
"    <sub>",
"     2",
"    </sub>",
"    may rise slightly, but is unlikely to result in severe central nervous system (CNS) depression unless the PaCO",
"    <sub>",
"     2",
"    </sub>",
"    exceeds 85 to 90 mmHg. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Effects of hypercapnia'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Effects of hypoxemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Venturi masks may be used to permit tight regulation of the maximum FiO",
"    <sub>",
"     2",
"    </sub>",
"    administered to the patient (",
"    <a class=\"graphic graphic_figure graphicRef80020 \" href=\"UTD.htm?1/60/1988\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3064/abstract/34\">",
"     34",
"    </a>",
"    ]. When using nasal cannula, the oxygen flow rate should generally be increased by 1 L per minute at a time; remembering that it is very difficult to predict the FIO",
"    <sub>",
"     2",
"    </sub>",
"    when administering supplemental oxygen by nasal cannula.",
"   </p>",
"   <p>",
"    By keeping the O",
"    <sub>",
"     2",
"    </sub>",
"    saturation at or just above 90 percent, worsening hypoventilation can be detected via alarms triggered to a drop in O",
"    <sub>",
"     2",
"    </sub>",
"    saturation below 89 percent. Since hypoventilation leads to a decrease in alveolar PAO",
"    <sub>",
"     2",
"    </sub>",
"    and a consequent drop in arterial PaO",
"    <sub>",
"     2",
"    </sub>",
"    , keeping the O",
"    <sub>",
"     2",
"    </sub>",
"    saturation at the intersection between the ascending limb and the plateau of the hemoglobin-oxygen saturation curve (eg, PaO",
"    <sub>",
"     2",
"    </sub>",
"    60 to 70 mmHg) will allow you to monitor closely the onset of hypoventilation (",
"    <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The development of acute hypercapnia with significant acidemia (eg, pH&lt;7.20)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a marked depression in the level of consciousness is an indication for intubation and mechanical ventilation. Oxygen should not be removed entirely from the patient in an effort to avert intubation. Noninvasive positive pressure ventilation may help avoid the need for endotracheal intubation. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Effect of withdrawing oxygen'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8120?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory failure complicating COPD\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12669902\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Overview",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypercapnia generally results from an increase in carbon dioxide (CO",
"      <sub>",
"       2",
"      </sub>",
"      ) production or a decrease in alveolar ventilation. Reduced alveolar ventilation, the most common cause of hypercapnia, is caused by decreased minute ventilation (VE) or poor matching of ventilation and perfusion of airspaces",
"      <span class=\"nowrap\">",
"       (V/Q",
"      </span>",
"      mismatching), described physiologically as an increased ratio of dead space to tidal volume ventilation",
"      <span class=\"nowrap\">",
"       (VD/VT).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Causes of hypercapnia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute hypercapnia may produce a depressed level of consciousness, increases in cerebral blood flow and intracranial pressure, and depression of myocardial contractility. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Effects of hypercapnia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Normal individuals do not exhibit a depressed level of consciousness until the arterial tension of carbon dioxide (PaCO",
"      <sub>",
"       2",
"      </sub>",
"      ) is greater than 60 to 70 mmHg (8.0 to 9.3 kPa), while patients with chronic hypercapnia may not develop symptoms until the PaCO",
"      <sub>",
"       2",
"      </sub>",
"      rises acutely to greater than 90 to 100 mmHg. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Effects of hypercapnia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to decreased VE and",
"      <span class=\"nowrap\">",
"       V/Q",
"      </span>",
"      mismatching, the increase in PaCO",
"      <sub>",
"       2",
"      </sub>",
"      caused by administration of oxygen to hypercapnic COPD patients is felt to be due to the reduced capacity for oxygenated hemoglobin to carry carbon dioxide (ie, rightward displacement of the CO",
"      <sub>",
"       2",
"      </sub>",
"      -hemoglobin dissociation curve in the presence of increased oxygen concentration), known as the Haldane effect (",
"      <a class=\"graphic graphic_figure graphicRef63166 \" href=\"UTD.htm?17/29/17886\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Causes of hypercapnia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Effects of supplemental oxygen'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For hypercapnic patients with hypoxemia, safe administration of oxygen therapy can be achieved using the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The inspired concentration of oxygen (FIO",
"      <sub>",
"       2",
"      </sub>",
"      ) is gradually increased by increments of 4 to 7 percent (eg, from 24 to 28 percent) with close monitoring of both PaO",
"      <sub>",
"       2",
"      </sub>",
"      and PaCO",
"      <sub>",
"       2",
"      </sub>",
"      . Venturi masks may be used to permit tight regulation of the maximal FiO",
"      <sub>",
"       2",
"      </sub>",
"      that is administered to the patient (",
"      <a class=\"graphic graphic_figure graphicRef80020 \" href=\"UTD.htm?1/60/1988\">",
"       figure 5",
"      </a>",
"      ). When using nasal cannula, the oxygen flow rate is generally increased by 1 L per minute at a time. The goal is a pulse oxygen saturation (SpO",
"      <sub>",
"       2",
"      </sub>",
"      ) of 90 to 93 percent or a PaO",
"      <sub>",
"       2",
"      </sub>",
"      of 60 to 70 mmHg (8 to 9.3 kPa). (See",
"      <a class=\"local\" href=\"#H12669889\">",
"       'Safe administration of oxygen to hypercapnic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treat the underlying causes of acute respiratory failure (eg, COPD, heart failure, pneumonia) simultaneously. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link\">",
"       \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The development of acute hypercapnia with significant acidemia (eg, pH&lt;7.20)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a marked depression in the level of consciousness is an indication for intubation and mechanical ventilation. Oxygen should not be removed entirely from the patient in an effort to avert intubation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Effect of withdrawing oxygen'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8120?source=see_link\">",
"       \"Mechanical ventilation in acute respiratory failure complicating COPD\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Noninvasive positive pressure ventilation may help avoid the need for endotracheal intubation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"       \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/1\">",
"      Bradley JM, Lasserson T, Elborn S, et al. A systematic review of randomized controlled trials examining the short-term benefit of ambulatory oxygen in COPD. Chest 2007; 131:278.",
"     </a>",
"    </li>",
"    <li>",
"     von Euler C. Neural organization and rhythm generation. In: The Lung: Scientific Foundations, 2nd ed, Crystal RG, West JB, Weibel ER, Barnes PJ (Eds), Lippincott-Raven Publishers, Philadelphia 1997. p.1711.",
"    </li>",
"    <li>",
"     Lahiri S. Physiological responses: Peripheral chemoreceptors and chemoreflexes. In: The Lung: Scientific Foundations, 2nd ed, Crystal RG, West JB, Weibel ER, Barnes PJ (Eds), Lippincott-Raven Publishers, Philadelphia 1997. p.1747.",
"    </li>",
"    <li>",
"     Cherniack N, Altose MD. Central chemoreceptors. In: The Lung: Scientific Foundations, 2nd ed, Crystal RG, West JB, Weibel ER, Barnes PJ (Eds), Lippincott-Raven Publishers, Philadelphia 1997. p.1767.",
"    </li>",
"    <li>",
"     Berger AJ. Control of breathing. In: Textbook of Respiratory Medicine, 2nd ed, Murray J, Nadel J (Eds), WB Saunders, Philadelphia 1994. p.199.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/6\">",
"      Fleetham JA, Arnup ME, Anthonisen NR. Familial aspects of ventilatory control in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 129:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/7\">",
"      Burns BH, Howell JB. Disproportionately severe breathlessness in chronic bronchitis. Q J Med 1969; 38:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/8\">",
"      Dales RE, Spitzer WO, Schechter MT, Suissa S. The influence of psychological status on respiratory symptom reporting. Am Rev Respir Dis 1989; 139:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/9\">",
"      PRICE HL. Effects of carbon dioxide on the cardiovascular system. Anesthesiology 1960; 21:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/10\">",
"      Juan G, Calverley P, Talamo C, et al. Effect of carbon dioxide on diaphragmatic function in human beings. N Engl J Med 1984; 310:874.",
"     </a>",
"    </li>",
"    <li>",
"     Kazemi H. Cerebrospinal fluid and the control of ventilation. In: The Lung: Scientific Foundations, 2nd ed, Crystal RG, West JB, Weibel ER, Barnes PJ (Eds), Lippincott-Raven Publishers, Philadelphia 1997. p.1777.",
"    </li>",
"    <li>",
"     Gutierrez G. Cellular effects of hypoxemia and ischemia. In: The Lung: Scientific Foundations, 2nd ed, Crystal RG, West JB, Weibel ER, Barnes PJ (Eds), Lippincott-Raven Publishers, Philadelphia 1997. p.1969.",
"    </li>",
"    <li>",
"     Hornbein TF. Hypoxia and the brain. In: The Lung: Scientific Foundations, 2nd ed, Crystal RG, West JB, Weibel ER, Barnes PJ (Eds), Lippincott-Raven Publishers, Philadelphia 1997. p.1981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/14\">",
"      West JB. Causes of carbon dioxide retention in lung disease. N Engl J Med 1971; 284:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/15\">",
"      Weinberger SE, Schwartzstein RM, Weiss JW. Hypercapnia. N Engl J Med 1989; 321:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/16\">",
"      Sorli J, Grassino A, Lorange G, Milic-Emili J. Control of breathing in patients with chronic obstructive lung disease. Clin Sci Mol Med 1978; 54:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/17\">",
"      Javaheri S, Blum J, Kazemi H. Pattern of breathing and carbon dioxide retention in chronic obstructive lung disease. Am J Med 1981; 71:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/18\">",
"      Parot S, Miara B, Milic-Emili J, Gautier H. Hypoxemia, hypercapnia, and breathing pattern in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1982; 126:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/19\">",
"      Aubier M, Murciano D, Fournier M, et al. Central respiratory drive in acute respiratory failure of patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1980; 122:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/20\">",
"      O'Donnell DE, Ora J, Webb KA, et al. Mechanisms of activity-related dyspnea in pulmonary diseases. Respir Physiol Neurobiol 2009; 167:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/21\">",
"      Rudolf M, Banks RA, Semple SJ. Hypercapnia during oxygen therapy in acute exacerbations of chronic respiratory failure. Hypothesis revisited. Lancet 1977; 2:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/22\">",
"      Aubier M, Murciano D, Milic-Emili J, et al. Effects of the administration of O2 on ventilation and blood gases in patients with chronic obstructive pulmonary disease during acute respiratory failure. Am Rev Respir Dis 1980; 122:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/23\">",
"      Christiansen J, Douglas CG, Haldane JS. The absorption and dissociation of carbon dioxide by human blood. J Physiol 1914; 48:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/24\">",
"      Dick CR, Liu Z, Sassoon CS, et al. O2-induced change in ventilation and ventilatory drive in COPD. Am J Respir Crit Care Med 1997; 155:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/25\">",
"      Robinson TD, Freiberg DB, Regnis JA, Young IH. The role of hypoventilation and ventilation-perfusion redistribution in oxygen-induced hypercapnia during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/26\">",
"      Hanson CW 3rd, Marshall BE, Frasch HF, Marshall C. Causes of hypercarbia with oxygen therapy in patients with chronic obstructive pulmonary disease. Crit Care Med 1996; 24:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/27\">",
"      Crossley DJ, McGuire GP, Barrow PM, Houston PL. Influence of inspired oxygen concentration on deadspace, respiratory drive, and PaCO2 in intubated patients with chronic obstructive pulmonary disease. Crit Care Med 1997; 25:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/28\">",
"      Campbell EJ. The J. Burns Amberson Lecture. The management of acute respiratory failure in chronic bronchitis and emphysema. Am Rev Respir Dis 1967; 96:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/29\">",
"      Bone RC, Pierce AK, Johnson RL Jr. Controlled oxygen administration in acute respiratory failure in chronic obstructive pulmonary disease: a reappraisal. Am J Med 1978; 65:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/30\">",
"      Joosten SA, Koh MS, Bu X, et al. The effects of oxygen therapy in patients presenting to an emergency department with exacerbation of chronic obstructive pulmonary disease. Med J Aust 2007; 186:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/31\">",
"      Gay PC, Edmonds LC. Severe hypercapnia after low-flow oxygen therapy in patients with neuromuscular disease and diaphragmatic dysfunction. Mayo Clin Proc 1995; 70:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/32\">",
"      Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932.",
"     </a>",
"    </li>",
"    <li>",
"     Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Updated 2007 file://www.goldcopd.org (Accessed on May 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3064/abstract/34\">",
"      Durrington HJ, Flubacher M, Ramsay CF, et al. Initial oxygen management in patients with an exacerbation of chronic obstructive pulmonary disease. QJM 2005; 98:499.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1458 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-0E3ADE63EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_63_3064=[""].join("\n");
var outline_f2_63_3064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12669902\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONTROL OF VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanoreceptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chemoreceptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Behavioral control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CAUSES OF HYPERCAPNIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EFFECTS OF HYPERCAPNIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EFFECTS OF HYPOXEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HYPERCAPNIA IN COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Effects of supplemental oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Response to oxygen administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Effect of withdrawing oxygen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HYPERCAPNIA IN NEUROMUSCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12669889\">",
"      SAFE ADMINISTRATION OF OXYGEN TO HYPERCAPNIC PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12669902\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1458\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1458|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/16/38157\" title=\"figure 1\">",
"      Ventilatory response to hypercapnia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27086\" title=\"figure 2\">",
"      Ventilatory response to hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/29/17886\" title=\"figure 3\">",
"      CO2 dissociation curves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/26/2479\" title=\"figure 4\">",
"      Hemoglobin oxygen dissociation curve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/60/1988\" title=\"figure 5\">",
"      Oxygen face masks",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28852?source=related_link\">",
"      Chapter 11C: Effect of arterial pH on ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=related_link\">",
"      Control of ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22520?source=related_link\">",
"      Disorders of ventilatory control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8120?source=related_link\">",
"      Mechanical ventilation in acute respiratory failure complicating COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_63_3065="Popliteal artery aneurysm";
var content_f2_63_3065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Popliteal artery aneurysm",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/63/3065/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3065/contributors\">",
"     Amy B Reed, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/63/3065/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3065/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3065/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/63/3065/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3065/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/63/3065/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1231035278\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneurysm of the popliteal artery can occur in isolation, or in association with other large vessel aneurysms (eg, abdominal aorta, femoral artery). Popliteal aneurysm is often diagnosed as a result of screening tests or other imaging studies (other aneurysm, peripheral artery disease) in patients who do not have obvious symptoms of vascular disease. When symptoms are present, they are due to a variable degree of lower extremity ischemic symptoms that can include claudication, distal ischemia due to chronic embolization or acute limb-threatening ischemia due to thrombosis of the aneurysm or acute thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with symptomatic popliteal aneurysm should be referred for vascular evaluation and repair. The management of asymptomatic popliteal aneurysms depends upon patient comorbidities, the size of the aneurysm and the presence or absence of arterial thrombus.",
"   </p>",
"   <p>",
"    Issues related to popliteal artery aneurysm will be reviewed here. The surgical and endovascular management of popliteal aneurysm is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/45/31450?source=see_link\">",
"     \"Surgical and endovascular repair of popliteal artery aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231035293\">",
"    <span class=\"h1\">",
"     ANATOMIC ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231035309\">",
"    <span class=\"h2\">",
"     Popliteal anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The popliteal artery is in continuity with the superficial femoral artery. Anatomic landmarks include the tendinous insertion of the adductor magnus muscle in the distal femur superiorly, and the bifurcation of the popliteal artery into the anterior tibial artery and tibioperoneal trunk at the level of the tibial tuberosity inferiorly.",
"   </p>",
"   <p>",
"    Popliteal aneurysms are true aneurysms involving all layers of the vessel wall (intima, media, adventitia). Pseudoaneurysm formation in the popliteal artery has also been described but is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Popliteal aneurysms are described as fusiform (ie, diffusely dilated) or saccular (ie, rounded and typically asymmetric). Fusiform dilation of the popliteal artery may be contiguous with fusiform dilation of the superficial femoral artery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/3\">",
"     3",
"    </a>",
"    ]. Aneurysm shape may have clinical implications. (See",
"    <a class=\"local\" href=\"#H1315277\">",
"     'Rupture'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20025875\">",
"    <span class=\"h2\">",
"     Definition of popliteal aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any vessel, the popliteal artery is defined as aneurysmal when focal dilation is identified and the diameter of the vessel is increased more than 50 percent relative to the vessel's normal diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/4\">",
"     4",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    The normal diameter of the mid-popliteal artery ranges from 0.7 to 1.1 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The normal superficial femoral artery (SFA) diameter can be used as a reference if the entire extent of the popliteal artery is aneurysmal. In one ultrasound study, the distal SFA most closely approximated normal mid-popliteal artery diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231035316\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The media and adventitia provide the strength of the vessel wall. The elements of the extracellular matrix (ECM) of the media, which include elastin, collagen and glycosaminoglycans (GAGs), bear the circumferential stress imparted by blood pressure on the arterial wall. Smooth muscle of the media (ie, cellular component) produces ECM in response to a variety of factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H705779749\">",
"    <span class=\"h2\">",
"     Aneurysm formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneurysm formation is due to a loss of the mechanical integrity of the vessel wall due to an altered balance between the production and degradation of these vascular wall constituents [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/8\">",
"     8",
"    </a>",
"    ]. The etiology of this imbalance is multifactorial and likely a complex interplay of inflammatory, immunologic and potentially mechanical and genetic factors. A common systemic etiology for large vessel (eg, aorta, femoral, iliac, popliteal) aneurysm formation is supported by the occurrence of multiple aneurysms in the same patient.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Inflammation",
"      </strong>",
"      &mdash; Inflammatory infiltrate is seen within the wall of the popliteal artery and is similar to that seen in aortic aneurysms [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. The exact role of the inflammatory process is unknown, although the release of reactive oxygen species and matrix metalloproteinases appears to underlie elastin and collagen degradation. Depletion of medial smooth muscle cells through apoptosis is an important mechanism that reduces extracellular matrix production impairing arterial wall repair [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Immunologic",
"      </strong>",
"      &mdash; A dysregulated autoimmune response against components of the aortic wall is postulated to contribute to aneurysm formation. Although autoantigens have been identified within the wall of abdominal aortic aneurysms, the role of autoimmunity in the development of popliteal aneurysm has not been addressed [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Genetic factors",
"      </strong>",
"      &mdash; Patients with peripheral aneurysm have a 10 percent familial incidence rate for aneurysm. Males are more likely to be affected than females [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/12\">",
"       12",
"      </a>",
"      ]. Multiple observational studies have also found that patients with arteriomegaly have an increased incidence of aneurysm formation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/7,13-16\">",
"       7,13-16",
"      </a>",
"      ]. These observations, together with an increased incidence of aneurysm formation in multiple genetic conditions, suggest that genetic factors play a role in aneurysmal degeneration of the arterial wall. For abdominal aneurysm, genetic markers for inflammatory mediators have been identified; however, specific mechanisms in the development of popliteal aneurysm are unknown [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Mechanical factors",
"      </strong>",
"      &mdash; Mechanical factors are also believed to contribute to the formation of popliteal aneurysm. Abnormal arterial wall stress (due to hypertension), vibration and turbulence may contribute to arterial wall degeneration. Repeated flexion and extension of the knee may be another factor [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/1\">",
"       1",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Turbulent flow beyond a relative stenosis is known to cause vessel dilation in the distal segment (ie, post-stenotic dilatation). Within the lower extremity arterial system, the adductor hiatus and arcuate popliteal ligament may represent areas of relative arterial stenosis. As an example, popliteal entrapment due to abnormal insertions of the thigh muscle tendons can lead to popliteal aneurysm formation, which can be bilateral [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231035323\">",
"    <span class=\"h2\">",
"     Expansion and thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of popliteal aneurysm growth is not as well-defined as that of abdominal aortic aneurysm. Aneurysm expansion rates similarly depend upon artery diameter; however, in prospective observational studies, expansion of ectatic (ie, dilated but not aneurysmal) popliteal arteries is generally slow, but variable and difficult to predict.",
"    <strong>",
"    </strong>",
"    Published expansion rates for small (ie, 1.5 to 2.0 cm) popliteal aneurysms range from 0.7 to 1.5",
"    <span class=\"nowrap\">",
"     mm/year",
"    </span>",
"    while growth rates for larger aneurysms range from 1.5 to 3.7",
"    <span class=\"nowrap\">",
"     mm/year",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. A significant number of popliteal aneurysms do not demonstrate expansion. In one study, for example, 60 of 67 popliteal aneurysms did not demonstrate progression [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/19\">",
"     19",
"    </a>",
"    ]. As with abdominal aortic aneurysm, a concurrent diagnosis of diabetes has been correlated with slower expansion rates.",
"   </p>",
"   <p>",
"    The presence of mural thrombus within the popliteal aneurysm may have clinical implications. Mural thrombus may be associated with aneurysm enlargement, but it is unclear if the thrombus contributes to the etiology or is merely a byproduct of expansion. The mean growth rate of vessels with and without mural thrombus was 1.9 and 0",
"    <span class=\"nowrap\">",
"     mm/year,",
"    </span>",
"    respectively, in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/19\">",
"     19",
"    </a>",
"    ]. Others have suggested that thrombus increases the risk of embolism and thus thrombus, in addition to size and symptoms, is an indicator of the need for treatment. (See",
"    <a class=\"local\" href=\"#H1231035395\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a retrospective review of thrombosed aneurysms, proximal superficial femoral artery occlusion and poor distal runoff were independent factors associated with popliteal artery thrombosis probably due to stagnant flow [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231035330\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Popliteal artery aneurysms are the most common true peripheral aneurysm, occurring more frequently than femoral artery aneurysms, but less frequently than abdominal aortic aneurysm. The prevalence of popliteal aneurysm in the general population is difficult to determine, but appears to be increasing possibly due to more common use of imaging modalities and an aging population [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A screening study of 1074 men identified popliteal artery aneurysm in 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/24\">",
"     24",
"    </a>",
"    ]. In another screening study of men between the ages of 65 and 74, abdominal aortic aneurysms were identified in 4.9 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/25\">",
"     25",
"    </a>",
"    ]. Of these patients, 6.8 percent had femoral artery aneurysms and 9.6 percent had popliteal artery aneurysms.",
"   </p>",
"   <p>",
"    Men are more commonly affected than women and present at a younger age. In one study of hospitalized patients, the incidence of femoral or popliteal artery aneurysms was 7.4 per 100,000 males and 1.0 per 100,000 females [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231035337\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors for popliteal aneurysm are similar to those of other large vessel aneurysms (abdominal aorta, iliac, femoral) and include smoking, hypertension, male sex, advancing age, and arteriomegaly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11450?source=see_link&amp;anchor=H1460375#H1460375\">",
"     \"Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H1382371318#H1382371318\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fifty to 75 percent of patients are smokers and 40 to 60 percent have hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Ten percent of patients also have cerebrovascular disease and more than 40 percent have significant cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/27\">",
"     27",
"    </a>",
"    ]. Up to 15 percent of patients with popliteal aneurysm have diabetes mellitus; however, diabetes appears to provide a protective effect with slower aneurysm growth rates similar to that seen with abdominal aortic aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/19,31\">",
"     19,31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1231035323\">",
"     'Expansion and thrombosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Approximately 40 percent of patients with popliteal artery aneurysms will have an abdominal aortic aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/1,32\">",
"     1,32",
"    </a>",
"    ]. For this reason, patients with popliteal aneurysm should be screened for abdominal aortic aneurysm. (See",
"    <a class=\"local\" href=\"#H1316494\">",
"     'Screening for other aneurysm'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231035344\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of popliteal artery aneurysm ranges from the finding of an asymptomatic pulsatile popliteal mass on routine physical examination to acute limb-threatening ischemia. (See",
"    <a class=\"local\" href=\"#H1231035388\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231035351\">",
"    <span class=\"h2\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 30 to 40 percent of patients are asymptomatic at the time of initial diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/1,33\">",
"     1,33",
"    </a>",
"    ]. For some patients, popliteal aneurysm is identified as an incidental finding on a radiologic study (eg, plain film, magnetic resonance imaging) performed for another indication (eg, knee pain) or in the course of evaluating aneurysmal disease elsewhere. (See",
"    <a class=\"local\" href=\"#H1231035388\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231035358\">",
"    <span class=\"h2\">",
"     Symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The probability of developing complications increases over time, with 60 to 74 percent of patients with popliteal aneurysm developing symptoms due to thromboembolism, localized mass effect, or rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/1,22,34-38\">",
"     1,22,34-38",
"    </a>",
"    ]. Popliteal aneurysms &ge;2.0 cm are at a higher risk for thromboembolic events compared with smaller aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/1,39\">",
"     1,39",
"    </a>",
"    ]. Depending upon time course, thrombosis can cause symptoms of acute or chronic arterial insufficiency as a result of popliteal occlusion, distal embolization or popliteal stenosis. Symptoms may also develop as a result of localized \"mass effect\" within the confined space of the popliteal fossa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1314527\">",
"    <span class=\"h3\">",
"     Chronic ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can present with claudication to varying degrees as the initial symptom of popliteal aneurysm. Progressive luminal narrowing of the popliteal artery or even occlusion of the popliteal artery from thrombus can cause insidious or more sudden onset of claudication. In one retrospective review, one-third of patients who presented with aneurysm thrombosis had some degree of claudication [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/22\">",
"     22",
"    </a>",
"    ]. Claudication may improve as collateral blood flow develops, or the patient may develop clinical signs of more progressive ischemia (ie, ischemic rest pain, gangrene). Repeated episodes of distal embolization can progressively occlude the outflow vessels (anterior tibial, tibioperoneal trunk), slowing flow and leading to thrombosis of the aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/40\">",
"     40",
"    </a>",
"    ]. Some patients initially present with thromboemboli manifested as a \"blue toe syndrome\". (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    If the patient does not have adequate collateral arterial blood flow around a thrombosed aneurysm, symptoms and signs of chronic limb ischemia will develop which may be indistinguishable from occlusive atherosclerotic disease. Patients with claudication from a thrombosed popliteal aneurysm usually have a more sudden onset of symptoms compared with patients who have atherosclerotic occlusion. Smaller aneurysms may have more of a propensity to thrombose compared with larger aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/41\">",
"     41",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1314534\">",
"    <span class=\"h3\">",
"     Acute ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most dramatic presentation of popliteal artery aneurysm is acute limb threatening ischemia due to abrupt popliteal aneurysm thrombosis, which occurs in up to one-third of patients who are followed conservatively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/1\">",
"     1",
"    </a>",
"    ]. About two-thirds of patients with thrombosed popliteal artery aneurysms will present with acute ischemia; the remainder will have chronic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/22\">",
"     22",
"    </a>",
"    ]. Embolization of thrombotic debris can also acutely reduce perfusion to the extremity leading to classic symptoms of acute ischemia (ie, pain, pallor, poikilothermia, pulselessness) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=see_link\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Risk factors for popliteal aneurysm thrombosis include diameter &gt;2 cm, the presence of thrombus, and poor distal runoff [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/1\">",
"     1",
"    </a>",
"    ]. The incidence of limb loss ranges between 20 and 60 percent for patients presenting with acute limb ischemia, in spite of timely and adequate treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1315270\">",
"    <span class=\"h3\">",
"     Local compressive symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local symptoms are uncommon unless the aneurysm is large (&gt;3.0 cm). Local pain or a sensation of fullness behind the knee is due to a mass effect from the aneurysm. Patients may experience sensory or motor nerve deficits from compression of the sciatic, tibial, or peroneal nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/44\">",
"     44",
"    </a>",
"    ]. Compression of the popliteal veins can lead to ipsilateral extremity swelling, the development of varicose veins or symptoms of phlebitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1315277\">",
"    <span class=\"h3\">",
"     Rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture leading to severe pain behind the knee occurs in fewer than 5 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In these cases, the hemorrhage is usually confined to the popliteal space [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/46\">",
"     46",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Saccular aneurysms are thought to have a higher risk for this complication compared with fusiform aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Popliteal aneurysm rupture into the popliteal vein causing arteriovenous fistula has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231035388\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a part of a routine vascular examination, the popliteal fossae bilaterally should be routinely palpated, ideally with the knee slightly flexed. Sixty percent of patients with popliteal aneurysm have a pulsatile popliteal mass which is located at or above the level of the knee joint. Bilateral popliteal artery aneurysms are present in about 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/1,22\">",
"     1,22",
"    </a>",
"    ]. A popliteal aneurysm may not be palpable if the aneurysm is small (ie, &lt;2 cm), or if thrombosis has occurred. The patient should also be examined for clinical signs of distal embolization. The clinical signs of thromboembolism due to popliteal aneurysm are similar to those due to aortic pathologies, which are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=see_link&amp;anchor=H10#H10\">",
"     \"Embolism from aortic plaque: Thromboembolism\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of popliteal aneurysm is confirmed with the noninvasive radiographic visualization of an abnormally dilated (ie, &ge;1.5 times normal diameter) popliteal artery. Noninvasive imaging can be accomplished with duplex ultrasound, computed tomographic (CT) angiography, or magnetic resonance (MR) angiography. The choice of modality depends upon institutional resources and the clinical presentation. These modalities can also exclude other entities that present as a popliteal mass (eg, Baker&rsquo;s cyst) or cause lower extremity pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27016?source=see_link\">",
"     \"Popliteal (Baker's) cyst\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Duplex ultrasonography is the first-line imaging modality when popliteal aneurysm is suspected (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65760 \" href=\"UTD.htm?11/43/11952\">",
"     image 1",
"    </a>",
"    ). Ultrasound quickly confirms the diagnosis of popliteal aneurysm, provides information about patency (or occlusion) of the popliteal artery and outflow vessels, and identifies the presence (or absence) and nature of thrombus, as well as the presence of coexisting aneurysmal disease. When duplex ultrasonography is not available, CT or MR angiography can be used. Conventional arteriography does not accurately determine aneurysm size when intraluminal thrombus is present.",
"   </p>",
"   <p>",
"    Imaging the inflow and outflow vessels is important for planning elective popliteal aneurysm repair (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50705 \" href=\"UTD.htm?6/18/6447\">",
"     image 2",
"    </a>",
"    ). The main advantage of CT and MR angiography over conventional arteriography is their ability to accurately measure true lumen arterial diameters if endovascular therapy is under consideration and to define surrounding structures, which may have other anatomic abnormalities (eg, abnormal muscle attachments, tumor). These modalities, like duplex ultrasound, can also be used to evaluate the presence of associated aneurysms.",
"   </p>",
"   <p>",
"    Conventional arteriography is more appropriate for the patient who presents with acute symptoms because it provides an opportunity for thrombolytic therapy, if indicated. Depending upon the severity of ischemia, urgent or emergent arteriography should be performed to identify a suitable outflow vessel for lower extremity revascularization. For patients with non-critical ischemia, the interventional radiology suite is suitable; however, patients with immediate limb-threatening ischemia (Rutherford IIb, III) should be evaluated in the operating room. (See",
"    <a class=\"local\" href=\"#H16064863\">",
"     'Role of antithrombotic therapy and thrombolysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Noninvasive vascular testing (ankle-brachial index, segmental pressures, pulse volume recordings) does not establish a diagnosis of popliteal aneurysm. However, these tests are useful for documenting the severity of lower extremity ischemia suggested by the patient's symptoms and clinical examination, and for ongoing patient evaluation after repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link\">",
"     \"Noninvasive diagnosis of arterial disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1316494\">",
"    <span class=\"h2\">",
"     Screening for other aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a popliteal artery aneurysm have a high risk of new aneurysm formation in the contralateral popliteal artery, femoral arteries or abdominal aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/32\">",
"     32",
"    </a>",
"    ]. Thus, patients found to have a popliteal aneurysm should be screened with duplex ultrasound for aneurysms at other locations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24488?source=see_link\">",
"     \"Screening for abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of coexistent abdominal aortic aneurysm is about 40 percent overall [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/23-25,34,35,48\">",
"     23-25,34,35,48",
"    </a>",
"    ] but much higher with bilateral compared with unilateral popliteal artery aneurysms (50 to 70 versus 25 to 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/23,32,34,35\">",
"     23,32,34,35",
"    </a>",
"    ]. Screening for abdominal aortic aneurysm is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24488?source=see_link\">",
"     \"Screening for abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of abdominal aortic aneurysm or contralateral popliteal, iliac, or femoral artery aneurysms may impact the management of the popliteal aneurysm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231035395\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the clinical presentation, size of the popliteal artery aneurysm, presence of other aneurysms, and patient factors, popliteal artery aneurysms can be repaired (surgical or endovascular) or managed conservatively.",
"   </p>",
"   <p>",
"    All patients with popliteal aneurysm should be treated to manage their risk factors. Risk factor reduction is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20038379\">",
"    <span class=\"h2\">",
"     Indications for repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Popliteal aneurysm repair is indicated for [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All symptomatic aneurysms that present with acute limb ischemia regardless of size, to relieve symptoms and minimize the risk of limb loss.",
"     </li>",
"     <li>",
"      Patients with patent popliteal aneurysms &ge;2.0 cm in diameter, as these patients have a 30 to 40 percent risk of developing acute ischemic complications which are associated with a high risk for limb loss [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/1,29,39,50\">",
"       1,29,39,50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decision to perform a surgical repair must be balanced against the operative risk of the individual patient. A conservative nonoperative approach is safe in a subset of asymptomatic higher-risk patients with small popliteal aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/51\">",
"     51",
"    </a>",
"    ].The choice of procedure and technical issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/45/31450?source=see_link\">",
"     \"Surgical and endovascular repair of popliteal artery aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small (&lt;2.0 cm in diameter) asymptomatic popliteal aneurysms are typically managed conservatively. The optimal approach remains controversial because the natural history of these smaller aneurysms is not well defined and comparative randomized trials have not been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/52\">",
"     52",
"    </a>",
"    ]. Between 18 to 35 percent of patients will become symptomatic with conservative management [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/1,30,53,54\">",
"     1,30,53,54",
"    </a>",
"    ]. In addition, the presence of thrombus within the aneurysm is associated with the development of symptoms and may also increase the risk of expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/20,30\">",
"     20,30",
"    </a>",
"    ]. Thus, some clinicians feel the presence of popliteal thrombus supports a decision for repair, and that outcomes are improved with elective repair [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Others argue for conservative management using serial ultrasound and potentially anti-thrombotic therapy. (See",
"    <a class=\"local\" href=\"#H16064863\">",
"     'Role of antithrombotic therapy and thrombolysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Asymptomatic or minimally symptomatic patients such as those with claudication who are found incidentally to have a thrombosed popliteal aneurysm are treated similar to patients with occlusive atherosclerotic disease and claudication with medical management of cardiovascular risk factors, exercise therapy and a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38502?source=see_link\">",
"     cilostazol",
"    </a>",
"    . The occluded popliteal aneurysm is left alone.(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link\">",
"     \"Medical management of claudication\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with chronic critical limb ischemia due to chronic popliteal aneurysm thrombosis or chronic embolization may benefit from lower extremity revascularization and are treated similar to patients with occlusive atherosclerotic disease and chronic ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with multiple large vessel aneurysms, the approach must be individualized. Abdominal aortic aneurysm is generally treated first, followed by repair of the popliteal aneurysm unless limb-threatening ischemia is present. While it is likely that popliteal artery aneurysm thrombosis is the cause of the limb-threatening ischemia, embolization to the popliteal artery from an aortic aneurysm cannot be excluded. Thus, once the popliteal aneurysm repair is completed, aortic aneurysm repair should be undertaken as soon as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of concomitant ipsilateral common or superficial femoral artery aneurysms, popliteal artery aneurysms are typically repaired at the same time with a bypass procedure. Contralateral peripheral aneurysms are usually treated in a staged fashion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/45/31450?source=see_link\">",
"     \"Surgical and endovascular repair of popliteal artery aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16064863\">",
"    <span class=\"h2\">",
"     Role of antithrombotic therapy and thrombolysis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      &ndash; Intravenous heparin followed by a continuous heparin infusion should be initiated immediately in patients diagnosed with popliteal artery aneurysm and evidence of acute thrombosis, distal embolization, or chronic critical limb ischemia. This approach is recommended by the 2012 American College of Chest Physicians (ACCP) guideline on antithrombotic therapy for peripheral artery disease and the 2007 TASC II consensus document on the management of acute ischemia in peripheral artery disease [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/56\">",
"       56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=see_link&amp;anchor=H15#H15\">",
"       \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\", section on 'Anticoagulation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombolysis &ndash; Intra-arterial thrombolytic therapy (catheter-directed or direct intraoperative) is indicated if arteriography demonstrates no target vessel or multiple distal thrombi are seen [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/42,57-64\">",
"       42,57-64",
"      </a>",
"      ]. However, most clinicians would not use lytic therapy on a patient who has adequate vein conduit and an appropriate target vessel because dissolution of the thrombus with distal showering can compromise the outflow [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      &ndash; A select group of patients who have undergone successful thrombolysis for complications related to a popliteal aneurysm but who are not immediate candidates for surgical or endovascular repair may benefit from anticoagulation with warfarin.",
"      <br/>",
"      <br/>",
"      The use of warfarin in patients with asymptomatic popliteal artery aneurysm has not been well studied. Patients with small popliteal aneurysms &lt;2.0 cm may be candidates for anticoagulation, particularly if mural thrombus is present. Only one small study found a lower incidence of thrombus formation in patients with popliteal artery aneurysm treated with warfarin compared with antiplatelet therapy; however, the number of events was small [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/20\">",
"       20",
"      </a>",
"      ]. It should be noted, however, that with aneurysms in other locations, anticoagulation has not been found to decrease the incidence of distal thromboembolism, and some speculate that it may actually increase the incidence of events.",
"     </li>",
"     <li>",
"      Antiplatelet therapy &ndash; The role of antiplatelet therapy in the treatment of popliteal artery aneurysm is not defined. Antiplatelet therapy is indicated for secondary prevention in patients with risk factors of cardiovascular disease, and could potentially limit the development of luminal thrombus in patients managed conservatively. Randomized trials are needed to determine the role, if any, of antithrombotic therapy in the conservative management of small popliteal artery aneurysms. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231035447\">",
"    <span class=\"h2\">",
"     Surveillance ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who do not have an indication for popliteal aneurysm repair should be followed with serial physical examination and duplex ultrasonography. Surveillance duplex scanning should be performed every 6 to 12 months in patients with a popliteal aneurysm who are managed conservatively. A scanning interval of 12 months has been suggested for patients with popliteal arteries &lt;1.7 mm and every 6 months for those &ge;1.7 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/20\">",
"     20",
"    </a>",
"    ]. Rather than basing ultrasound frequency on strict size criteria, intervals can be customized after consideration of risk factors for increased aneurysm growth (hypertension, contralateral popliteal aneurysm repair, presence of other large vessel aneurysm), or decreased growth (diabetes) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3065/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1231035323\">",
"     'Expansion and thrombosis'",
"    </a>",
"    above.) &nbsp;",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231035468\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Popliteal artery aneurysms are the most common true peripheral aneurysm. The popliteal artery is defined as aneurysmal when a localized diameter is 1.5 times normal artery diameter. Risk factors for popliteal aneurysm include smoking, hypertension, male sex, advancing age, other large vessel aneurysm, and arteriomegaly. (See",
"      <a class=\"local\" href=\"#H1231035330\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1231035293\">",
"       'Anatomic issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Arterial obstruction as a complication of a popliteal artery aneurysm may be due to popliteal artery thrombosis or distal embolization of intraluminal thrombus. The time course of ischemic symptoms can be acute presenting as limb-threatening ischemia (a surgical emergency), or chronic if sufficient collateral flow is established around areas of occlusion. (See",
"      <a class=\"local\" href=\"#H1231035344\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of popliteal aneurysm is based upon noninvasive radiographic visualization of an abnormally dilated (ie, &ge;1.5 times normal diameter) popliteal artery. Duplex ultrasound is the initial test of choice, although computed tomographic (CT) angiography or magnetic resonance (MR) angiography may also be appropriate depending upon availability of ultrasound, and the urgency of the clinical situation. Conventional arteriography alone does not reliably demonstrate the presence of an aneurysm but is essential for planning surgical repair or performing endovascular repair or thrombolysis, if indicated. (See",
"      <a class=\"local\" href=\"#H1231035388\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute lower extremity ischemic symptoms due to popliteal aneurysm (any size), we recommend emergent popliteal aneurysm repair due to the high risk of limb loss without treatment (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest thrombolytic therapy prior to repair for patients with absent or limited distal runoff; restoration of outflow improves the long-term patency of revascularization (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Lytic agents can be administered intraoperatively or using catheter-based techniques depending upon the clinical scenario. The patient should be anticoagulated with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      while awaiting repair. (See",
"      <a class=\"local\" href=\"#H1231035395\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with patent popliteal aneurysm &ge;2.0 cm, we suggest elective repair of the aneurysm over conservative management for patients at low risk for perioperative surgical morbidity (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Elective aneurysm repair is associated with a lower long-term risk of limb-threatening ischemia and limb loss. (See",
"      <a class=\"local\" href=\"#H1231035395\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with popliteal aneurysm &lt;2.0 cm are typically observed. However, the presence of mural thrombus may increase the propensity for artery expansion and risk of thromboembolic complications. The role of antiplatelet and anticoagulant therapy in the conservative management of small popliteal artery aneurysms, and particularly those with mural thrombus, has not been defined. As such, some clinicians prefer to repair popliteal aneurysm &lt;2.0 cm when they are associated with significant thrombus. (See",
"      <a class=\"local\" href=\"#H1231035395\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We perform serial physical examination and duplex ultrasonography every 6 to 12 months for patients who are managed conservatively. The time interval between examinations depends on the patients&rsquo; risk factors for expansion. (See",
"      <a class=\"local\" href=\"#H1231035447\">",
"       'Surveillance ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/1\">",
"      Dawson I, Sie RB, van Bockel JH. Atherosclerotic popliteal aneurysm. Br J Surg 1997; 84:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/2\">",
"      Matsushita M, Nishikimi N, Sakurai T, Nimura Y. Pseudoaneurysm of the popliteal artery caused by exostosis of the femur: case report and review of the literature. J Vasc Surg 2000; 32:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/3\">",
"      Jarrett F, Makaroun MS, Rhee RY, Bertges DJ. Superficial femoral artery aneurysms: an unusual entity? J Vasc Surg 2002; 36:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/4\">",
"      Johnston KW, Rutherford RB, Tilson MD, et al. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg 1991; 13:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/5\">",
"      Wolf YG, Kobzantsev Z, Zelmanovich L. Size of normal and aneurysmal popliteal arteries: a duplex ultrasound study. J Vasc Surg 2006; 43:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/6\">",
"      Davis RP, Neiman HL, Yao JS, Bergan JJ. Ultrasound scan in diagnosis of peripheral aneurysms. Arch Surg 1977; 112:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/7\">",
"      Callum KG, Lea Thomas M, Browse NL. A definition of arteriomegaly and the size of arteries supplying the lower limbs. Br J Surg 1983; 70:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/8\">",
"      Jacob T, Hingorani A, Ascher E. Examination of the apoptotic pathway and proteolysis in the pathogenesis of popliteal artery aneurysms. Eur J Vasc Endovasc Surg 2001; 22:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/9\">",
"      Jacob T, Schutzer R, Hingorani A, Ascher E. Differential expression of YAMA/CPP-32 by T lymphocytes in popliteal artery aneurysm. J Surg Res 2003; 112:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/10\">",
"      Thompson RW, Liao S, Curci JA. Vascular smooth muscle cell apoptosis in abdominal aortic aneurysms. Coron Artery Dis 1997; 8:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/11\">",
"      Jagadesham VP, Scott DJ, Carding SR. Abdominal aortic aneurysms: an autoimmune disease? Trends Mol Med 2008; 14:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/12\">",
"      Lawrence PF, Wallis C, Dobrin PB, et al. Peripheral aneurysms and arteriomegaly: is there a familial pattern? J Vasc Surg 1998; 28:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/13\">",
"      Tilson MD, Dang C. Generalized arteriomegaly. A possible predisposition to the formation of abdominal aortic aneurysms. Arch Surg 1981; 116:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/14\">",
"      Chan O, Thomas ML. The incidence of popliteal aneurysms in patients with arteriomegaly. Clin Radiol 1990; 41:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/15\">",
"      Tilson MD, Seashore MR. Fifty families with abdominal aortic aneurysms in two or more first-order relatives. Am J Surg 1984; 147:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/16\">",
"      Tilson MD, Ozsvath KJ, Hirose H, Xia S. A genetic basis for autoimmune manifestations in the abdominal aortic aneurysm resides in the MHC class II locus DR-beta-1. Ann N Y Acad Sci 1996; 800:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/17\">",
"      Rasmussen TE, Hallett JW Jr. Inflammatory aortic aneurysms. A clinical review with new perspectives in pathogenesis. Ann Surg 1997; 225:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/18\">",
"      L&oacute;pez Garcia D, Arranz MA, Tagarro S, et al. Bilateral popliteal aneurysm as a result of vascular type IV entrapment in a young patient: a report of an exceptional case. J Vasc Surg 2007; 46:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/19\">",
"      Surveillance of ectatic popliteal arteries. Eur J Vasc Endovasc Surg 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/20\">",
"      Stiegler H, Mendler G, Baumann G. Prospective study of 36 patients with 46 popliteal artery aneurysms with non-surgical treatment. Vasa 2002; 31:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/21\">",
"      Pittathankal AA, Dattani R, Magee TR, Galland RB. Expansion rates of asymptomatic popliteal artery aneurysms. Eur J Vasc Endovasc Surg 2004; 27:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/22\">",
"      Martelli E, Ippoliti A, Ventoruzzo G, et al. Popliteal artery aneurysms. Factors associated with thromboembolism and graft failure. Int Angiol 2004; 23:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/23\">",
"      Ravn H, Wanhainen A, Bj&ouml;rck M. Risk of new aneurysms after surgery for popliteal artery aneurysm. Br J Surg 2008; 95:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/24\">",
"      Trickett JP, Scott RA, Tilney HS. Screening and management of asymptomatic popliteal aneurysms. J Med Screen 2002; 9:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/25\">",
"      Diwan A, Sarkar R, Stanley JC, et al. Incidence of femoral and popliteal artery aneurysms in patients with abdominal aortic aneurysms. J Vasc Surg 2000; 31:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/26\">",
"      Lawrence PF, Lorenzo-Rivero S, Lyon JL. The incidence of iliac, femoral, and popliteal artery aneurysms in hospitalized patients. J Vasc Surg 1995; 22:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/27\">",
"      Whitehouse WM Jr, Wakefield TW, Graham LM, et al. Limb-threatening potential of arteriosclerotic popliteal artery aneurysms. Surgery 1983; 93:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/28\">",
"      Anton GE, Hertzer NR, Beven EG, et al. Surgical management of popliteal aneurysms. Trends in presentation, treatment, and results from 1952 to 1984. J Vasc Surg 1986; 3:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/29\">",
"      Vermilion BD, Kimmins SA, Pace WG, Evans WE. A review of one hundred forty-seven popliteal aneurysms with long-term follow-up. Surgery 1981; 90:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/30\">",
"      Lowell RC, Gloviczki P, Hallett JW Jr, et al. Popliteal artery aneurysms: the risk of nonoperative management. Ann Vasc Surg 1994; 8:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/31\">",
"      Portik-Dobos V, Anstadt MP, Hutchinson J, et al. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 2002; 51:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/32\">",
"      Dent TL, Lindenauer SM, Ernst CB, Fry WJ. Multiple arteriosclerotic arterial aneurysms. Arch Surg 1972; 105:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/33\">",
"      Duffy ST, Colgan MP, Sultan S, et al. Popliteal aneurysms: a 10-year experience. Eur J Vasc Endovasc Surg 1998; 16:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/34\">",
"      Huang Y, Gloviczki P, Noel AA, et al. Early complications and long-term outcome after open surgical treatment of popliteal artery aneurysms: is exclusion with saphenous vein bypass still the gold standard? J Vasc Surg 2007; 45:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/35\">",
"      Dawson I, van Bockel JH, Brand R, Terpstra JL. Popliteal artery aneurysms. Long-term follow-up of aneurysmal disease and results of surgical treatment. J Vasc Surg 1991; 13:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/36\">",
"      Schr&ouml;der A, Gohlke J, Gross-Fengels W, Horstmann R. [Popliteal aneurysms--surgical management versus conservative procedure]. Langenbecks Arch Chir Suppl Kongressbd 1996; 113:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/37\">",
"      Poirier NC, Verdant A, Pag&eacute; A. [Popliteal aneurysm: surgical treatment is mandatory before complications occur]. Ann Chir 1996; 50:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/38\">",
"      Farina C, Cavallaro A, Schultz RD, et al. Popliteal aneurysms. Surg Gynecol Obstet 1989; 169:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/39\">",
"      Ascher E, Markevich N, Schutzer RW, et al. Small popliteal artery aneurysms: are they clinically significant? J Vasc Surg 2003; 37:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/40\">",
"      Lilly MP, Flinn WR, McCarthy WJ 3rd, et al. The effect of distal arterial anatomy on the success of popliteal aneurysm repair. J Vasc Surg 1988; 7:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/41\">",
"      Inahara T, Toledo AC. Complications and treatment of popliteal aneurysms. Surgery 1978; 84:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/42\">",
"      Kropman RH, Schrijver AM, Kelder JC, et al. Clinical outcome of acute leg ischaemia due to thrombosed popliteal artery aneurysm: systematic review of 895 cases. Eur J Vasc Endovasc Surg 2010; 39:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/43\">",
"      Robinson WP 3rd, Belkin M. Acute limb ischemia due to popliteal artery aneurysm: a continuing surgical challenge. Semin Vasc Surg 2009; 22:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/44\">",
"      Selvam A, Shetty K, James NV, et al. Giant popliteal aneurysm presenting with foot drop. J Vasc Surg 2006; 44:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/45\">",
"      Walsh JJ, Williams LR, Driscoll JL, Lee JF. Vein compression by arterial aneurysms. J Vasc Surg 1988; 8:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/46\">",
"      Illig KA, Eagleton MJ, Shortell CK, et al. Ruptured popliteal artery aneurysm. J Vasc Surg 1998; 27:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/47\">",
"      Reed MK, Smith BM. Popliteal aneurysm with spontaneous arteriovenous fistula. J Cardiovasc Surg (Torino) 1991; 32:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/48\">",
"      Ashton HA, Buxton MJ, Day NE, et al. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet 2002; 360:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/49\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/50\">",
"      Szilagyi DE, Schwartz RL, Reddy DJ. Popliteal arterial aneurysms. Their natural history and management. Arch Surg 1981; 116:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/51\">",
"      Schellack J, Smith RB 3rd, Perdue GD. Nonoperative management of selected popliteal aneurysms. Arch Surg 1987; 122:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/52\">",
"      Galland RB. History of the management of popliteal artery aneurysms. Eur J Vasc Endovasc Surg 2008; 35:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/53\">",
"      Michaels JA, Galland RB. Management of asymptomatic popliteal aneurysms: the use of a Markov decision tree to determine the criteria for a conservative approach. Eur J Vasc Surg 1993; 7:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/54\">",
"      Roggo A, Brunner U, Ottinger LW, Largiader F. The continuing challenge of aneurysms of the popliteal artery. Surg Gynecol Obstet 1993; 177:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/55\">",
"      Chaikof EL, Brewster DC, Dalman RL, et al. The care of patients with an abdominal aortic aneurysm: the Society for Vascular Surgery practice guidelines. J Vasc Surg 2009; 50:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/56\">",
"      Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e669S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/57\">",
"      Ravn H, Bj&ouml;rck M. Popliteal artery aneurysm with acute ischemia in 229 patients. Outcome after thrombolytic and surgical therapy. Eur J Vasc Endovasc Surg 2007; 33:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/58\">",
"      Thrombolysis in the management of lower limb peripheral arterial occlusion--a consensus document. Working Party on Thrombolysis in the Management of Limb Ischemia. Am J Cardiol 1998; 81:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/59\">",
"      Debing E, Van den Brande P, van Tussenbroek F, et al. Intra-arterial thrombolysis followed by elective surgery for thrombo-embolic popliteal aneurysms. Acta Chir Belg 1997; 97:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/60\">",
"      Taurino M, Calisti A, Grossi R, et al. Outcome after early treatment of popliteal artery aneurysms. Int Angiol 1998; 17:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/61\">",
"      Greenberg R, Wellander E, Nyman U, et al. Aggressive treatment of acute limb ischemia due to thrombosed popliteal aneurysms. Eur J Radiol 1998; 28:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/62\">",
"      Marty B, Wicky S, Ris HB, et al. Success of thrombolysis as a predictor of outcome in acute thrombosis of popliteal aneurysms. J Vasc Surg 2002; 35:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/63\">",
"      Dorigo W, Pulli R, Turini F, et al. Acute leg ischaemia from thrombosed popliteal artery aneurysms: role of preoperative thrombolysis. Eur J Vasc Endovasc Surg 2002; 23:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3065/abstract/64\">",
"      Gibbons CP. Thrombolysis or immediate surgery for thrombosed popliteal aneurysms? Eur J Vasc Endovasc Surg 2010; 39:458.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15187 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_63_3065=[""].join("\n");
var outline_f2_63_3065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1231035468\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231035278\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231035293\">",
"      ANATOMIC ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231035309\">",
"      Popliteal anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20025875\">",
"      Definition of popliteal aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231035316\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H705779749\">",
"      Aneurysm formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231035323\">",
"      Expansion and thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231035330\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231035337\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231035344\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231035351\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231035358\">",
"      Symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1314527\">",
"      - Chronic ischemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1314534\">",
"      - Acute ischemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1315270\">",
"      - Local compressive symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1315277\">",
"      - Rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231035388\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1316494\">",
"      Screening for other aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231035395\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20038379\">",
"      Indications for repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16064863\">",
"      Role of antithrombotic therapy and thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231035447\">",
"      Surveillance ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231035468\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15187\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15187|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/43/11952\" title=\"diagnostic image 1\">",
"      Ultrasound of popliteal artery aneursym",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/18/6447\" title=\"diagnostic image 2\">",
"      Popliteal aneurysm on CT angiography",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=related_link\">",
"      Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=related_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11450?source=related_link\">",
"      Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=related_link\">",
"      Medical management of claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27016?source=related_link\">",
"      Popliteal (Baker's) cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24488?source=related_link\">",
"      Screening for abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/45/31450?source=related_link\">",
"      Surgical and endovascular repair of popliteal artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=related_link\">",
"      Treatment of chronic lower extremity critical limb ischemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_63_3066="Overview of the management of epidermolysis bullosa";
var content_f2_63_3066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of epidermolysis bullosa",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/63/3066/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3066/contributors\">",
"     Dedee F Murrell, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3066/contributors\">",
"     Lizbeth Intong, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/63/3066/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3066/contributors\">",
"     Susan J Bayliss, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/63/3066/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/63/3066/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/63/3066/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13245609\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermolysis bullosa (EB) is a heterogeneous group of hereditary mechanobullous diseases characterized by varying degrees of skin and mucosa fragility caused by mutations in skin structural proteins. There are four major types of EB, based upon the ultrastructural level of tissue cleavage in the skin: EB simplex, junctional EB, dystrophic EB, and Kindler syndrome (",
"    <a class=\"graphic graphic_table graphicRef76897 \" href=\"UTD.htm?23/11/23740\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Severity is determined by the level of blistering and type of mutation and is highly variable among subtypes of EB (",
"    <a class=\"graphic graphic_table graphicRef77709 graphicRef67202 graphicRef55262 \" href=\"UTD.htm?10/34/10787\">",
"     table 2A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is no targeted therapy for EB, although this is an active area of investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The management of patients with EB is largely supportive and includes wound care and prevention and treatment of complications.",
"   </p>",
"   <p>",
"    This topic will provide an overview of the management of EB. The pathogenesis, clinical characteristics, and diagnosis of EB are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28106?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39255?source=see_link\">",
"     \"Diagnosis of epidermolysis bullosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10204934\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70257089\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific therapy for any form of epidermolysis bullosa (EB). Treatment is largely supportive and includes wound care, control of infection, nutritional support, and prevention and treatment of complications.",
"   </p>",
"   <p>",
"    The management of patients with EB involves a multidisciplinary team usually composed of a dermatologist, an EB nurse, primary care provider, occupational therapist, nutritionist, and social worker. Specialists, including gastroenterology, ophthalmology, nephrology, hematology, endocrinology, cardiology, pain management, plastic surgery, and specialized dentistry, are consulted as needed.",
"   </p>",
"   <p>",
"    Care plans for EB patients should be individualized according to age, severity, symptoms, complications, and patient priorities. We typically see patients with severe forms of EB, such as severe, generalized recessive dystrophic EB or junctional EB, at three- to six month- intervals; they often require inpatient multidisciplinary care. Patients with less severe forms of EB, such as localized EB simplex or mild dominant dystrophic EB, can be seen once a year in dedicated outpatient clinics.",
"   </p>",
"   <p>",
"    The burden for families with children with severe forms of EB is enormous [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/7\">",
"     7",
"    </a>",
"    ]. Support groups in the community, such as the",
"    <a class=\"external\" href=\"file://www.debra.org/\">",
"     Dystrophic Epidermolysis Bullosa Research Association",
"    </a>",
"    , are important for families of children with this chronic, debilitating disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70257120\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory and imaging monitoring is an important aspect of management of patients with epidermolysis bullosa. Patients with EB require regular monitoring for complications and sequelae. The laboratory and imaging tests and the frequency of these tests vary depending upon the type of EB and the presence of complications (",
"    <a class=\"graphic graphic_table graphicRef87123 \" href=\"UTD.htm?40/51/41788\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56675661\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF NEONATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early management of neonates with EB should be undertaken in a neonatal or pediatric unit with the expertise, staffing, and resources necessary to manage extensive erosions or potential complications related to widespread skin sloughing [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/9\">",
"     9",
"    </a>",
"    ]. Expert nursing care is key to successful treatment of neonates with EB. Pediatric nurse specialists are involved in coordinating the multidisciplinary in-hospital management, training parents and non-specialist nurses at other centers, and organizing the child's return home.",
"   </p>",
"   <p>",
"    Newborns presenting with skin lesions suspicious of EB should be handled with extreme care. They should be placed on a thick foam pad and the pad should be used for transporting the infant (eg, from the bed to the caregiver&rsquo;s arms). Heat may induce blisters in some neonates with EB; the risks and benefits of using an incubator must be determined individually.",
"   </p>",
"   <p>",
"    If suction is necessary, a soft catheter should be chosen and minimal suction pressure exerted [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/10\">",
"     10",
"    </a>",
"    ]. In newborns with severe dystrophic EB, over-zealous suction can strip the mucosa, resulting in scarring and earlier development of pharyngeal strictures.",
"   </p>",
"   <p>",
"    It is preferable to delay bathing until lesions present at birth have healed. The erosions can be cleaned by gentle irrigation with warm sterile normal saline and covered with nonadherent dressings [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Dressings are changed on one limb at a time to prevent self-inflicted trauma from kicking the bare skin on the opposite limb if the infant is agitated during the change. (See",
"    <a class=\"local\" href=\"#H12936348\">",
"     'Wound dressing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Disposable diapers can be used but should be lined with a soft material to reduce trauma from the elastic edges. Erosions on the diaper area can be protected by liberal application of a mixture of white soft paraffin and liquid paraffin in equal parts [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/10\">",
"     10",
"    </a>",
"    ]. Clothing helps to prevent self-inflicted skin damage from kicking or rubbing. Clothes should be turned inside out to prevent skin damage from the seams.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13245661\">",
"    <span class=\"h1\">",
"     SKIN AND WOUND CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12936341\">",
"    <span class=\"h2\">",
"     Bathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bathing is painful for patients with severe forms of EB and open wounds. In our clinical experience, pain is greatly reduced by bathing with salt water that approximates isotonic saline for bathing. This can be prepared by dissolving approximately one kg (two pounds) of pool salt in a full tub (approximately 40 gallons [160 L]) of warm water [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/11\">",
"     11",
"    </a>",
"    ]. Pool salt is less expensive than table salt and available commercially.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12936348\">",
"    <span class=\"h2\">",
"     Wound dressing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonstick or nonadherent silicone dressings and foam dressings that absorb exudates are ideal for EB wounds. They can be left in place for several days and are easy to remove. The recommended dressings for specific subtypes of EB are listed in the tables (",
"    <a class=\"graphic graphic_table graphicRef87148 graphicRef87149 graphicRef87150 \" href=\"UTD.htm?11/52/12110\">",
"     table 4A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H55268776#H55268776\">",
"     \"Basic principles of wound management\", section on 'Wound dressings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with wounds covering large areas of the body, dressing change is laborious, time consuming, and painful [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/13\">",
"     13",
"    </a>",
"    ]. The frequency of change depends upon the patient&rsquo;s preference, time availability, amount of exudate, and presence of infection. Wounds with bacterial colonization or frank infection may require more frequent changes and specific types of dressings (",
"    <a class=\"graphic graphic_table graphicRef87151 \" href=\"UTD.htm?1/29/1501\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3707630\">",
"     'Prevention and management of infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    General measures to reduce the discomfort associated with wound care include [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Turning off fans before removing dressings to reduce pain from circulating air",
"     </li>",
"     <li>",
"      Cutting templates for dressing specific wounds or body areas",
"     </li>",
"     <li>",
"      Cutting all dressings before starting the dressing change",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using tubular bandage rather than tape to cover dressings and hold them in place",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3707630\">",
"    <span class=\"h2\">",
"     Prevention and management of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial colonization of EB wounds, usually with",
"    <em>",
"     Staphylococcus",
"    </em>",
"    sp.,",
"    <em>",
"     Streptococcus",
"    </em>",
"    sp., and",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    , is common [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/14\">",
"     14",
"    </a>",
"    ]. Wounds that are &ldquo;critically colonized&rdquo; (ie, active multiplication of organisms without invasion) or frankly infected fail to heal [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. In addition to nonhealing, clinical signs of critical colonization include increased exudate, red, friable tissue, debris, and smell. Wounds that are frankly infected present with increased size and depth,",
"    <span class=\"nowrap\">",
"     erythema/edema",
"    </span>",
"    of surrounding skin, and increased exudate and smell. Systemic signs (eg, lymphadenopathy, fever, malaise) also may be present.",
"   </p>",
"   <p>",
"    In critically colonized wounds, the bacterial load can be reduced with topical agents, including diluted bleach baths or compresses, topical antiseptics, and topical antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/19\">",
"     19",
"    </a>",
"    ]. Bacterial cultures of critically colonized wounds are not routinely performed. If required, cultures should be obtained before starting topical antimicrobial treatments.",
"   </p>",
"   <p>",
"    Bleach baths are prepared by diluting 100 mL of bleach in an adult-sized bath tub. Patients are soaked in the bath for 10 minutes and then rinsed with lukewarm water. &nbsp;",
"   </p>",
"   <p>",
"    Topical antiseptic agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    , benzalkonium chloride, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"     silver sulfadiazine",
"    </a>",
"    . However, a prolonged use of silver preparations over extended wounds may induce systemic silver toxicity (argyria) and a slate-gray metallic skin discoloration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H369372661#H369372661\">",
"     \"Basic principles of wound management\", section on 'Antiseptics and antimicrobials'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link&amp;anchor=H21593928#H21593928\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\", section on 'Topical antimicrobial agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21651?source=see_link\">",
"     fusidic acid",
"    </a>",
"    ) should be used in moderation to avoid the emergence of antibiotic-resistant bacteria. If used, different agents should be rotated every two to six weeks to minimize the induction of bacterial resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wounds with frank infection usually require systemic antibiotics. The choice of antibiotic therapy should be based on bacterial culture and antibiogram results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71484649\">",
"    <span class=\"h1\">",
"     PAIN MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is a constant feature of EB and an important management issue. Pain may be inherent (eg, from skin blisters and wounds, oral or corneal erosions, dental problems, etc) or elicited by bathing or dressing change. A comprehensive approach to EB pain management is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef87169 \" href=\"UTD.htm?40/18/41260\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For mild to moderate pain, analgesics (eg, paracetamol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ) can be used alone or in conjunction with a nonsteroidal antiinflammatory drug [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/21\">",
"     21",
"    </a>",
"    ]. For more severe pain, opioids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ) or anxiolytics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ) may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Opioids may be used topically to provide analgesia without adverse effects or induction of tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/22\">",
"     22",
"    </a>",
"    ]. A preparation of 10 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine sulfate",
"    </a>",
"    mixed with 15 g of hydrogel (eg, IntraSite) can be applied directly to open wounds at dressing changes.",
"   </p>",
"   <p>",
"    Oral pain can be reduced by rinsing the mouth with coating products (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    ) or topical anesthetics [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70257708\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF NUTRITIONAL COMPROMISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with severe forms of EB, particularly recessive dystrophic EB or junctional EB have nutritional compromise and require nutritional support. Major causes of macro- and micro-nutrient deficiency include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral, oropharyngeal,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gastrointestinal complications (eg, ulcerations, strictures, painful defecation) which limit nutritional intake",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nutrient absorption",
"     </li>",
"     <li>",
"      Hypercatabolic state due to chronic inflammation and infection of skin lesions",
"     </li>",
"     <li>",
"      Nutrient loss due to loss of fluid and blood through cutaneous and mucosal lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed approach to the evaluation and management of nutritional compromise in children with severe EB is beyond the scope of this topic review, but available in the",
"    <a class=\"external\" href=\"file://www.debra.org.uk/uploads/resources/EB_Guidelines_Final_for_web.pdf\">",
"     Clinical Practice Guidelines for Nutrition Support in Infants and Children with Epidermolysis Bullosa",
"    </a>",
"    . &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70257715\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nutritional status of children with severe forms of EB can be evaluated by the Tool to Help Identify Nutritional Compromise (THINC), a scoring system based upon the child&rsquo;s height, weight, and gain or loss of weight in the previous six months; gastroenterologic aspects (eg, tethered tongue, dysphagia, painful defecation, presence of a gastrostomy tube); and dermatologic aspects (eg, body surface area of denuded skin, skin infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/24\">",
"     24",
"    </a>",
"    ]. The THINC is included in the",
"    <a class=\"external\" href=\"file://www.debra.org.uk/uploads/resources/EB_Guidelines_Final_for_web.pdf\">",
"     Clinical Practice Guidelines for Nutrition Support in Infants and Children with Epidermolysis Bullosa",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70257722\">",
"    <span class=\"h2\">",
"     Nutritional support",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aims of nutritional support include [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alleviating the stress associated with feeding difficulties",
"     </li>",
"     <li>",
"      Addressing macro- and micro-nutrient deficiencies, (eg, hypoproteinemia, zinc or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      deficiency)",
"     </li>",
"     <li>",
"      Promoting normal bowel function and alleviating painful defecation",
"     </li>",
"     <li>",
"      Promoting optimal growth rates for age, sex, and sexual maturation &nbsp;",
"     </li>",
"     <li>",
"      Promoting optimal immune status and wound healing",
"     </li>",
"     <li>",
"      Promoting mobility and quality of life",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Breastfeeding is recommended for infants with EB. Supplementation with a more nutrient-dense formula may be necessary if breast feeding is not possible or weight gain is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/25\">",
"     25",
"    </a>",
"    ]. In infants with failure to thrive, temporary supplemented feeding using nasogastric (NG) tubes may be necessary. However, NG tubes should not be used for more than six to eight weeks, since they can cause mucosal trauma and scarring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/16/30985?source=see_link\">",
"     \"Management of failure to thrive (undernutrition) in children younger than two years\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A gastrostomy tube (G-tube) may be beneficial for children with severe dystrophic EB who require long-term supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=see_link&amp;anchor=H3#H3\">",
"     \"Enteral feeding: Gastric versus post-pyloric\", section on 'Gastric feeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11529?source=see_link&amp;anchor=H869597#H869597\">",
"     \"Enteral nutrition in infants and children\", section on 'Gastrostomy route'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Placement of a G-tube is indicated in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Growth rate is lower than expected despite nutritional interventions",
"     </li>",
"     <li>",
"      Eating and drinking are aversive or painful",
"     </li>",
"     <li>",
"      Supplements or medications are refused",
"     </li>",
"     <li>",
"      Mealtimes are increasingly stressful and protracted",
"     </li>",
"     <li>",
"      Esophageal dilation does not alleviate the above issues",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with impaired gastric emptying, intractable gastro-esophageal reflux, and risk of aspiration may benefit from jejunal feeding with partially hydrolyzed feeds. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=see_link&amp;anchor=H11#H11\">",
"     \"Enteral feeding: Gastric versus post-pyloric\", section on 'Post-pyloric feeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children receiving enteral feeding should be encouraged to maintain oral sucking and swallowing skills.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70257736\">",
"    <span class=\"h2\">",
"     Micronutrients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum levels of micronutrients such as iron, zinc,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    , vitamin B12, vitamin A, and folate should be checked at regular intervals (3 to 6 months for iron, 12 months for vitamins and trace elements) (",
"    <a class=\"graphic graphic_table graphicRef87123 \" href=\"UTD.htm?40/51/41788\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Iron",
"      </strong>",
"      &ndash; Iron levels are frequently low in severe forms of EB due to chronic blood loss from cutaneous and visceral wounds and reduced intake. Iron deficiency usually is treated with oral iron; liquid formulations are generally more acceptable than tablets for young children. If oral iron is not tolerated or inadequately absorbed, iron should be given intravenously. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38949?source=see_link\">",
"       \"Iron deficiency in infants and young children: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Calcium and",
"      </strong>",
"      <strong>",
"       vitamin D",
"      </strong>",
"      &ndash; Children with recessive dystrophic EB often have a low bone mineral density for age and increased risk of fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7616095\">",
"       'Osteopenia and osteoporosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Combined supplementation of calcium and vitamin D is required even in patients with adequate intake of milk and milk products, since chronic inflammation and infection can adversely affect bone turnover and gastrointestinal complications may interfere with absorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link&amp;anchor=H23365759#H23365759\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Causes of vitamin D deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Zinc",
"      </strong>",
"      &ndash; Zinc is essential for wound healing and immune function. Since most plasma zinc is bound to albumin, zinc levels may be low in patients with hypoalbuminemia. If supplementation is required for young children, the liquid form is preferable and daily doses may be split into two to reduce nausea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=see_link&amp;anchor=H12503302#H12503302\">",
"       \"Zinc deficiency and supplementation in children and adolescents\", section on 'Recommended intake'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       Selenium",
"      </a>",
"      &ndash; Supplementation with selenium and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      is indicated in children with recessive dystrophic EB [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/25\">",
"       25",
"      </a>",
"      ]. In these patients, low levels of selenium and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      may play a role in the development of dilated cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link&amp;anchor=H52#H52\">",
"       \"Overview of dietary trace minerals\", section on 'Deficiency'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link&amp;anchor=H31#H31\">",
"       \"Causes of dilated cardiomyopathy\", section on 'Nutritional deficiencies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Vitamins",
"      </strong>",
"      &ndash; If vitamin intake is not optimal, an age-appropriate multivitamin supplement is recommended. However, the total vitamin intake (particularly of vitamin A) should not exceed the recommended safe upper limits. In children with severe EB, vitamin supplementation up to 150 to 200 percent of normal national recommendations is considered safe [",
"      <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/25\">",
"       25",
"      </a>",
"      ]. Vitamin supplementation is given orally in most cases. Children with feeding difficulties or esophageal strictures may need intravenous supplementation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18441?source=see_link&amp;anchor=H2#H2\">",
"       \"Dietary recommendations for toddlers, preschool, and school-age children\", section on 'Nutritional requirements'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7615964\">",
"    <span class=\"h2\">",
"     Related problems",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7616088\">",
"    <span class=\"h3\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with EB, anemia develops as a result of chronic inflammation, blood loss from cutaneous and mucosal wounds, and malabsorption of iron and other micronutrients from the gastrointestinal tract. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Parenteral iron supplementation may be necessary for patients who are unable to tolerate oral iron supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/30\">",
"     30",
"    </a>",
"    ]. Treatment with erythropoietin plus parenteral iron may be beneficial in severely anemic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Transfusions may be required for rapid correction of anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of anemia due to iron deficiency\", section on 'Parenteral iron therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H19#H19\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Erythropoietin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7616095\">",
"    <span class=\"h3\">",
"     Osteopenia and osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone mineral density is decreased in most patients with recessive dystrophic EB and junctional EB, due to reduced mobility, poor nutritional status, and low 25-[OH] vitamin D levels [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/33\">",
"     33",
"    </a>",
"    ]. Annual screening with dual-energy x-ray absorptiometry scans is suggested for detecting osteopenia and osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/28,33\">",
"     28,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with decreased bone density, calcium and vitamin D supplementation should be commenced and the serum bone profile monitored. (See",
"    <a class=\"local\" href=\"#H70257736\">",
"     'Micronutrients'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology and treatment of calcipenic rickets in children\", section on 'Nutritional rickets'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=see_link&amp;anchor=H9#H9\">",
"     \"Calcium requirements in adolescents\", section on 'Recommended intake'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71482543\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF EXTRACUTANEOUS COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of extracutaneous complications of severe forms of EB requires consultation with appropriate specialists. Modified approaches are often needed to avoid further tissue damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70256810\">",
"    <span class=\"h2\">",
"     Ocular lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular involvement in EB ranges from mild conjunctival irritation to severe blistering and scarring of conjunctiva, cornea, and eyelids leading to symblepharon and progressive visual impairment (",
"    <a class=\"graphic graphic_table graphicRef86396 \" href=\"UTD.htm?10/29/10719\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28106?source=see_link&amp;anchor=H61550917#H61550917\">",
"     \"Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa\", section on 'Eye'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For conjunctival irritation, regular use of preservative-free ocular lubricants is generally sufficient. Corneal erosions are treated with antibiotic ointments. Less common approaches used in severe cases include the application of amniotic membranes or cell sheets derived from autologous oral or limbal epithelium and corneal transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic blepharitis can result in cicatricial ectropion and exposure keratitis. Conservative treatment includes moisture chambers and topical lubricants. Patients who do not improve with conservative treatment may require full-thickness skin grafting to the upper eyelid.",
"   </p>",
"   <p>",
"    A large proportion of children with EB has clinically significant refractive errors and strabismus requiring orthoptic and ophthalmic surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=see_link\">",
"     \"Refractive errors in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link\">",
"     \"Evaluation and management of strabismus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71482647\">",
"    <span class=\"h2\">",
"     Oral and dental lesions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71482672\">",
"    <span class=\"h3\">",
"     Oral hygiene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gentle tooth brushing with a soft, small brush is possible in all patients with EB, even those with severe mucosal involvement. Mouth rinses with normal saline can be used for gentle cleaning of the mucosal surfaces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71482679\">",
"    <span class=\"h3\">",
"     Dental treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dental care should be provided with great caution to patients with junctional EB or recessive dystrophic EB who have severe mucosal fragility, varying degrees of ankyloglossia, vestibule obliteration, and microstomia. These patients require a modified approach for dental treatments which includes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lubrication of lips, oral mucosa, gloves, and instruments with petroleum jelly,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/32/14852?source=see_link\">",
"       glycerin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/28/29123?source=see_link\">",
"       methylcellulose",
"      </a>",
"     </li>",
"     <li>",
"      Avoidance of contact of suction tips with mucosal surface",
"     </li>",
"     <li>",
"      Drainage or incision of oral bullae to avoid spreading",
"     </li>",
"     <li>",
"      Avoidance of lateral traction and compression to prevent tissue sloughing &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with generalized enamel hypoplasia may require staged restoration of dentition with full crowns with or without dental implants to improve appearance and feeding ability [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/41\">",
"     41",
"    </a>",
"    ]. Impression taking may be cumbersome in patients with microstomia. Custom-made gel or acrylic application trays are usually needed. &nbsp;",
"   </p>",
"   <p>",
"    Tooth extractions should be performed by atraumatic techniques (eg, mucosal incisions) to prevent the formation of bullae. Hemostasis is obtained by applying gentle pressure with gauze packs. Sutures may or may not be used.",
"   </p>",
"   <p>",
"    Perioperative complications include mucosal sloughing or blistering. Post-operative complications are rare and healing of oral tissues including alveolar sockets generally occurs in one to two weeks.",
"   </p>",
"   <p>",
"    Orthodontic treatment is generally tolerated by patients with EB [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/39\">",
"     39",
"    </a>",
"    ]. In patients with recessive dystrophic EB and microstomia, serial extractions during the appropriate stage of dental development can prevent dental crowding.",
"   </p>",
"   <p>",
"    Anesthesia for dental procedures is most often local. However, conscious sedation or general anesthesia may be necessary for more extensive procedures in patients with severe forms of EB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6850928\">",
"    <span class=\"h2\">",
"     Delayed puberty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed onset of puberty and reduced pubertal growth is common in children with severe EB. Abnormalities in the secretion of gonadotropin releasing hormone (GnRH), growth hormone (GH), and insulin-like growth factor-1 (IGF-1) result from a multiplicity of factors, including chronic inflammation and malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/28,42\">",
"     28,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If delayed puberty is suspected, basal serum levels of luteinizing hormone, follicle stimulating hormone, and estradiol (in girls) or testosterone (in boys) should be obtained. Bone age can be assessed by radiographs of the left hand and wrist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis and treatment of delayed puberty\", section on 'Laboratory testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hormonal treatment for puberty induction should be evaluated on a case-by-case basis in collaboration with a pediatric endocrinologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis and treatment of delayed puberty\", section on 'Therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1740852\">",
"    <span class=\"h2\">",
"     Esophageal strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal strictures are a frequent complication and a major cause of poor nutrition in recessive dystrophic EB and junctional EB. They are managed by esophageal dilation using endoscopic balloon dilators or fluoroscopy-guided, over-the-guidewire hydrostatic balloon dilators [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=see_link\">",
"     \"Management of benign esophageal strictures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple procedures are often required because of recurrence. In one study including 126 patients with recessive dystrophic EB, the median interval between procedures was 5 years (range 1 to 13 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/43\">",
"     43",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Despite esophageal dilation, some patients present with significant failure to thrive and require the placement of a gastrostomy tube for supplemental enteral feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=see_link&amp;anchor=H3#H3\">",
"     \"Enteral feeding: Gastric versus post-pyloric\", section on 'Gastric feeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11529?source=see_link&amp;anchor=H869597#H869597\">",
"     \"Enteral nutrition in infants and children\", section on 'Gastrostomy route'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1740859\">",
"    <span class=\"h2\">",
"     Mitten deformity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudosyndactyly or &ldquo;mitten&rdquo; deformity of the hands and feet is a major complication of recessive dystrophic EB, occurring in over 95 percent of affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/46\">",
"     46",
"    </a>",
"    ]. Pseudosyndactyly results from repeated blistering and scarring of the hands that initially induces obliteration of the web spaces and with time leads to the encasement of the entire distal extremity in an epidermal cocoon (",
"    <a class=\"graphic graphic_picture graphicRef86598 \" href=\"UTD.htm?13/15/13554\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28106?source=see_link&amp;anchor=H476064#H476064\">",
"     \"Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa\", section on 'Recessive DEB, severe generalized'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Surgery is indicated when loss of hand function compromises the patient&rsquo;s independence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/47\">",
"     47",
"    </a>",
"    ]. Ideally, surgery should be performed when the patient&rsquo;s skin, medical, and nutritional conditions are optimal. The aims of surgery include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Providing simple pinch grip and grasp, by releasing the first web space and flexion contractures",
"     </li>",
"     <li>",
"      Allowing independent finger movement, by releasing pseudosyndactyly",
"     </li>",
"     <li>",
"      Improving the appearance of the hand",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Postoperative use of custom-made splints and hand therapy are important to maintain the benefits of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients are educated about measures to prevent the loss of web spaces such as using nonadherent bandages or dressings (eg, petroleum jelly gauze) and wearing rings [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/47\">",
"     47",
"    </a>",
"    ]. However, despite optimal postoperative care, contractures recur within two to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repeat surgery is planned on a case-by-case basis. Since the thumb contributes to the majority of hand function, the release of the first web space alone produces significant functional improvement. Many patients can cope well merely with the release of the dominant thumb.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1740866\">",
"    <span class=\"h2\">",
"     Squamous cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinoma (SCC) arising in chronic wounds is a major cause of death for patients with recessive dystrophic EB [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/50\">",
"     50",
"    </a>",
"    ]. Full body skin examinations every three to six months are recommended between age 10 and 16 years and every three months after age 16 years. Digital pictures taken at each appointment may be useful for comparison during follow-up visits. &nbsp;",
"   </p>",
"   <p>",
"    Any skin areas that are suspicious for SCC (eg, non-healing, painful wounds) should be biopsied (",
"    <a class=\"graphic graphic_picture graphicRef86599 graphicRef86600 \" href=\"UTD.htm?16/26/16808\">",
"     picture 2A-B",
"    </a>",
"    ). SCCs confirmed by histologic examination are treated with wide local excision or Mohs micrographic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21226?source=see_link\">",
"     \"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=see_link\">",
"     \"Mohs surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preoperative localized imaging studies, including magnetic resonance imaging (MRI), computerized tomography (CT) scan, or ultrasonography, are helpful in assessing local invasion. Locally invasive lesions (eg, lesions involving the tendons or bones) may require amputation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21226?source=see_link&amp;anchor=H90084812#H90084812\">",
"     \"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the aggressive nature of SCC associated with EB, patients with invasive tumors should undergo staging evaluation. Imaging studies of chest, abdomen, and pelvis are generally performed by ultrasonography, CT scan, or MRI. Positron emission tomography scans can also be used to determine the extent and presence of hematogenous or lymphatic metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21226?source=see_link&amp;anchor=H90084812#H90084812\">",
"     \"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with locally advanced or metastatic disease may be treated with adjunctive radiotherapy or chemotherapy. However, there is limited experience and lack of consensus among experts on the appropriate chemotherapy or radiotherapy regimens for patients with EB.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    , a monoclonal antibody against the epidermal growth factor receptor (EGFR), has been used to treat advanced or unresectable cutaneous SCCs expressing EGFR and negative for K-ras mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. However, the evidence supporting this approach in patients with EB is limited to a single case report [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71485171\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research related to the treatment of epidermolysis bullosa (EB) is focused on the development of gene-, protein-, and cell-based molecular therapies targeting specific gene defects in severe forms of EB, such as recessive dystrophic EB and junctional EB Herlitz [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28106?source=see_link&amp;anchor=H381977#H381977\">",
"     \"Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most of these targeted approaches are still in a preclinical stage of development, some have been evaluated in small clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/5,50\">",
"     5,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71485203\">",
"    <span class=\"h2\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene therapy strategies include genomic locus transfer, cDNA transfer, ex vivo gene transfer, and in vivo gene transfer [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/6\">",
"     6",
"    </a>",
"    ]. Functional correction of gene expression by spliceosome-mediated RNA trans-splicing (SMaRT) appears to be promising for recessive dystrophic EB, epidermolysis bullosa simplex (EBS)-muscular dystrophy, and in autosomal dominant EBS [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/55-59\">",
"     55-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71485210\">",
"    <span class=\"h2\">",
"     Cell-based therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cell-based therapies include fibroblast therapy and bone marrow transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/4\">",
"     4",
"    </a>",
"    ]. Collagen type VII is synthesized in culture by epidermal keratinocytes and dermal fibroblasts. Following studies in murine models of recessive dystrophic EB, it was hypothesized that the injection of normal fibroblasts in the dermis of patients with recessive dystrophic EB could restore collagen synthesis and reduce skin fragility.",
"   </p>",
"   <p>",
"    In a small study, five patients with recessive dystrophic EB received a single intradermal injection of allogenic fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/60\">",
"     60",
"    </a>",
"    ]. Increased expression of type VII collagen at the dermal&ndash;epidermal junction was noted at two weeks and up to three months after the injection, although the allogenic fibroblasts were not detectable at the injection site. The mechanisms underlying the upregulation of collagen synthesis in these patients is unknown and may involve the expression of cytokines such as the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    binding&ndash;EGF-like growth factor (HB-EGF) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stem cell therapy with allogenic bone marrow transplantation is based upon the observation that bone marrow pluripotent stem cells can reprogram to keratinocytes and home to the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/5,62-65\">",
"     5,62-65",
"    </a>",
"    ]. In a murine model of recessive dystrophic EB, donor cells producing collagen type VII were detected at the dermal-epidermal junction in the recipient&rsquo;s skin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stem cell therapy has been evaluated in a small clinical trial including seven children with recessive dystrophic EB [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/5\">",
"     5",
"    </a>",
"    ]. All children underwent immuno-myeloablative chemotherapy followed by allogenic stem-cell transplantation. Two children died from complications associated with the procedure. All the surviving children achieved improved wound healing and reduced blistering between 30 to 130 days after transplantation. Because of the high mortality associated with bone marrow transplantation with myeloablation, there is a need of further studies evaluating less aggressive, nonmyeloablative preparative regimens in EB patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link\">",
"     \"Preparative regimens for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13245731\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of death among patients with EB differs markedly by EB subtype in terms of specific cause and magnitude of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/66\">",
"     66",
"    </a>",
"    ]. Most children with EB who survive the first 12 to 24 months of life will live into at least adulthood, if meticulous, aggressive medical care is provided. In particular, advances in wound care have greatly reduced the risk of death from sepsis in patients with extensive wounds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20835560\">",
"    <span class=\"h2\">",
"     Epidermolysis bullosa simplex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for patients with localized epidermolysis bullosa simplex (EBS) is favorable. Patients have a normal life expectancy and in most cases are able to live a normal life. In contrast, patients with generalized EBS Dowling Meara experience inflammatory flares throughout their life. Children with the rare, recessive forms of EBS (eg, autosomal recessive lethal acantholytic EBS, EBS-pyloric atresia with extensive aplasia cutis) usually do not survive beyond the first year of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6850724\">",
"    <span class=\"h2\">",
"     Junctional EB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with junctional epidermolysis bullosa Herlitz (JEB-H) and non-Herlitz (JEB-nH) do not survive past infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. In one study, 19 of 22 children with JEB-H died before age 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/67\">",
"     67",
"    </a>",
"    ]. Sepsis, failure to thrive, and respiratory failure are the major causes of death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6850731\">",
"    <span class=\"h2\">",
"     Dystrophic EB",
"    </span>",
"    &nbsp;&mdash;&nbsp;With improved nutritional support, wound care, and management of complications, patients with recessive dystrophic EB usually survive to their early 30s to 40s. Metastatic squamous cell carcinoma and renal failure are major causes of death. Patients with dominant dystrophic EB generally survive to adulthood with few complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6850738\">",
"    <span class=\"h2\">",
"     Kindler syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Kindler syndrome generally have a good prognosis. However, they have increased photosensitivity and are at risk of developing skin cancer, particularly squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/63/3066/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1741120\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of EB patients is largely supportive and involves a multidisciplinary team, usually composed of a dermatologist, an EB nurse, a primary care provider, an occupational therapist, a nutritionist, and a social worker. Specialty teams (eg, ophthalmology, nephrology, hematology, endocrinology, cardiology, pain management, plastic surgery, specialized dentistry) are consulted as needed. (See",
"      <a class=\"local\" href=\"#H13245609\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10204934\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The early management of neonates with EB should be undertaken in a neonatal or pediatric unit with the expertise, staffing, and resources necessary to manage extensive erosions or potential complications related to widespread skin sloughing. Since heat may induce blisters, the risks and benefits of using an incubator must be determined individually. Bathing should be delayed until the lesions present at birth have healed. (See",
"      <a class=\"local\" href=\"#H56675661\">",
"       'Management of neonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EB wounds should be dressed with nonadherent silicone dressings, foam dressings that absorb exudates, and nonadherent silicone-based tape (",
"      <a class=\"graphic graphic_table graphicRef87148 graphicRef87149 graphicRef87150 \" href=\"UTD.htm?11/52/12110\">",
"       table 4A-C",
"      </a>",
"      ). Diluted bleach baths or compresses, topical antiseptics, and topical antibiotics are used to reduce the bacterial load in wounds with critical bacterial colonization. Frankly infected wounds usually require systemic antibiotics. (See",
"      <a class=\"local\" href=\"#H12936348\">",
"       'Wound dressing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3707630\">",
"       'Prevention and management of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain control is an important aspect of the management of EB patients (",
"      <a class=\"graphic graphic_table graphicRef87169 \" href=\"UTD.htm?40/18/41260\">",
"       table 6",
"      </a>",
"      ). For mild to moderate pain, analgesics (eg, paracetamol,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ) can be used alone or in conjunction with a nonsteroidal antiinflammatory drug. For severe pain, opioids or anxiolytics may be required. (See",
"      <a class=\"local\" href=\"#H71484649\">",
"       'Pain management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with severe forms of EB have nutritional compromise and require nutritional support. Anemic patients require iron supplementation with or without erythropoietin. Calcium and vitamin D supplementation should be initiated in patients with evidence of osteopenia or osteoporosis. (See",
"      <a class=\"local\" href=\"#H70257708\">",
"       'Management of nutritional compromise'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7615964\">",
"       'Related problems'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Ocular lesions (eg, conjunctival irritation, corneal erosions, chronic blepharitis) generally are treated conservatively with ocular lubricants and ointments. Severe cases may require autologous transplantation of limbal epithelium or allogenic corneal transplantation. (See",
"      <a class=\"local\" href=\"#H70256810\">",
"       'Ocular lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral hygiene should be encouraged with gentle tooth brushing and normal saline rinses. Dental treatments require a modified approach to limit local trauma and tissue damage. (See",
"      <a class=\"local\" href=\"#H71482647\">",
"       'Oral and dental lesions'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Disabling and severe complications of recessive dystrophic EB such as esophageal strictures, pseudosyndactyly, and squamous cell carcinoma, require surgical management:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Esophageal strictures are treated with fluoroscopy-guided hydrostatic balloon dilation. Recurrence is common and repeated treatments may be needed. (See",
"      <a class=\"local\" href=\"#H1740852\">",
"       'Esophageal strictures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pseudosyndactyly with loss of hand function may be corrected by surgical release of the first web space and flexion contractures. (See",
"      <a class=\"local\" href=\"#H1740859\">",
"       'Mitten deformity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Squamous cell carcinoma is treated with wide local excision or Mohs surgery. Locally invasive lesions may require amputations. (See",
"      <a class=\"local\" href=\"#H1740866\">",
"       'Squamous cell carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/1\">",
"      Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008; 58:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/2\">",
"      Fine JD. Inherited epidermolysis bullosa. Orphanet J Rare Dis 2010; 5:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/3\">",
"      Intong LR, Murrell DF. Inherited epidermolysis bullosa: new diagnostic criteria and classification. Clin Dermatol 2012; 30:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/4\">",
"      Uitto J, Has C, Bruckner-Tuderman L. Cell-based therapies for epidermolysis bullosa - from bench to bedside. J Dtsch Dermatol Ges 2012; 10:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/5\">",
"      Wagner JE, Ishida-Yamamoto A, McGrath JA, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 2010; 363:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/6\">",
"      Titeux M, Pendaries V, Hovnanian A. Gene therapy for recessive dystrophic epidermolysis bullosa. Dermatol Clin 2010; 28:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/7\">",
"      Fine JD, Johnson LB, Weiner M, Suchindran C. Impact of inherited epidermolysis bullosa on parental interpersonal relationships, marital status and family size. Br J Dermatol 2005; 152:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/8\">",
"      Martinez AE. Tests to monitor in patients with severe types of epidermolysis bullosa. Dermatol Clin 2010; 28:271, ix.",
"     </a>",
"    </li>",
"    <li>",
"     Fine JD. Inherited epidermolysis bullosa. In: Rook's Textbook of Dermatology, 8th Edition, Burns T, Breathnach S, Cox N, Griffiths C.  (Eds), 2010. Vol II.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/10\">",
"      Denyer J. Management of severe blistering disorders. Semin Neonatol 2000; 5:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/11\">",
"      Arbuckle HA. Bathing for individuals with epidermolysis bullosa. Dermatol Clin 2010; 28:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/12\">",
"      Denyer JE. Wound management for children with epidermolysis bullosa. Dermatol Clin 2010; 28:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/13\">",
"      Grocott P, Blackwell R, Weir H, Pillay E. Living in dressings and bandages: findings from workshops with people with Epidermolysis bullosa. Int Wound J 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/14\">",
"      Brandling-Bennett HA, Morel KD. Common wound colonizers in patients with epidermolysis bullosa. Pediatr Dermatol 2010; 27:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/15\">",
"      Sibbald RG, Woo K, Ayello EA. Increased bacterial burden and infection: the story of NERDS and STONES. Adv Skin Wound Care 2006; 19:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/16\">",
"      Howell-Jones RS, Wilson MJ, Hill KE, et al. A review of the microbiology, antibiotic usage and resistance in chronic skin wounds. J Antimicrob Chemother 2005; 55:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/17\">",
"      Mellerio JE. Infection and colonization in epidermolysis bullosa. Dermatol Clin 2010; 28:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/18\">",
"      Lara-Corrales I, Arbuckle A, Zarinehbaf S, Pope E. Principles of wound care in patients with epidermolysis bullosa. Pediatr Dermatol 2010; 27:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/19\">",
"      Pope E, Lara-Corrales I, Mellerio J, et al. A consensus approach to wound care in epidermolysis bullosa. J Am Acad Dermatol 2012; 67:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/20\">",
"      Goldschneider KR, Lucky AW. Pain management in epidermolysis bullosa. Dermatol Clin 2010; 28:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/21\">",
"      Mellerio JE, Weiner M, Denyer JE, et al. Medical management of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005. Int J Dermatol 2007; 46:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/22\">",
"      Watterson G, Howard R, Goldman A. Peripheral opioids in inflammatory pain. Arch Dis Child 2004; 89:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/23\">",
"      Marini I, Vecchiet F. Sucralfate: a help during oral management in patients with epidermolysis bullosa. J Periodontol 2001; 72:691.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical practice guidelines for nutrition support in infants and children with epidermolysis bullosa file://www.debra.org.uk/uploads/resources/EB_Guidelines_Final_for_web.pdf (Accessed on December 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/25\">",
"      Haynes L. Nutrition for children with epidermolysis bullosa. Dermatol Clin 2010; 28:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/26\">",
"      Haynes L. Nutritional support for children with epidermolysis bullosa. Br J Nurs 2006; 15:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/27\">",
"      Colomb V, Bourdon-Lannoy E, Lambe C, et al. Nutritional outcome in children with severe generalized recessive dystrophic epidermolysis bullosa: a short- and long-term evaluation of gastrostomy and enteral feeding. Br J Dermatol 2012; 166:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/28\">",
"      Martinez AE, Mellerio JE. Osteopenia and osteoporosis in epidermolysis bullosa. Dermatol Clin 2010; 28:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/29\">",
"      Lara-Corrales I, Pope E. Dilated cardiomyopathy in epidermolysis bullosa. Dermatol Clin 2010; 28:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/30\">",
"      Hubbard L, Haynes L, Sklar M, et al. The challenges of meeting nutritional requirements in children and adults with epidermolysis bullosa: proceedings of a multidisciplinary team study day. Clin Exp Dermatol 2011; 36:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/31\">",
"      Kuo DJ, Bruckner AL, Jeng MR. Darbepoetin alfa and ferric gluconate ameliorate the anemia associated with recessive dystrophic epidermolysis bullosa. Pediatr Dermatol 2006; 23:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/32\">",
"      Fridge JL, Vichinsky EP. Correction of the anemia of epidermolysis bullosa with intravenous iron and erythropoietin. J Pediatr 1998; 132:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/33\">",
"      Fewtrell MS, Allgrove J, Gordon I, et al. Bone mineralization in children with epidermolysis bullosa. Br J Dermatol 2006; 154:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/34\">",
"      Tong L, Hodgkins PR, Denyer J, et al. The eye in epidermolysis bullosa. Br J Ophthalmol 1999; 83:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/35\">",
"      Fine JD, Johnson LB, Weiner M, et al. Eye involvement in inherited epidermolysis bullosa: experience of the National Epidermolysis Bullosa Registry. Am J Ophthalmol 2004; 138:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/36\">",
"      Figueira EC, Murrell DF, Coroneo MT. Ophthalmic involvement in inherited epidermolysis bullosa. Dermatol Clin 2010; 28:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/37\">",
"      Smith KA, Jones SM, Nischal KK. Refractive and ocular motility findings in children with epidermolysis bullosa. Am Orthopt J 2009; 59:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/38\">",
"      Kr&auml;mer SM. Oral care and dental management for patients with epidermolysis bullosa. Dermatol Clin 2010; 28:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/39\">",
"      Kr&auml;mer SM, Serrano MC, Zillmann G, et al. Oral health care for patients with epidermolysis bullosa--best clinical practice guidelines. Int J Paediatr Dent 2012; 22 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/40\">",
"      Feijoo JF, Bugallo J, Limeres J, et al. Inherited epidermolysis bullosa: an update and suggested dental care considerations. J Am Dent Assoc 2011; 142:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/41\">",
"      Candel-Marti ME, Ata-Ali J, Pe&ntilde;arrocha-Oltra D, et al. Dental implants in patients with oral mucosal alterations: An update. Med Oral Patol Oral Cir Bucal 2011; 16:e787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/42\">",
"      Martinez AE, Allgrove J, Brain C. Growth and pubertal delay in patients with epidermolysis bullosa. Dermatol Clin 2010; 28:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/43\">",
"      Mortell AE, Azizkhan RG. Epidermolysis bullosa: management of esophageal strictures and enteric access by gastrostomy. Dermatol Clin 2010; 28:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/44\">",
"      Spiliopoulos S, Sabharwal T, Krokidis M, et al. Fluoroscopically guided dilation of esophageal strictures in patients with dystrophic epidermolysis bullosa: long-term results. AJR Am J Roentgenol 2012; 199:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/45\">",
"      Alshammari J, Quesnel S, Pierrot S, Couloigner V. Endoscopic balloon dilatation of esophageal strictures in children. Int J Pediatr Otorhinolaryngol 2011; 75:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/46\">",
"      Fine JD, Johnson LB, Weiner M, et al. Pseudosyndactyly and musculoskeletal contractures in inherited epidermolysis bullosa: experience of the National Epidermolysis Bullosa Registry, 1986-2002. J Hand Surg Br 2005; 30:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/47\">",
"      Bernardis C, Box R. Surgery of the hand in recessive dystrophic epidermolysis bullosa. Dermatol Clin 2010; 28:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/48\">",
"      Formsma SA, Maathuis CB, Robinson PH, Jonkman MF. Postoperative hand treatment in children with recessive dystrophic epidermolysis bullosa. J Hand Ther 2008; 21:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/49\">",
"      Campiglio GL, Pajardi G, Rafanelli G. A new protocol for the treatment of hand deformities in recessive dystrophic epidermolysis bullosa (13 cases). Ann Chir Main Memb Super 1997; 16:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/50\">",
"      Venugopal SS, Murrell DF. Treatment of skin cancers in epidermolysis bullosa. Dermatol Clin 2010; 28:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/51\">",
"      Saxena A, Lee JB, Humphreys TR. Mohs micrographic surgery for squamous cell carcinoma associated with epidermolysis bullosa. Dermatol Surg 2006; 32:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/52\">",
"      Giacchero D, Barri&egrave;re J, Benezery K, et al. Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma--a report of eight cases. Clin Oncol (R Coll Radiol) 2011; 23:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/53\">",
"      Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011; 29:3419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/54\">",
"      Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology 2009; 219:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/55\">",
"      Hengge UR. SMaRT technology enables gene expression repair in skin gene therapy. J Invest Dermatol 2008; 128:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/56\">",
"      Murauer EM, Gache Y, Gratz IK, et al. Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa. J Invest Dermatol 2011; 131:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/57\">",
"      Wally V, Klausegger A, Koller U, et al. 5' trans-splicing repair of the PLEC1 gene. J Invest Dermatol 2008; 128:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/58\">",
"      Wally V, Brunner M, Lettner T, et al. K14 mRNA reprogramming for dominant epidermolysis bullosa simplex. Hum Mol Genet 2010; 19:4715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/59\">",
"      Fritsch A, Spassov S, Elfert S, et al. Dominant-negative effects of COL7A1 mutations can be rescued by controlled overexpression of normal collagen VII. J Biol Chem 2009; 284:30248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/60\">",
"      Wong T, Gammon L, Liu L, et al. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2008; 128:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/61\">",
"      Uitto J. Cell-based therapy for RDEB: how does it work? J Invest Dermatol 2011; 131:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/62\">",
"      Kiuru M, Itoh M, Cairo MS, Christiano AM. Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa. Dermatol Clin 2010; 28:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/63\">",
"      Tolar J, Ishida-Yamamoto A, Riddle M, et al. Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood 2009; 113:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/64\">",
"      Tolar J, Xia L, Riddle MJ, et al. Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2011; 131:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/65\">",
"      Tolar J, Mehta PA, Walters MC. Hematopoietic cell transplantation for nonmalignant disorders. Biol Blood Marrow Transplant 2012; 18:S166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/66\">",
"      Fine JD, Johnson LB, Weiner M, Suchindran C. Cause-specific risks of childhood death in inherited epidermolysis bullosa. J Pediatr 2008; 152:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/67\">",
"      Yuen WY, Duipmans JC, Molenbuur B, et al. Long-term follow-up of patients with Herlitz-type junctional epidermolysis bullosa. Br J Dermatol 2012; 167:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/63/3066/abstract/68\">",
"      Lai-Cheong JE, McGrath JA. Kindler syndrome. Dermatol Clin 2010; 28:119.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15453 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-EF161DC620-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_63_3066=[""].join("\n");
var outline_f2_63_3066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1741120\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13245609\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10204934\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70257089\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70257120\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56675661\">",
"      MANAGEMENT OF NEONATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13245661\">",
"      SKIN AND WOUND CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12936341\">",
"      Bathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12936348\">",
"      Wound dressing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3707630\">",
"      Prevention and management of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H71484649\">",
"      PAIN MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70257708\">",
"      MANAGEMENT OF NUTRITIONAL COMPROMISE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70257715\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70257722\">",
"      Nutritional support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70257736\">",
"      Micronutrients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7615964\">",
"      Related problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7616088\">",
"      - Anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7616095\">",
"      - Osteopenia and osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H71482543\">",
"      MANAGEMENT OF EXTRACUTANEOUS COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70256810\">",
"      Ocular lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H71482647\">",
"      Oral and dental lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H71482672\">",
"      - Oral hygiene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H71482679\">",
"      - Dental treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6850928\">",
"      Delayed puberty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1740852\">",
"      Esophageal strictures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1740859\">",
"      Mitten deformity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1740866\">",
"      Squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H71485171\">",
"      EXPERIMENTAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H71485203\">",
"      Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H71485210\">",
"      Cell-based therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13245731\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20835560\">",
"      Epidermolysis bullosa simplex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6850724\">",
"      Junctional EB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6850731\">",
"      Dystrophic EB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6850738\">",
"      Kindler syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1741120\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15453\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15453|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/15/13554\" title=\"picture 1\">",
"      Mitten deformity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/15/15603\" title=\"picture 2A\">",
"      DEB squamous cell carcinoma 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/34/9763\" title=\"picture 2B\">",
"      DEB squamous cell carcinoma 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15453|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/11/23740\" title=\"table 1\">",
"      Epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/16/6415\" title=\"table 2A\">",
"      EB simplex variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/28/9678\" title=\"table 2B\">",
"      JEB variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/9/21662\" title=\"table 2C\">",
"      DEB variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/51/41788\" title=\"table 3\">",
"      EB lab monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/7/14460\" title=\"table 4A\">",
"      Dressings for EB simplex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/54/3948\" title=\"table 4B\">",
"      Dressings for junctional EB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/58/23468\" title=\"table 4C\">",
"      Dressings for dystrophic EB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/29/1501\" title=\"table 5\">",
"      Dressings for EB infected wounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/18/41260\" title=\"table 6\">",
"      Pain management in EB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/29/10719\" title=\"table 7\">",
"      EB extracutaneous complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=related_link\">",
"      Basic principles of wound management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=related_link\">",
"      Calcium requirements in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=related_link\">",
"      Diagnosis and treatment of delayed puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39255?source=related_link\">",
"      Diagnosis of epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18441?source=related_link\">",
"      Dietary recommendations for toddlers, preschool, and school-age children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=related_link\">",
"      Enteral feeding: Gastric versus post-pyloric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11529?source=related_link\">",
"      Enteral nutrition in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28106?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=related_link\">",
"      Etiology and treatment of calcipenic rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38949?source=related_link\">",
"      Iron deficiency in infants and young children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=related_link\">",
"      Local treatment of burns: Topical antimicrobial agents and dressings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=related_link\">",
"      Management of benign esophageal strictures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/16/30985?source=related_link\">",
"      Management of failure to thrive (undernutrition) in children younger than two years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=related_link\">",
"      Mohs surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=related_link\">",
"      Overview of dietary trace minerals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21226?source=related_link\">",
"      Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=related_link\">",
"      Refractive errors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=related_link\">",
"      Treatment of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=related_link\">",
"      Vitamin D insufficiency and deficiency in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=related_link\">",
"      Zinc deficiency and supplementation in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_63_3067="Transjugular liver biopsy indications";
var content_f2_63_3067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Specific indications for transjugular liver biopsy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Severe coagulopathy or thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Large-volume ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morbid obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suspected vascular tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Failure of previous percutaneous liver biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Simultaneous indication for hepatic venous pressure gradient measurement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Simultaneous indication for transjugular intrahepatic portosystemic shunt placement",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_63_3067=[""].join("\n");
var outline_f2_63_3067=null;
var title_f2_63_3068="Asthma adherence III";
var content_f2_63_3068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Take steps to solve your medicine-taking problems",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Achieve success one step at a time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Set specific goals such as \"I'll place my inhaler on the",
"kitchen table and use it at lunch at least five times this week.\" or",
"\"I'll put my antibiotic in the kitchen cabinet next to the salt and",
"pepper shakers and take it at breakfast, lunch, and supper today.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Make goals large enough to matter, but small enough to achieve; don't set your sights too high, you may fail.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        It's better to set a series of smaller goals that you can easily achieve, then move up to slightly harder goals.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Monitor your progress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Write down successes as well as problems. Use a medicine record as you did before or develop your own monitoring system.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use small successes to motivate yourself to keep going.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep an eye out for remaining problems.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Reward your success",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use small, frequent rewards soon after the successful activity. Don't try to wait too long or build up to a large reward.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Use problem solving methods as necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Make sure you have correctly identified the problem.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Work on just one problem at a time.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        List as many solutions as you can think of.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cross out solutions you know won't work.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Try to come up with positive and negative effects from the solutions that could work.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Choose the solution you think will work best.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Try it out and see if it works. If not, try another solution.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_63_3068=[""].join("\n");
var outline_f2_63_3068=null;
var title_f2_63_3069="Wigglesworth classification";
var content_f2_63_3069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Expanded Wigglesworth classification worksheet",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cause of death",
"       </td>",
"       <td class=\"subtitle1\">",
"        Subclassification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"18\">",
"        Congenital anomaly",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Chromosomal defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Numerical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Structural",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Microdeletion/uniparental disomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Monogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart and circulatory system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digestive system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urogenital system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Musculoskeletal system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endocrine/metabolic system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neoplasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Single organ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Multiple organ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Placenta",
"       </td>",
"       <td>",
"        Placental bed pathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Placental pathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Development",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Parenchyma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Localization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Umbilical cord complication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NOS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Prematurity/immaturity",
"       </td>",
"       <td>",
"        PPROM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preterm labor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iatrogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NOS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Infection",
"       </td>",
"       <td>",
"        Transplacental",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascending",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NOS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Other",
"       </td>",
"       <td>",
"        Fetal hydrops of unknown origin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Maternal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fetal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Out of the ordinary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Unknown",
"       </td>",
"       <td>",
"        Despite thorough investigation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Important information missing",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wigglesworth, JS. Monitoring perinatal mortality. A pathophysiological approach. Lancet 1980; 2:684. Copyright &copy;1980 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_63_3069=[""].join("\n");
var outline_f2_63_3069=null;
var title_f2_63_3070="Contents: Hospital Medicine";
var content_f2_63_3070=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      Hospital Medicine",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hospital Medicine",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     You receive the entire UpToDate library of specialties with your ",
"							subscription. Click on a section below to view a detailed list of topics associated ",
"							with that particular section. If you'd like to see the table of contents for other ",
"							specialties,",
"     <a href=\"UTD.htm?3/3/3134\">",
"      click here",
"     </a>",
"     .",
"     <br/>",
"     <br/>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?40/11/41149\">",
"         Hospital allergy and immunology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?21/22/21856\">",
"         Hospital cardiovascular medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?31/10/31918\">",
"         Hospital endocrinology and diabetes",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?40/39/41598\">",
"         Hospital gastroenterology and hepatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?16/45/17119\">",
"         Hospital hematology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?0/21/351\">",
"         Hospital infectious diseases",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?25/60/26574\">",
"         Hospital medicine calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?23/26/23981\">",
"         Hospital medicine quality and safety",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?1/28/1486\">",
"         Hospital medicine women���������s health, obstetrics and gynecology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?24/33/25119\">",
"         Hospital nephrology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?43/23/44413\">",
"         Hospital neurology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?10/49/11038\">",
"         Hospital oncology",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?39/31/40445\">",
"         Hospital practice",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?33/41/34461\">",
"         Hospital psychiatry",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?43/13/44255\">",
"         Hospital pulmonary, critical care, and sleep medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?15/37/15966\">",
"         Hospital rheumatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?2/33/2581\">",
"         What's new in hospital medicine",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        &nbsp;",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-65E0895C18-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f2_63_3070=[""].join("\n");
var outline_f2_63_3070=null;
var title_f2_63_3071="Natural hx occupational asthma";
var content_f2_63_3071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Natural history of occupational asthma with a latency period",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 336px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_63_3071=[""].join("\n");
var outline_f2_63_3071=null;
